Anti-SARS-CoV-2 spike glycoprotein antibody and antigen-binding fragment

JP2026140720A5Pending Publication Date: 2026-11-19REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2026084554
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-03-10
Filing Date
2026-05-20
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current technologies lack effective treatments and preventative measures against SARS-CoV-2, especially highly effective neutralizing antibody therapies targeting its spike protein.

Method used

Fully human antibodies and antigen-binding fragments that specifically bind to the SARS-CoV-2 spike protein were developed. By selecting non-overlapping epitopes for binding, the frequency of viral mutants was reduced. Combined with other therapies such as anti-inflammatory, antimalarial, and antiviral agents, the efficacy was enhanced.

Benefits of technology

It significantly reduced the frequency of SARS-CoV-2 spike protein escape variants and enhanced the therapeutic effect against COVID-19.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000132_0000
    Figure 00000132_0000
  • Figure 00000132_0001
    Figure 00000132_0001
  • Figure 00000132_0002
    Figure 00000132_0002
Patent Text Reader

Abstract

The present invention provides a method for selecting multiple antibodies or their antigen-binding fragments for use in the treatment of viral infections, a method for treating viral infections, and a pharmaceutical composition. [Solution] A method for selecting a plurality of antibodies or antigen-binding fragments thereof for use in the treatment of a viral infection, comprising: a) determining a first frequency of escape variants arising from a first antibody or antigen-binding fragment alone; b) determining a second frequency of escape variants arising from a second antibody or antigen-binding fragment alone; c) determining a third frequency of escape variants arising from a combination of the first antibody or antigen-binding fragment and the second antibody or antigen-binding fragment; and d) selecting the combination for use in the treatment of the viral infection if the third frequency is lower than the first and second frequencies.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application is a compilation of U.S. Provisional Applications No. 63 / 030,260 filed on May 26, 2020, No. 63 / 033,198 filed on June 1, 2020, No. 63 / 093,888 filed on October 20, 2020, No. 63 / 112,143 filed on November 10, 2020, and No. 63 / 141 filed on January 26, 2021. Patent No. 956, No. 63 / 142,472 filed on 27 January 2021, No. 63 / 145,389 filed on 3 February 2021, and No. 63 / 159,437 filed on 10 March 2021, each claiming interest under Section 119(e) of the United States Patent Act, each of which is incorporated herein by reference in whole for all purposes. Federal government-funded research or development

[0002] This invention was approved by the U.S. Department of Health and Human Services. This invention was carried out with government support under Agreement HHSO100201700020C, which was awarded by [organization name]. The government has certain rights in this invention.

[0003] Sequence List This application incorporates by reference a sequence listing prepared on 24 May 2021 and submitted in computer-readable format as file 10810WO01-Sequence.txt, containing 922,784 bytes.

[0004] The present invention relates to antibodies and antigen-binding fragments that specifically bind to coronavirus spike protein, and to methods for treating or preventing coronavirus infection using said antibodies and fragments. [Background technology]

[0005] Newly identified viruses, such as coronaviruses, are not well-characterized and can be difficult to treat. The emergence of these newly identified viruses highlights the need to develop new antiviral strategies. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a severe virus. SARS-CoV-2 is a newly emerging coronavirus that causes the acute respiratory disease COVID-19. First identified in Wuhan, China, as of March 20, 2020, the World Health Organization reported 209,839 confirmed cases in 168 countries, territories, or regions, with 8,778 deaths. Clinical features of COVID-19 include fever, dry cough, and fatigue, and the disease can lead to respiratory failure and death.

[0006] To date, there have been no vaccines or treatments to prevent or treat SARS-CoV-2 infection. Given the ongoing threat to human health, there is an urgent need for prophylactic and therapeutic antiviral therapies to control SARS-CoV-2. This spike protein is an attractive target for antibody therapy because the virus uses its spike glycoprotein to interact with the cell receptor ACE2 and the serine protease TMPRSS2 to enter target cells. In particular, fully human antibodies that specifically bind to the SARS-CoV-2 spike protein (SARS-CoV-2-S) with high affinity and inhibit viral infectivity may be important for the prevention and treatment of COVID-19. [Overview of the project]

[0007] Therapeutic anti-SARS-CoV-2 spike protein (SARS-CoV-2-S) It is necessary to neutralize the body and use them to treat or prevent viral infections. This disclosure addresses this need in part by providing human anti-SARS-CoV-2-S antibodies, such as those in Table 1, and combinations thereof, including combinations with other therapeutic agents (e.g., anti-inflammatory agents, antimalarial agents, antiviral agents, or other antibody or antigen-binding fragments), as well as methods of using them to treat viral infections.

[0008] This disclosure provides neutralizing human antigen-binding proteins, such as antibodies or antigen-binding fragments thereof, that specifically bind to SARS-CoV-2-S.

[0009] In one embodiment, the present disclosure provides a method for selecting a plurality of antibodies or antigen-binding fragments thereof for use in the treatment of a viral infection, comprising: a) determining a first frequency of escape variants arising from a first antibody or antigen-binding fragment alone; b) determining a second frequency of escape variants arising from a second antibody or antigen-binding fragment alone; c) determining a third frequency of escape variants arising from a combination of the first antibody or antigen-binding fragment and the second antibody or antigen-binding fragment; and d) selecting a combination for use in the treatment of a viral infection if the third frequency is lower than the first and second frequencies, wherein the first antibody or antigen-binding fragment binds to a first epitope of a viral surface protein, the second antibody or antigen-binding fragment binds to a second epitope of a viral surface protein, and further, the first and second epitopes do not overlap.

[0010] In some cases, the viral infection is a coronavirus infection. In some embodiments, the coronavirus is SARS-CoV-2. In some cases, the escape variant is a variant in the SARS-CoV-2 surface protein. In some embodiments, the surface protein is the spike protein.

[0011] In some embodiments of the method, the frequency of SARS-CoV-2 spike protein escape variants is determined by a) contacting a population of cells with a first antibody or its antigen-binding fragment and a virus expressing the SARS-CoV-2 spike protein, sequencing nucleic acids from the cell population, and determining the first frequency of SARS-CoV-2 spike protein variants; and b) contacting an equivalent population of cells with a second antibody or its antigen-binding fragment and a virus expressing the SARS-CoV-2 spike protein, and further sequencing the nucleic acids from the cell population. The frequency is measured by: a) sequencing nucleic acids from a population of cells to determine a second frequency of SARS-CoV-2 spike protein mutations; c) contacting a population of equivalent cells with a first antibody or its antigen-binding fragment, a second antibody or its antigen-binding fragment, and a virus expressing the SARS-CoV-2 spike protein, sequencing nucleic acids from the cell population to determine a third frequency of SARS-CoV-2 spike protein mutations; and d) comparing the first, second, and third frequencies.

[0012] In some cases, the first and second epitopes are selected from the group consisting of a) amino acids 432-452 of SEQ ID NO: 832, b) amino acids 471-486 of SEQ ID NO: 832, and c) amino acids 491-515 of SEQ ID NO: 832.

[0013] In various embodiments, the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment are selected from the antibodies or antigen-binding fragments in Table 1. In some cases, the first and second antibodies are selected from two of the following groups: a) mAb10987, mAb10922, mAb10936, and mAb10934, b) mAb10989, mAb10977, and mAb10933, c) mAb10920, d) mAb10954, mAb10986, and mAb10964, and e) mAb10984. In some embodiments, the first and second antibodies are mAb10987, mAb10934, mA The group is selected from b10989 and mAb10933.

[0014] In one embodiment, the present disclosure provides a method for treating a viral infection in a subject, comprising administering a first antibody or its antigen-binding fragment and a second antibody or its antigen-binding fragment to the subject, wherein a) the first antibody or its antigen-binding fragment binds to a first epitope of the SARS-CoV-2 spike protein, the second antibody or its antigen-binding fragment binds to a second epitope of the SARS-CoV-2 spike protein, b) the first and second epitopes are different, and c) the administration of the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment results in a reduction in the frequency of SARS-CoV-2 spike protein escape variants compared to the administration of the first antibody or its antigen-binding fragment alone or the second antibody or its antigen-binding fragment alone.

[0015] In some embodiments of the method, the frequency of SARS-CoV-2 spike protein escape variants is measured by a) contacting a population of cells with a first antibody or its antigen-binding fragment, a second antibody or its antigen-binding fragment, and a virus expressing the SARS-CoV-2 spike protein, sequencing the nucleic acids from the cell population, and determining a first frequency of SARS-CoV-2 spike protein mutations; b) contacting an equivalent population of cells with only the first antibody or its antigen-binding fragment, or only the second antibody or its antigen-binding fragment, and a virus expressing the SARS-CoV-2 spike protein, sequencing the nucleic acids from the cell population, and determining a second frequency of SARS-CoV-2 spike protein mutations; and c) comparing the first and second frequencies.

[0016] In some cases, the first and second epitopes do not overlap. In some embodiments, the first and second epitopes are selected from the group consisting of a) amino acids 432-452 of SEQ ID NO: 832, b) amino acids 471-486 of SEQ ID NO: 832, and c) amino acids 491-515 of SEQ ID NO: 832.

[0017] In various embodiments, the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment are selected from the antibodies or antigen-binding fragments in Table 1. In some cases, the first and second antibodies are selected from two of the following groups: a) mAb10987, mAb10922, mAb10936, and mAb10934; b) mAb10989, mAb10977, and mAb10933; c) mAb10920; d) mAb10954, mAb10986, and mAb10964; and e) mAb10984. In some embodiments, the first and second antibodies are selected from the group consisting of mAb10987, mAb10934, mAb10989, and mAb10933.

[0018] In various embodiments, the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment are administered simultaneously. In various embodiments, the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment are administered sequentially.

[0019] In some cases, the subjects are infected with SARS-CoV-2. In some embodiments, the subjects have COVID-19.

[0020] In one embodiment, the present disclosure provides a method for treating a viral infection in a subject, comprising administering a first antibody or its antigen-binding fragment and a second antibody or its antigen-binding fragment to the subject, wherein a) the first antibody or its antigen-binding fragment binds to a first epitope of the SARS-CoV-2 spike protein, and the second antibody or its antigen-binding fragment binds to a second epitope of the SARS-CoV-2 spike protein, b) the first and second epitopes do not overlap, and c) the administration of the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment binds to overlapping epitopes of the SARS-CoV-2 spike protein. This invention provides a method that results in a reduction in the frequency of SARS-CoV-2 spike protein escape variants compared to the administration of a combination of binding antibodies.

[0021] In some embodiments of the method, the frequency of SARS-CoV-2 spike protein escape variants is measured by a) contacting a population of cells with a first antibody or its antigen-binding fragment, a second antibody or its antigen-binding fragment, and a virus expressing the SARS-CoV-2 spike protein, sequencing the nucleic acids from the cell population, and determining a first frequency of SARS-CoV-2 spike protein mutations; b) contacting an equivalent population of cells with a combination of antibodies that bind to overlapping epitopes of the SARS-CoV-2 spike protein, and a virus expressing the SARS-CoV-2 spike protein, sequencing the nucleic acids from the cell population, and determining a second frequency of SARS-CoV-2 spike protein mutations; and c) comparing the first and second frequencies.

[0022] In some cases, the first and second epitopes are selected from the group consisting of a) amino acids 432-452 of SEQ ID NO: 832, b) amino acids 471-486 of SEQ ID NO: 832, and c) amino acids 491-515 of SEQ ID NO: 832.

[0023] In various embodiments, the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment are selected from the antibodies or antigen-binding fragments in Table 1. In some cases, the first and second antibodies are selected from two of the following groups: a) mAb10987, mAb10922, mAb10936, and mAb10934; b) mAb10989, mAb10977, and mAb10933; c) mAb10920; d) mAb10954, mAb10986, and mAb10964; and e) mAb10984. In some cases, the first and second antibodies are selected from the group consisting of mAb10987, mAb10934, mAb10989, and mAb10933. In some cases, the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment are administered simultaneously. In some cases, the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment are administered sequentially.

[0024] In some embodiments, the subject is infected with SARS-CoV-2. In some embodiments, the subject has COVID-19.

[0025] In one embodiment, the present disclosure provides a method for controlling the proliferation of a viral escape variant, comprising administering a first antibody or its antigen-binding fragment and a second antibody or its antigen-binding fragment to a subject, wherein both the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment bind to a viral surface protein, the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment do not compete with each other for binding to the viral surface protein, and the subject is infected with a virus expressing the viral surface protein.

[0026] In some embodiments, the virus is a coronavirus. In some cases, the coronavirus is SARS-CoV-2, and the viral surface protein is the spike protein.

[0027] In various embodiments, the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment are selected from the antibodies or antigen-binding fragments in Table 1. In some cases, the first and second antibodies are selected from two of the following groups: a) mAb10987, mAb10922, mAb10936, and mAb10934, b) mAb10989, mAb10977, and mAb10933, c) mAb10920, d) mAb10954, mAb10986, and mAb10964, and e) mAb10984. In this example, the first and second antibodies are selected from the group consisting of mAb10987, mAb10934, mAb10989, and mAb10933.

[0028] In one embodiment, the present disclosure provides a pharmaceutical composition comprising a first antibody or its antigen-binding fragment and a second antibody or its antigen-binding fragment, wherein a) the first antibody or its antigen-binding fragment binds to a first epitope of the SARS-CoV-2 spike protein, the second antibody or its antigen-binding fragment binds to a second epitope of the SARS-CoV-2 spike protein, b) the first and second epitopes are different, and c) the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment result in a reduction in the frequency of SARS-CoV-2 spike protein escape variants compared to the first antibody or its antigen-binding fragment alone, or the second antibody or its antigen-binding fragment alone.

[0029] In some embodiments, the frequency of SARS-CoV-2 spike protein escape variants is measured by a) contacting a population of cells with a first antibody or its antigen-binding fragment, a second antibody or its antigen-binding fragment, and a virus expressing the SARS-CoV-2 spike protein, sequencing the nucleic acids from the cell population, and determining a first frequency of SARS-CoV-2 spike protein mutations; b) contacting an equivalent population of cells with only the first antibody or its antigen-binding fragment, or only the second antibody or its antigen-binding fragment, and a virus expressing the SARS-CoV-2 spike protein, sequencing the nucleic acids from the cell population, and determining a second frequency of SARS-CoV-2 spike protein mutations; and c) comparing the first and second frequencies.

[0030] In some cases, the first and second epitopes do not overlap. In some embodiments, the first and second epitopes are selected from the group consisting of a) amino acids 432-452 of SEQ ID NO: 832, b) amino acids 471-486 of SEQ ID NO: 832, and c) amino acids 491-515 of SEQ ID NO: 832.

[0031] In various embodiments, the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment are selected from the antibodies or antigen-binding fragments in Table 1. In some cases, the first and second antibodies are selected from two of the following groups: a) mAb10987, mAb10922, mAb10936, and mAb10934; b) mAb10989, mAb10977, and mAb10933; c) mAb10920; d) mAb10954, mAb10986, and mAb10964; and e) mAb10984. In some embodiments, the first and second antibodies are selected from the group consisting of mAb10987, mAb10934, mAb10989, and mAb10933.

[0032] In some cases, the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment are administered to the subject simultaneously. In some cases, the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment are administered to the subject sequentially. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

[0033] In one embodiment, the Disclosure relates to a composition comprising: a) a first antibody or antigen-binding fragment thereof that binds to a SARS-CoV-2 spike protein comprising the amino acid sequence described in SEQ ID NO: 832, wherein the isolated antibody or antigen-binding fragment comprises: three chain complementarity determining regions (CDRs) (A-HCDR1, A-HCDR2, and A-HCDR3) contained within a heavy chain variable region (A-HCVR) comprising the amino acid sequence described in SEQ ID NO: 202; and three CDRs (A-LCDR1, A-LCDR2, and A-LCDR3) contained within a light chain variable region (A-LCVR) comprising the amino acid sequence described in SEQ ID NO: 210; and b) the first antibody or antigen-binding fragment comprising the amino acid sequence described in SEQ ID NO: 832 A second antibody or antigen-binding fragment thereof that binds to the SARS-CoV-2 spike protein containing the amino acid sequence described above, wherein the isolated antibody or antigen-binding fragment comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) contained within a heavy chain variable region (B-HCVR) containing the amino acid sequence described in SEQ ID NO: 640, and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) contained within a light chain variable region (B-LCVR) containing the amino acid sequence described in SEQ ID NO: 646, and c) the second antibody or antigen-binding fragment thereof described in SEQ ID NO: 832 The present invention provides a composition comprising a third antibody or antigen-binding fragment thereof that binds to a SARS-CoV-2 spike protein containing the amino acid sequence described herein, wherein the isolated antibody or antigen-binding fragment comprises three heavy chain CDRs (C-HCDR1, C-HCDR2, and C-HCDR3) contained within a heavy chain variable region (C-HCVR) containing the amino acid sequence described in SEQ ID NO: 608, and three light chain CDRs (C-LCDR1, C-LCDR2, and C-LCDR3) contained within a light chain variable region (C-LCVR) containing the amino acid sequence described in SEQ ID NO: 614.

[0034] In some embodiments, A-HCDR1 includes the amino acid sequence described in SEQ ID NO: 204, A-HCDR2 includes the amino acid sequence described in SEQ ID NO: 206, A-HCDR3 includes the amino acid sequence described in SEQ ID NO: 208, A-LCDR1 includes the amino acid sequence described in SEQ ID NO: 212, A-LCDR2 includes the amino acid sequence described in SEQ ID NO: 55, and A-LCDR3 includes the amino acid sequence described in SEQ ID NO: 214.

[0035] In some embodiments, A-LCVR comprises the amino acid sequence described in SEQ ID NO: 202.

[0036] In some embodiments, A-HCVR comprises the amino acid sequence described in SEQ ID NO: 210.

[0037] In some embodiments, A-HCVR comprises the amino acid sequence described in SEQ ID NO: 202, and A-LCVR comprises the amino acid sequence described in SEQ ID NO: 210.

[0038] In some embodiments, B-HCDR1 includes the amino acid sequence described in SEQ ID NO: 642, B-HCDR2 includes the amino acid sequence described in SEQ ID NO: 499, B-HCDR3 includes the amino acid sequence described in SEQ ID NO: 644, B-LCDR1 includes the amino acid sequence described in SEQ ID NO: 648, B-LCDR2 includes the amino acid sequence described in SEQ ID NO: 650, and B-LCDR3 includes the amino acid sequence described in SEQ ID NO: 652.

[0039] In some embodiments, B-HCVR comprises the amino acid sequence described in SEQ ID NO: 640.

[0040] In some embodiments, B-LCVR comprises the amino acid sequence described in SEQ ID NO: 646.

[0041] In some embodiments, B-HCVR comprises the amino acid sequence described in SEQ ID NO: 640, and B-LCVR comprises the amino acid sequence described in SEQ ID NO: 646.

[0042] In some embodiments, C-HCDR1 comprises the amino acid sequence described in SEQ ID NO: 169, C-HCDR2 comprises the amino acid sequence described in SEQ ID NO: 610, C-HCDR3 comprises the amino acid sequence described in SEQ ID NO: 612, C-LCDR1 comprises the amino acid sequence described in SEQ ID NO: 616, C-LCDR2 comprises the amino acid sequence described in SEQ ID NO: 584, and C-LCDR3 comprises the amino acid sequence described in SEQ ID NO: 618.

[0043] In some embodiments, C-HCVR comprises the amino acid sequence described in SEQ ID NO: 608.

[0044] In some embodiments, C-LCVR comprises the amino acid sequence described in SEQ ID NO: 614.

[0045] In some embodiments, C-HCVR comprises the amino acid sequence described in SEQ ID NO: 608, and C-LCVR comprises the amino acid sequence described in SEQ ID NO: 614.

[0046] In one embodiment, the present disclosure relates to a method for use in the treatment of a viral infection, a pharmaceutical composition comprising a plurality of antibodies or antigen-binding fragments thereof, wherein the antibodies or antigen-binding fragments a) determine a first frequency of escape variants arising from a first antibody or antigen-binding fragment alone, b) determine a second frequency of escape variants arising from a second antibody or antigen-binding fragment alone, c) determine a third frequency of escape variants arising from a combination of the first antibody or antigen-binding fragment and the second antibody or antigen-binding fragment, and d) the third frequency is equal to the first frequency and When the frequency is lower than 2, a combination is selected for use in treating viral infections, and a pharmaceutical composition is provided in which a first antibody or its antigen-binding fragment binds to a first epitope of the viral surface protein, a second antibody or its antigen-binding fragment binds to a second epitope of the viral surface protein, and the first and second epitopes are selected from the group consisting of a) amino acids 432-452 of SEQ ID NO: 832, ii) amino acids 471-486 of SEQ ID NO: 832, and iii) amino acids 491-515 of SEQ ID NO: 832.

[0047] In some cases, the viral infection is a coronavirus infection. In some cases, the coronavirus is SARS-CoV-2.

[0048] In some embodiments, the escape variant is a variant in the SARS-CoV-2 surface protein. In some cases, the surface protein is the spike protein.

[0049] In some embodiments, the frequency of SARS-CoV-2 spike protein escape variants is determined by a) contacting a population of cells with a first antibody or its antigen-binding fragment and a virus expressing the SARS-CoV-2 spike protein, sequencing nucleic acids from the cell population, and determining the first frequency of SARS-CoV-2 spike protein variants; and b) contacting an equivalent population of cells with a second antibody or its antigen-binding fragment and a virus expressing the SARS-CoV-2 spike protein, and sequencing the cells. The frequency is measured by: a) sequencing nucleic acids from a population to determine a second frequency of SARS-CoV-2 spike protein mutations; c) contacting a population of equivalent cells with a first antibody or its antigen-binding fragment, a second antibody or its antigen-binding fragment, and a virus expressing the SARS-CoV-2 spike protein, sequencing nucleic acids from the cell population to determine a third frequency of SARS-CoV-2 spike protein mutations; and d) comparing the first, second, and third frequencies.

[0050] In some embodiments, the first and second epitopes are selected from the group consisting of a) amino acids 432-452 of SEQ ID NO: 832, b) amino acids 471-486 of SEQ ID NO: 832, and c) amino acids 491-515 of SEQ ID NO: 832.

[0051] In various embodiments, the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment are selected from the antibodies or antigen-binding fragments in Table 1. In some cases, the first antibody The first and second antibodies are selected from two of the following groups: a) mAb10987, mAb10922, mAb10936, and mAb10934; b) mAb10989, mAb10977, and mAb10933; c) mAb10920; d) mAb10954, mAb10986, and mAb10964; and e) mAb10984. In some cases, the first and second antibodies are selected from the group consisting of mAb10987, mAb10934, mAb10989, and mAb10933.

[0052] In various embodiments, any combination of features or components of the embodiments discussed above or herein may be used, and such combinations are included within the scope of this disclosure. Any particular value discussed above or herein may be combined with other relevant values ​​discussed above or herein to enumerate ranges in which those values ​​represent upper and lower limits, and such ranges are included within the scope of this disclosure. [Brief explanation of the drawing]

[0053] [Figure 1] This shows mutant amino acids in viral RNA after incubation with either individual anti-SARS-CoV-2 spike protein antibodies or combinations of anti-SARS-CoV-2 spike protein antibodies. Viral RNA changes are shown from the well with the highest antibody concentration and detectable cytopathic effect (CPE) in passage 1 compared to the input virus. All mutant amino acid residues present at a frequency greater than 10% under the described conditions are indicated by a shaded box. The spike protein residues at positions 444, 445, 450, 453, 484, and 486 are located within the receptor-binding domain. Mutant amino acids under isotype control and virus-only conditions are more likely to represent the tissue culture suitability of the virus. [Figure 2] This shows ELISA blockade data for selected anti-SARS-CoV-2-S antibodies against the SARS-CoV-2 spike protein, which prevents the spike protein from binding to its receptor, ACE2. [Figure 3] This shows ELISA blockade data for selected anti-SARS-CoV-2-S antibodies against the SARS-CoV-2 spike protein, which prevents the spike protein from binding to its receptor, ACE2. [Figure 4] This shows ELISA blockade data for selected anti-SARS-CoV-2-S antibodies against the SARS-CoV-2 spike protein, which prevents the spike protein from binding to its receptor, ACE2. [Figure 5]This shows ELISA blockade data for selected anti-SARS-CoV-2-S antibodies against the SARS-CoV-2 spike protein, which prevents the spike protein from binding to its receptor, ACE2. [Figure 6] This shows ELISA blockade data for selected anti-SARS-CoV-2-S antibodies against the SARS-CoV-2 spike protein, which prevents the spike protein from binding to its receptor, ACE2. [Figure 7] This shows ELISA blockade data for selected anti-SARS-CoV-2-S antibodies against the SARS-CoV-2 spike protein, which prevents the spike protein from binding to its receptor, ACE2. [Figure 8] This shows ELISA blockade data for selected anti-SARS-CoV-2-S antibodies against the SARS-CoV-2 spike protein, which prevents the spike protein from binding to its receptor, ACE2. [Figure 9] This shows ELISA blockade data for selected anti-SARS-CoV-2-S antibodies against the SARS-CoV-2 spike protein, which prevents the spike protein from binding to its receptor, ACE2. [Figure 10A] Figure 10A; N=185) shows the V gene frequencies of the heavy chain (X axis) and light chain (Y axis) of isolated neutralizing antibody pairs against SARS-CoV-2 from VelocImmune® mice and convalescent human donors (Figure 10B; N=68). The color and size of the circles correspond to the number of heavy chain and light chain pairs present in the repertoire of isolated neutralizing antibodies. Neutralization is defined as >70% by diluting the antibody 1:4 (approximately 2 μg / ml) in a VSV pseudoparticle neutralization assay. [Figure 10B]Figure 10A; N=185) shows the V gene frequencies of the heavy chain (X axis) and light chain (Y axis) of isolated neutralizing antibody pairs against SARS-CoV-2 from VelocImmune® mice and convalescent human donors (Figure 10B; N=68). The color and size of the circles correspond to the number of heavy chain and light chain pairs present in the repertoire of isolated neutralizing antibodies. Neutralization is defined as >70% by diluting the antibody 1:4 (approximately 2 μg / ml) in a VSV pseudoparticle neutralization assay. [Figure 11A] Figures 11A-11D show the neutralizing efficacy of anti-SARS-CoV-2 spike mAbs. Serial dilutions of anti-spike mAbs, IgG1 isotype control, and recombinant dimer ACE2 (hACE2.hFc) were added to Vero cells along with pVSV-SARS-CoV-2-S-mNeon, and mNeon expression was measured 24 hours post-infection as a readout of viral infectivity. The data are graphed as neutralization rates compared to a control infected with the virus alone. [Figure 11B] This study demonstrates the neutralizing efficacy of anti-spike mAbs, recombinant dimer ACE2, and IgG1 isotypes against non-replicating pVSV-SARS-CoV-2-S-mNeon in Calu3 cells. [Figure 11C] This study demonstrates the neutralizing efficacy of individual anti-spike mAbs and mAb combinations against VSV-SARS-CoV-2-S virus replication in Vero cells. Cells were infected with the virus's MOI1, and infectivity was measured 24 hours after infection by staining for viral proteins. [Figure 11D] This study demonstrates the neutralizing efficacy of individual antispike mAbs and mAb combinations against SARS-CoV-2-S virus in VeroE6 cells. [Figure 12A] Figures 12A-12C show the effects of cleavage site mutations on neutralization and infectivity. The WT amino acid sequences of the S1 / S2 polynucleotide cleavage sites are underlined. Substitutions incorporated into SARS-CoV-2 S FurMut and FurKO mutants are marked in red. [Figure 12B]These are the four-point neutralization curves for lead antibodies in Vero cells (Log M: -7.48, -8.48, -9.48, and -10.48). [Figure 12C] The infectivity of WT and truncated mutants in Vero and Calu-3 cells at 24 and 48 hours, respectively. The infectivity of the mutants was normalized to the infectivity of the WT virus in each cell type. [Figure 13] This study demonstrates the neutralizing efficacy of antigen-binding fragments (Fab) and full-length antibodies against VSV spike pseudoparticles in Vero cells. [Figure 14] This shows epitope bin analysis from the matrix of various anti-SARS-CoV-2 mAb premix binding assays. Epitope binning was performed for nine anti-SARS-CoV-2 mAbs as described. There were three phases (I, II, and III) for each graph. In phase I, anti-SARS-CoV-2 mAbs (20 ug / ml) were loaded onto anti-human Fc probes. In phase II, human IgG1-blocking mAb solution (100 ug / ml) was used. In phase III, a solution of 100 nM SARS-CoV-2 RBD-MMH premix complex with 600 nM anti-SARS-CoV-2 mAb binding sites flowed over the mAb capture probes. [Figure 15] This displays a 3D surface model of the spike protein RBD domain structure, showing the ACE2 interface and HDX-MS epitope mapping results. RBD residues in contact with ACE2 are shown in yellow (top panel). RBD residues protected by the anti-SARS-CoV-2 spike antibody are shown in a color indicating the degree of protection determined by HDX-MS experiments. The RBD structure is reproduced from PDB6M17. [Figure 16A]Figure 16A shows the complexes of mAb10933 and mAb10987 with SARS-CoV-2 RBD. The 3.9 Å cryoEM map of the mAb10933+RBD+mAb10987 complex, colored according to the chain in the purified model of Figure 16B. The RBD is colored dark blue, the mAb10933 heavy and light chains are green and cyan, respectively, and the mAb10987 heavy and light chains are yellow and red, respectively. [Figure 16B] Figure 16A shows the complexes of mAb10933 and mAb10987 with SARS-CoV-2 RBD. The 3.9 Å cryoEM map of the mAb10933+RBD+mAb10987 complex, colored according to the chain in the purified model of Figure 16B. The RBD is colored dark blue, the mAb10933 heavy and light chains are green and cyan, respectively, and the mAb10987 heavy and light chains are yellow and red, respectively. [Figure 17] The cryoEM data statistics are shown. Data collection and detailed statistics for the mAb10987+mAb10933+SARS-CoV-2 RBD complex structure shown in Figures 16A and 16B are reported. [Figure 18A] A schematic diagram of the VSV-SARS-CoV-2-S viral genome is shown, encoding residues 1-1255 of the spike protein instead of the VSV glycoprotein. N is the nucleoprotein, P is the phosphoprotein, M is the matrix, and L is the large polymerase. [Figure 18B]This shows that a total of 1.5 × 10⁶ pfu of parental VSV-SARS-CoV-2-S virus was passaged in Vero E6 cells for 4 days in the presence of antibody dilutions. Cells were screened for viral replication by monitoring virus-induced cytopathic effects (CPE). Supernatant and cellular RNA were collected from wells under the highest concentration antibody selection with detectable viral replication (circled wells ≥ 20% CPE). For a second selection, 100 μL of P1 supernatant was grown for 4 days under increased antibody selection in fresh Vero E6 cells. RNA was collected from wells at the highest antibody concentration with detectable viral replication. RNA was deep sequenced from both passages to identify escape variants. [Figure 18C] The passaging results of the escape study are shown, along with the percentage of CPE observed in each dilution (red indicates ≥20% CPE, blue indicates <20% CPE). Black boxes indicate dilutions that were passaged and sequenced in P1 or P2. Non-antibody controls were sequenced from each passage to monitor tissue culture suitability. [Figure 19] This study demonstrates that deep sequencing of passaged viruses can identify escape variants. VSV-SARS-CoV-2-S viruses were mixed with either individual or combination anti-spike mAbs. Viral RNA was isolated from wells where cytopathic effects (CPE) were detected at the highest mAb concentration and in passage 1 or 2 (collected 4 days post-infection), and RNA-seq analysis was performed to identify changes in the spike protein sequence relative to the input virus. All mutated amino acid residues within the spike protein are shown. Specific conditions (μg / ml concentration) for the wells selected for sequencing are shown in the left column (see Figure 18B for an overview of the assay design). Red boxes highlight residues mutated relative to the input virus under each condition specified in the left column. The percentage in each box identifies the % of sequencing reads containing the respective variant sequence. Residue mapping to the RBD domain is highlighted in blue. Sample 10989 / 87 was not sequenced from passage 2 due to undetectable CPE in the virus-only control well. [Figure 20] This shows the neutralizing potency of individual anti-spike antibodies and antibody combinations against pseudoparticles encoding individual escape variants. Escape variants identified by RNA-seq analysis within the RDB domain were cloned and expressed on pseudoparticles, and their effect on mAb neutralizing potency was evaluated. Blue-colored boxes highlight conditions in which IC50 decreased by at least 1.5 log compared to wild-type pseudoparticles. A reduction in IC50 of less than 1 log can be seen in mAb combination conditions in which one of the mAbs is ineffective (e.g., K444Q and mAb10933 / mAb10987). NC=IC50 could not be calculated due to insufficient neutralizing ability. [Figure 21] This study demonstrates that the combination of mAb10933 and mAb10987 is sufficient to neutralize VSVs expressing the SARS-CoV-2 UK B.1.1.7 variant spike protein. [Figure 22] This study demonstrates the ability of antibody combinations to reduce the frequency of escapes more effectively than individual antibodies, and shows that certain combinations can reduce escapes more effectively than others. Complete escapes were observed after 2 passages with mAb10933, after 3 passages with mAb10987, and after 1 passage with mAb10985. However, mAb10933 + mAb10987 pushed out complete escapes up to 7 passages, and no escapes were observed even after 11 passages with mAb10933 + mAb10987 + mAb10985. P1 = passage 1, P2 = passage 2, etc. [Figure 23A]Figure 23A shows the neutralization curve, and Figure 23B shows the reduction in the neutralization factor compared to the parent D614G variant. Complete UK B.1.1.7 (H69del, V70del, Y145del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H) and South African B.1.351 (D80Y, D215Y, L241del, L242del, A243del, L242del, K417N, E484K, N501Y, D614G, A701V) variants were evaluated. Major RBD residues from California B.1.429 (L452R) and Brazil P.1 (E484K / K417T) variants were evaluated. The E484K variant has been identified in many global strains, including the New York B.1.526 strain. [Figure 23B] Figure 23A shows the neutralization curve, and Figure 23B shows the reduction in the neutralization factor compared to the parent D614G variant. Complete UK B.1.1.7 (H69del, V70del, Y145del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H) and South African B.1.351 (D80Y, D215Y, L241del, L242del, A243del, L242del, K417N, E484K, N501Y, D614G, A701V) variants were evaluated. Major RBD residues from California B.1.429 (L452R) and Brazil P.1 (E484K / K417T) variants were evaluated. The E484K variant has been identified in many global strains, including the New York B.1.526 strain. [Figure 24A]This shows in vitro escape with individual antibodies and antibody combinations. VSV spike recombinant viruses were passaged under individual antibodies or antibody combinations. In Figure 24A, the passage number at which the virus completely escaped the neutralizing activity of the antibody, as demonstrated by the cytopathic effect (CPE), is indicated as "complete escape" for wells with antibody concentrations above 10 ug / ml and "partial escape" for wells with antibody concentrations between 1 and 10 ug / ml. In Figure 24B, the spike protein mutations identified by RNA-seq analysis of the supernatant from wells with complete escape selected under each antibody condition are listed in the table. The frequency of each mutation from the total viral readout at its amino acid position is listed in the table. Only those mutations present at a frequency of more than 15% are shown, as more minor variants are less likely to contribute to complete escape. *The COV2-2130+COV2-2196 combination was passaged only 3 times and retained its neutralizing potency throughout passage 3. Figure 24C shows the neutralizing potency of individual mAbs with two mAb combinations (REGN10987 + REGN10933) and three mAb combinations (REGN10987 + REGN10933 + REGN10985), and Figure 24D shows two views of the RBD-REGN10933-REGN10987-REGN10985 model. RBDs are colored white, REGN10933 is shown in blue, REGN10987 in red, and REGN10985 in green. The surface shows the white RBD of the contact patch for each antibody colored as in panel A. [Figure 24B]This shows in vitro escape with individual antibodies and antibody combinations. VSV spike recombinant viruses were passaged under individual antibodies or antibody combinations. In Figure 24A, the passage number at which the virus completely escaped the neutralizing activity of the antibody, as demonstrated by the cytopathic effect (CPE), is indicated as "complete escape" for wells with antibody concentrations above 10 ug / ml and "partial escape" for wells with antibody concentrations between 1 and 10 ug / ml. In Figure 24B, the spike protein mutations identified by RNA-seq analysis of the supernatant from wells with complete escape selected under each antibody condition are listed in the table. The frequency of each mutation from the total viral readout at its amino acid position is listed in the table. Only those mutations present at a frequency of more than 15% are shown, as more minor variants are less likely to contribute to complete escape. *The COV2-2130+COV2-2196 combination was passaged only 3 times and retained its neutralizing potency throughout passage 3. Figure 24C shows the neutralizing potency of individual mAbs with two mAb combinations (REGN10987 + REGN10933) and three mAb combinations (REGN10987 + REGN10933 + REGN10985), and Figure 24D shows two views of the RBD-REGN10933-REGN10987-REGN10985 model. RBDs are colored white, REGN10933 is shown in blue, REGN10987 in red, and REGN10985 in green. The surface shows the white RBD of the contact patch for each antibody colored as in panel A. [Figure 24C]This shows in vitro escape with individual antibodies and antibody combinations. VSV spike recombinant viruses were passaged under individual antibodies or antibody combinations. In Figure 24A, the passage number at which the virus completely escaped the neutralizing activity of the antibody, as demonstrated by the cytopathic effect (CPE), is indicated as "complete escape" for wells with antibody concentrations above 10 ug / ml and "partial escape" for wells with antibody concentrations between 1 and 10 ug / ml. In Figure 24B, the spike protein mutations identified by RNA-seq analysis of the supernatant from wells with complete escape selected under each antibody condition are listed in the table. The frequency of each mutation from the total viral readout at its amino acid position is listed in the table. Only those mutations present at a frequency of more than 15% are shown, as more minor variants are less likely to contribute to complete escape. *The COV2-2130+COV2-2196 combination was passaged only 3 times and retained its neutralizing potency throughout passage 3. Figure 24C shows the neutralizing potency of individual mAbs with two mAb combinations (REGN10987 + REGN10933) and three mAb combinations (REGN10987 + REGN10933 + REGN10985), and Figure 24D shows two views of the RBD-REGN10933-REGN10987-REGN10985 model. RBDs are colored white, REGN10933 is shown in blue, REGN10987 in red, and REGN10985 in green. The surface shows the white RBD of the contact patch for each antibody colored as in panel A. [Figure 24D]This shows in vitro escape with individual antibodies and antibody combinations. VSV spike recombinant viruses were passaged under individual antibodies or antibody combinations. In Figure 24A, the passage number at which the virus completely escaped the neutralizing activity of the antibody, as demonstrated by the cytopathic effect (CPE), is indicated as "complete escape" for wells with antibody concentrations above 10 ug / ml and "partial escape" for wells with antibody concentrations between 1 and 10 ug / ml. In Figure 24B, the spike protein mutations identified by RNA-seq analysis of the supernatant from wells with complete escape selected under each antibody condition are listed in the table. The frequency of each mutation from the total viral readout at its amino acid position is listed in the table. Only those mutations present at a frequency of more than 15% are shown, as more minor variants are less likely to contribute to complete escape. *The COV2-2130+COV2-2196 combination was passaged only 3 times and retained its neutralizing potency throughout passage 3. Figure 24C shows the neutralizing potency of individual mAbs with two mAb combinations (REGN10987 + REGN10933) and three mAb combinations (REGN10987 + REGN10933 + REGN10985), and Figure 24D shows two views of the RBD-REGN10933-REGN10987-REGN10985 model. RBDs are colored white, REGN10933 is shown in blue, REGN10987 in red, and REGN10985 in green. The surface shows the white RBD of the contact patch for each antibody colored as in panel A. [Figure 25A]Figure 25A shows the frequency of SARS-CoV-2 spike variants identified in the virus from the lungs of hamsters treated with either REGN10987 or REGN10933 as monotherapy, or with the REGEN-COV combination in both prophylactic and therapeutic settings. Figure 25A is the study design. In Figures 25B and 25C, the graphs show the distribution and frequency of amino acid variants across the entire spike protein sequence identified in samples from (Figure 25B) the prophylactic or (Figure 25C) the therapeutic group. Mutation sites are indicated by gray lines, and dots indicate the frequency of variants in each animal. The spike protein domains are color-coded as shown, and all amino acid changes in the RBD are labeled. [Figure 25B] Figure 25A shows the frequency of SARS-CoV-2 spike variants identified in the virus from the lungs of hamsters treated with either REGN10987 or REGN10933 as monotherapy, or with the REGEN-COV combination in both prophylactic and therapeutic settings. Figure 25A is the study design. In Figures 25B and 25C, the graphs show the distribution and frequency of amino acid variants across the entire spike protein sequence identified in samples from (Figure 25B) the prophylactic or (Figure 25C) the therapeutic group. Mutation sites are indicated by gray lines, and dots indicate the frequency of variants in each animal. The spike protein domains are color-coded as shown, and all amino acid changes in the RBD are labeled. [Figure 25C] Figure 25A shows the frequency of SARS-CoV-2 spike variants identified in the virus from the lungs of hamsters treated with either REGN10987 or REGN10933 as monotherapy, or with the REGEN-COV combination in both prophylactic and therapeutic settings. Figure 25A is the study design. In Figures 25B and 25C, the graphs show the distribution and frequency of amino acid variants across the entire spike protein sequence identified in samples from (Figure 25B) the prophylactic or (Figure 25C) the therapeutic group. Mutation sites are indicated by gray lines, and dots indicate the frequency of variants in each animal. The spike protein domains are color-coded as shown, and all amino acid changes in the RBD are labeled. [Figure 26A] This figure shows variant analysis of viral sequences in SARS-CoV-2 positive samples from hospitalized patients. The graph shows the distribution of amino acid variants across the entire spike protein sequence identified in samples from patients treated with placebo, low-dose REGEN-COV, and high-dose REGEN-COV. Mutation sites are indicated by arrows, and the length of the arrow indicates the number of patients whose samples contain one or more variants. The spike protein domains are color-coded as shown, and all amino acid changes in the RBD are labeled. In Figure 26A, arrows highlight variants identified in one or more samples from at least one patient. In Figure 26B, arrows highlight variants identified in two or more samples from at least one patient. [Figure 26B] This figure shows variant analysis of viral sequences in SARS-CoV-2 positive samples from hospitalized patients. The graph shows the distribution of amino acid variants across the entire spike protein sequence identified in samples from patients treated with placebo, low-dose REGEN-COV, and high-dose REGEN-COV. Mutation sites are indicated by arrows, and the length of the arrow indicates the number of patients whose samples contain one or more variants. The spike protein domains are color-coded as shown, and all amino acid changes in the RBD are labeled. In Figure 26A, arrows highlight variants identified in one or more samples from at least one patient. In Figure 26B, arrows highlight variants identified in two or more samples from at least one patient. [Figure 27A] This figure shows the viral load and variant frequencies over time in SARS-CoV-2 positive samples treated with REGN-COV2 from hospitalized patients. Viral load was determined by quantitative RT-PCR. The variant frequencies of N501T in Figure 27A and K537R in Figure 27B are shown by black lines as the percentage of reads containing nSNPs relative to the total number of reads covered. The histograms show the read coverage of total (blue) and variant (magenta) reads at variant locations. [Figure 27B]This figure shows the viral load and variant frequencies over time in SARS-CoV-2 positive samples treated with REGN-COV2 from hospitalized patients. Viral load was determined by quantitative RT-PCR. The variant frequencies of N501T in Figure 27A and K537R in Figure 27B are shown by black lines as the percentage of reads containing nSNPs relative to the total number of reads covered. The histograms show the read coverage of total (blue) and variant (magenta) reads at variant locations. [Figure 28A] This is a variant analysis of viral sequences in SARS-CoV-2 positive samples from non-hospitalized patients. The graph shows the distribution of amino acid variants across the entire spike protein sequence identified in samples from patients treated with placebo, low-dose REGEN-COV, and high-dose REGEN-COV. Mutation sites are indicated by arrows, and the length of the arrow indicates the number of patients whose samples contain one or more variants. The spike protein domains are color-coded as shown, and all amino acid changes in the RBD are labeled. In Figure 28A, arrows highlight variants identified in one or more samples from at least one patient. In Figure 28B, arrows highlight variants identified in two or more samples from at least one patient. [Figure 28B] This is a variant analysis of viral sequences in SARS-CoV-2 positive samples from non-hospitalized patients. The graph shows the distribution of amino acid variants across the entire spike protein sequence identified in samples from patients treated with placebo, low-dose REGEN-COV, and high-dose REGEN-COV. Mutation sites are indicated by arrows, and the length of the arrow indicates the number of patients whose samples contain one or more variants. The spike protein domains are color-coded as shown, and all amino acid changes in the RBD are labeled. In Figure 28A, arrows highlight variants identified in one or more samples from at least one patient. In Figure 28B, arrows highlight variants identified in two or more samples from at least one patient. [Figure 29A]This shows the viral load and variant frequency over time in SARS-CoV-2 positive samples from non-hospitalized patients. Viral load was determined by quantitative RT-PCR. The variant frequencies of S494P in Figure 29A and G446V in Figure 29B are shown by black lines as the percentage of reads containing nSNPs relative to the total number of reads covered. The histograms show the read coverage for sum (blue) and variant (magenta) at variant locations. [Figure 29B-1] This shows the viral load and variant frequency over time in SARS-CoV-2 positive samples from non-hospitalized patients. Viral load was determined by quantitative RT-PCR. The variant frequencies of S494P in Figure 29A and G446V in Figure 29B are shown by black lines as the percentage of reads containing nSNPs relative to the total number of reads covered. The histograms show the read coverage for sum (blue) and variant (magenta) at variant locations. [Figure 29B-2] This shows the viral load and variant frequency over time in SARS-CoV-2 positive samples from non-hospitalized patients. Viral load was determined by quantitative RT-PCR. The variant frequencies of S494P in Figure 29A and G446V in Figure 29B are shown by black lines as the percentage of reads containing nSNPs relative to the total number of reads covered. The histograms show the read coverage for sum (blue) and variant (magenta) at variant locations. [Figure 30] The statistics for sequencing data for each clinical group from two clinical studies (Study 2066 and Study 2067) are shown. The table shown in the figure includes patients, samples, and amino acid change counts for each study. [Figure 31A] This graph shows the viral load and frequency over time of S477N in SARS-CoV-2 positive samples from hospitalized patients. Viral load was determined by quantitative RT-PCR. Variant frequency is shown by the black line as the percentage of reads containing nSNPs relative to the total number of reads covered. The histogram shows the coverage of total (blue) and variant (magenta) reads at variant locations. [Figure 31B]This graph shows the viral load and frequency over time of S477N in SARS-CoV-2 positive samples from hospitalized patients. Viral load was determined by quantitative RT-PCR. Variant frequency is shown by the black line as the percentage of reads containing nSNPs relative to the total number of reads covered. The histogram shows the coverage of total (blue) and variant (magenta) reads at variant locations. [Figure 32A] This graph shows the viral load and frequency over time of S477N in SARS-CoV-2 positive samples from non-hospitalized patients. Viral load was determined by quantitative RT-PCR. Variant frequency is shown by the black line as the percentage of reads containing nSNPs relative to the total number of reads covered. The histogram shows the read coverage of sum (blue) and variant (magenta) at variant locations. [Figure 32B] This graph shows the viral load and frequency over time of S477N in SARS-CoV-2 positive samples from non-hospitalized patients. Viral load was determined by quantitative RT-PCR. Variant frequency is shown by the black line as the percentage of reads containing nSNPs relative to the total number of reads covered. The histogram shows the read coverage of sum (blue) and variant (magenta) at variant locations. [Figure 33A] The neutralization curve and the decrease in neutralization ratio compared to the parent D614G variant are shown. The G446V, S477N, N501Y, S494P, and K537R variants were evaluated. The N501Y variant was used to replace N501T. [Figure 33B] The neutralization curve and the decrease in neutralization ratio compared to the parent D614G variant are shown. The G446V, S477N, N501Y, S494P, and K537R variants were evaluated. The N501Y variant was used to replace N501T. [Figure 34]This report shows the relative neutralizing efficacy of REGEN-COV combinations and individual antibodies against spike protein variants identified in hamster lungs. For each variant identified through RNA-seq analysis of hamster lung RNA, the decrease in neutralizing efficacy against the parent virus is shown. Where neutralizing efficacy was not available for the exact variant identified in infected hamsters (N / A), data for a surrogate variant at the same location is shown. [Modes for carrying out the invention]

[0054] Before describing the methods of the present invention, it should be understood that the present invention is not limited to such methods and conditions, as the specific methods and experimental conditions described may vary. It should also be understood that the terms used herein are for the purpose of describing only specific embodiments and are not intended to limit the scope of the present invention, as it is limited only by the appended claims.

[0055] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention pertains. Any methods and materials similar to or equivalent to those described herein may be used in carrying out or testing the present invention, but preferred methods and materials are described herein. All publications referenced herein are incorporated herein by reference in their entirety.

[0056] The terms "coronavirus" or "CoV" refer to any virus in the coronavirus family, including but not limited to SARS-CoV-2, MERS-CoV, and SARS-CoV. SARS-CoV-2 refers to a newly emerging coronavirus that was identified as the cause of a serious outbreak that originated in Wuhan, China, and is rapidly spreading to other parts of the world. SARS-CoV-2 is also known as 2019-nCoV and Wuhan coronavirus. It binds to the human host cell receptor angiotensin-converting enzyme 2 (ACE2) via a viral spike protein. The spike protein also binds to TMPRSS2, which activates the spike protein for viral membrane fusion, thereby It will be cut off.

[0057] The term "CoV-S," also called "S" or "S protein," refers to the coronavirus spike protein and can refer to specific S proteins such as SARS-CoV-2-S, MERS-CoV-S, and SARS-CoV-S. The SARS-CoV-2 spike protein is a 1273-amino acid type I membrane glycoprotein that assembles into trimers that form a spike or peplomer on the surface of the enclosed coronavirus particle. This protein has two important functions: host receptor binding and membrane fusion, which are attributed to the N-terminal (S1) and C-terminal (S2) halves of the S protein. CoV-S binds to its homologous receptors via a receptor-binding domain (RBD) present in the S1 subunit. The amino acid sequence of the full-length SARS-CoV-2 spike protein is exemplified by the amino acid sequence provided in Sequence ID No. 832. The term "CoV-S" includes protein variants of CoV spike proteins isolated from different CoV isolates, as well as recombinant CoV spike proteins or fragments thereof. This term also encompasses CoV spike proteins or fragments thereof linked to signal sequences such as histidine tags, mouse or human Fc, or ROR1.

[0058] As used herein, the terms “coronavirus infection” or “CoV infection” refer to infection caused by coronaviruses such as SARS-CoV-2, MERS-CoV, or SARS-CoV. This term includes coronavirus respiratory infections, which most often affect the lower respiratory tract. Symptoms may include high fever, dry cough, shortness of breath, pneumonia, gastrointestinal symptoms such as diarrhea, organ failure (renal failure and renal dysfunction), septic shock, and, in severe cases, death.

[0059] virus The present invention includes methods for treating or preventing viral infection in a subject. The term “virus” includes any virus (e.g., a virus whose infectivity is at least partially dependent on CoV-S) whose infection in the subject's body is treatable or preventable by administration of an anti-CoV-S antibody or its antigen-binding fragment. In one embodiment of the present invention, “virus” is any virus that expresses a spike protein (e.g., CoV-S). The term “virus” also includes CoV-S-dependent respiratory viruses, which are viruses that infect the respiratory tissues of a subject (e.g., the upper and / or lower respiratory tract, trachea, bronchi, lungs) and are treatable or preventable by administration of an anti-CoV-S antibody or its antigen-binding fragment. For example, in one embodiment of the present invention, the virus includes coronaviruses, SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus), and MERS-CoV (Middle East Respiratory Syndrome (MERS) Coronavirus). Coronaviruses may include the genera alpha-coronavirus, beta-coronavirus, gamma-coronavirus, and delta-coronavirus. In some embodiments, the antibodies or antigen-binding fragments provided herein can bind to and / or neutralize alpha-coronaviruses, beta-coronaviruses, gamma-coronaviruses, and / or delta-coronaviruses. In certain embodiments, this binding and / or neutralization may be specific to a particular genus of coronavirus or a particular subgroup of a genus. "Viral infection" refers to the entry and replication of a virus into the body of a subject.

[0060] Coronavirus virions are spherical, with a diameter of approximately 125 nm. The most striking feature of coronaviruses is the club-shaped spike protrusions emanating from the surface of the virion. These spikes characterize the virion, giving it the appearance of the solar corona and prompting the name coronavirus. Within the envelope of the virion is the nucleocapsid. Coronaviruses have a helically symmetrical nucleocapsid, which is uncommon in positive-sense RNA viruses but far more common in negative-sense RNA viruses. SARS-CoV-2, MERS-CoV, and SARS-CoV are coronaviruses. It belongs to the virus family. The initial attachment of a virion to a host cell is initiated by the interaction between the S protein and its receptor. The location of the receptor-binding domain (RBD) within the S1 region of the coronavirus S protein varies among viruses, with some having the RBD at the C-terminus of S1. The S protein / receptor interaction is a major determinant for coronavirus infection of a host species and also governs the virus's histotropy. Many coronaviruses utilize peptidases as cell receptors. Following receptor binding, the virus must then access the cytosol of the host cell. This is generally achieved by acid-dependent proteolytic cleavage of the S protein by cathepsin, TMPRRS2, or another protease, followed by fusion of the viral membrane with the cell membrane.

[0061] Anti-CoV-S antibodies and antigen-binding fragments The present invention provides antigen-binding proteins such as antibodies that specifically bind to CoV spike proteins or their antigenic fragments, and antigen-binding fragments thereof.

[0062] As used herein, the term "antibody" refers to immunoglobulin molecules (i.e., "intact antibody molecules") comprising four polypeptide chains, two heavy chains (HC) and two light chains (LC) interconnected by disulfide bonds, as well as multimers thereof (e.g., IgM). Exemplary antibodies include, for example, those listed in Table 1. Each heavy chain comprises a heavy chain variable region ("HCVR" or "V H ") and a heavy chain constant region (C H 1 domain, C H 2 domain, and C H 3 domain). Each light chain comprises a light chain variable region ("LCVR, light chain variable region" or "V L ") and a light chain constant regio n (C L ). V H region and V L region can be further subdivided into hypervariable regions called complementarity determining regions (CDRs) interspersed with more conserved regions called framework regions (FR). Each V H and V LThis includes three CDRs and four FRs arranged from the amino terminus to the carboxyl terminus in the order FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The heavy chain CDRs are sometimes called HCDRs or CDR-H and are numbered as above (e.g., HCDR1, HCDR2, and HCDR3 or CDR-H1, CDR-H2, and CDR-H3). Similarly, the light chain CDRs are called LCDRs or CDR-L and are numbered LCDR1, LCDR2, and LCDR3 or CDR-L1, CDR-L2, and CDR-L3. In certain embodiments of the present invention, the FRs of the antibody (or its antigen-binding fragment) are identical to human germline sequences or are naturally or artificially modified. Exemplary human germline sequences include, but are not limited to, VH3-66 and Vk1-33. Accordingly, this disclosure provides an anti-CoV-S antibody or its antigen-binding fragment (e.g., an anti-SARS-CoV-2-S antibody or its antigen-binding fragment) containing the HCDR and LCDR sequences of Table 1 within the VH3-66 or Vk1-33 variable heavy chain region. Monoclonal antibodies as used herein can be designated by numbering after "mAb" (e.g., mAb10933) or by numbering after "REGN" (e.g., REGN10933). It should be understood that "mAb" and "REGN" are interchangeable (e.g., mAb10933 is the same antibody as REGN10933).

[0063] Typically, the variable domains of both the heavy and light chains of immunoglobulins contain three hypervariable regions, also called complementarity-determining regions (CDRs), located within a relatively conserved framework region (FR). Generally, from the N-terminus to the C-terminus, the variable domains of both the light and heavy chains include FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. In one embodiment of the present invention, the amino acid assignment to each domain is: Sequences of Proteins of Immunological Interest,Kabat,et al.;National Institutes of Health,Bethesda,Md.;5 thed.; NIH Publication No. 91-3242 (1991) ;Follow the definitions of Kabat (1978) Adv. Prot. Chem. 32:1-75, Kabat, et al., (1977) J. Biol. Chem. 252:6609-6616, Chothia, et al., (1987) J Mol. Biol. 196:901-917, or Chothia, et al., (1989) Nature 342:878-883.

[0064] The present invention comprises monoclonal anti-CoV-S antigen-binding proteins, such as antibodies and their antigen-binding fragments, and monoclonal compositions comprising a plurality of isolated monoclonal antigen-binding proteins. As used herein, the term “monoclonal antibody” refers to a substantially homogeneous population of antibodies, i.e., the antibody molecules constituting the population have identical amino acid sequences, except for possible spontaneous mutations that may be present in small amounts. “Pluried” such monoclonal antibodies and fragments in a composition refer to concentrations of identical antibodies and fragments (i.e., except for possible spontaneous mutations in the amino acid sequence that may be present in small amounts, as discussed above) that are higher than those that normally occur in nature, for example, in the blood of a host organism such as a mouse or a human.

[0065] In embodiments of the present invention, the anti-CoV-S antigen-binding protein, for example, an antibody or antigen-binding fragment, includes, for example, an IgA type (e.g., IgA1 or IgA2), an IgD type, an IgE type, an IgG type (e.g., IgG1, IgG2, IgG3, and IgG4), or an IgM type heavy chain constant domain. In embodiments of the present invention, the antigen-binding protein, for example, an antibody or antigen-binding fragment, includes, for example, a kappa type or a lambda type light chain constant domain.

[0066] As used herein, the term “human” antigen-binding protein, such as an antibody, includes antibodies having variable and constant regions derived from human germline immunoglobulin sequences, whether transplanted in human cells or into non-human cells, such as mouse cells. See, for example, U.S. Patent No. 8502018, No. 6596541, or No. 5789215. The human mAbs of the present invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-directed mutagenesis in vitro, or by somatic mutation in vivo), such as in CDR, particularly CDR3. However, as used herein, the term “human antibody” is not intended to include mAbs in which a CDR sequence derived from the germline of another mammalian species (e.g., mouse) is transplanted onto a human FR sequence. The term includes antibodies recombinantly produced in or in non-human mammals or in cells of non-human mammals. The term is not intended to include antibodies isolated from or produced in human subjects. See below.

[0067] The present invention includes anti-CoV-S chimeric antigen-binding proteins, such as antibodies and their antigen-binding fragments, and methods of using them. As used herein, “chimeric antibody” is an antibody having a variable domain from a primary antibody and a constant domain from a secondary antibody, wherein the primary and secondary antibodies are derived from different species. (U.S. Patent No. 4,816,567; and Morrison et al., (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855).

[0068] The term “recombinant” antigen-binding protein, such as an antibody or its antigen-binding fragment, refers to such molecules created, expressed, isolated, or obtained by techniques or methods known in the art, such as recombinant DNA technologies including DNA splicing and transgenic expression. This term includes antibodies expressed in non-human mammals (including transgenic non-human mammals, e.g., transgenic mice) or cell (e.g., CHO cells) expression systems, or antibodies isolated from recombinant combinatorial human antibody libraries. In some embodiments, recombinant antibodies are isolated from organisms (e.g., mice or humans). These antibodies share sequences with the antibodies that have been expressed via recombinant DNA technology. Such antibodies may have different post-translational modifications (e.g., glycosylation) than antibodies isolated from living organisms.

[0069] In some embodiments, the antibodies disclosed herein lack fucose in the glycosylation of their constant region. Methods for measuring fucose in antibody compositions are described in the Art, for example, in U.S. Patent No. 8,409,838 (Regeneron Pharmaceuticals), incorporated herein by reference. In some embodiments, fucose is undetectable in compositions comprising a population of antibody molecules. In some embodiments, the fucose-lacking antibodies have enhanced ADCC activity.

[0070] In some embodiments, fucose-deficient antibodies can be produced using cell lines that lack the ability to fucosylate proteins, i.e., have reduced or eliminated protein fucosylation capabilities. Glycan fucosylation requires the synthesis of GDP-fucose via either a de novo or salvage pathway, both involving the sequential functioning of multiple enzymes, leading to the addition of a fucose molecule to the first N-acetylglucosamine (GlcNAc) moiety at the reducing end of the glycan. Two key enzymes in the de novo pathway involved in GDP-fucose production are GDP-D-mannose-4,6-dehydratase (GMD) and GDP-keto-6-deoxymannose-3,5-epimerase,4-reductase (FX). In the absence of fucose, these two de novo pathway enzymes (GMD and FX) convert mannose and / or glucose to GDP-fucose, which is then transported to the Golgi complex, where nine fucosyltransferases (FUT1-9) work in coordination to fucosylate the first GlcNAc molecule of the glycan. However, in the presence of fucose, salvage pathway enzymes, fucose kinases, and GDP-fucose pyrophosphorylas convert fucose to GDP-fucose.

[0071] Cell lines lacking their ability to handle fucosilate proteins have been described in the art. In some embodiments, the cell lines lacking their ability to handle fucosilate proteins are mammalian cell lines (e.g., CHO cell lines such as CHO K1, DXB-11 CHO, and Veggie-CHO) that include mutations or gene modifications in one or more endogenous FUT1-9 genes resulting in the deletion of one or more functional fucosyltransferases. In some embodiments, the mammalian cell lines include mutations in the endogenous FUT8 gene (e.g., FUT8 knockout cell lines in which the FUT8 gene is disrupted, resulting in the deletion of functional α1,6-fucosyltransferase in the cell line, as described in, for example, U.S. Patent No. 7,214,775 (Kyowa Hakko Kogyo Co., Ltd.) and U.S. Patent No. 7,737,725 (Kyowa Hakko Kirin Co., Ltd.)), which are incorporated herein by reference. In some embodiments, the mammalian cell line includes a mutation or gene modification in the endogenous GMD gene, for example, as described in U.S. Patent No. 7,737,725 (Kyowa Hakko Kirin Co., Ltd), which results in a loss of functional GMD in the GMD knockout cell line. In some embodiments, the mammalian cell line includes a mutation or gene modification in the endogenous Fx gene, which results in a loss of functional Fx protein. In some embodiments, the mammalian cell line is an Fx knockout cell line in which the endogenous Fx gene is disrupted (see, for example, U.S. Patent No. 7,737,725 (Kyowa Hakko Kirin Co., Ltd), which is incorporated herein by reference). In some embodiments, the mammalian cell line includes a mutation in the endogenous Fx mutation that confers a temperature-sensitive phenotype (see, for example, U.S. Patent No. 8,409,838 (Regeneron Pharmaceuticals), which is incorporated herein by reference). In some embodiments, mammals lack their ability to handle fucosilate proteins. A cellular cell line is a cell line selected based on its resistance to a specific lectin, such as Lens culinaris lectin. See, for example, U.S. Patent No. 8,409,838 (Regeneron Pharmaceuticals), which is incorporated herein by reference.

[0072] The recombinant anti-CoV-S antigen-binding proteins disclosed herein, such as antibodies and antigen-binding fragments, can also be generated in an E. coli / T7 expression system. In this embodiment, the nucleic acids encoding the anti-CoV-S antibody immunoglobulin molecules of the present invention (e.g., found in Table 1) can be inserted into a pET-based plasmid and expressed in an E. coli / T7 system. For example, the present invention includes a method for expressing an antibody or its antigen-binding fragment or its immunoglobulin chain in a host cell (e.g., a bacterial host cell such as E. coli, such as BL21 or BL21DE3), which includes expressing T7 RNA polymerase in a cell that also contains a polynucleotide encoding an immunoglobulin chain operably linked to a T7 promoter. For example, in an embodiment of the present invention, a bacterial host cell such as E. coli contains a polynucleotide encoding a T7 RNA polymerase gene operably linked to a lac promoter, and the expression of the polymerase and chain is induced by incubation of the host cell with IPTG (isopropyl-beta-D-thiogalactopyranoside). U.S. Patent No. 4,952,496 and No. 5,693,489, or Studier & Moffatt, Use of bacteriophage See T7 RNA polymerase to direct selective high-level expression of cloned genes, J.Mol.Biol.1986 May 5189(1):113-30.

[0073] There are several known methods for generating recombinant antibodies in the art. One example of a method for generating recombinant antibodies is disclosed in U.S. Patent No. 4,816,567.

[0074] Transformation may be by any known method for introducing polynucleotides (e.g., including DNA or RNA, mRNA) into host cells. Methods for introducing heterologous polynucleotides into mammalian cells are well known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene-mediated transfection, protoplast fusion, electroporation, encapsulation of polynucleotides (maybe more than one) into liposomes, lipid nanoparticle technology, microparticle gun injection, and direct microinjection of DNA into the nucleus. In addition, nucleic acid molecules may be introduced into mammalian cells by viral vectors such as lentiviruses or adeno-associated viruses. Methods for transforming cells are well known in the art. See, for example, U.S. Patents 4,399,216, 4,912,040, 4,740,461, and 4,959,455. In some embodiments, the antibodies or antigen-binding fragments of the present disclosure may be introduced into a target in nucleic acid form (e.g., including DNA or RNA, mRNA) so that the target's own cells produce antibodies. This disclosure further provides modifications to the nucleotide sequences encoding the anti-CoV-S antibodies described herein, resulting in increased antibody expression against the CoV spike protein, increased antibody stability, increased nucleic acid (e.g., mRNA) stability, or improved antibody affinity or specificity.

[0075] Accordingly, the present invention relates to a recombinant method for producing an anti-CoV-S antigen-binding protein such as the antibody or its antigen-binding fragment or its immunoglobulin chain, comprising: (i) introducing an antigen-binding protein, for example, the light and / or heavy chain of an immunoglobulin in Table 1, or one or more polynucleotides encoding a CDR (for example, including one or more nucleotide sequences from any of the sequences in Table 2) (the polynucleotide is in a vector and / or integrated into a host cell chromosome and / or operably linked to a promoter); and (ii) a host cell (for example, C) under conditions favorable for the expression of the polynucleotide. The recombinant method comprises (iii) culturing HO (or Pichia or Pichia pastoris), and (iii) optionally isolating an antigen-binding protein (e.g., an antibody or fragment) or chain from the host cell and / or the culture medium in which the host cell grows. For example, polynucleotides can be incorporated into host cell chromosomes by cutting the chromosome using a gene editing system (e.g., CRISPR (e.g., CRISPR-Cas9), TALEN, megaTAL, zinc finger, or Argonaute) and then inserting a vector such as adeno-associated virus (AAV) as a target. Targeted insertions can occur at host cell loci, such as albumin or immunoglobulin genomic loci. Alternatively, insertions can be made at random loci using a vector such as a lentivirus. When producing antigen-binding proteins (e.g., antibodies or antigen-binding fragments) containing more than one immunoglobulin chain, such as an antibody containing two immunoglobulin heavy chains and two immunoglobulin light chains, co-expression of the chains in a single host cell results in the association of the chains intracellularly, on the cell surface, or extracellularly when such chains are secreted to form an antigen-binding protein (e.g., an antibody or antigen-binding fragment). This method includes the expression of either only immunoglobulin heavy chains or only immunoglobulin light chains (e.g., any of those discussed herein, including mature fragments and / or their variable domains). Such chains are useful, for example, as intermediates in the expression of antibodies or antigen-binding fragments containing such chains. For example, the present invention also includes an anti-CoV-S antigen-binding protein such as an antibody and its antigen-binding fragment, comprising a heavy chain immunoglobulin (or its variable domain or its CDR) encoded by a polynucleotide comprising the nucleotide sequence described in Table 2, and a light chain immunoglobulin (or its variable domain or its CDR) (which is a product of such a production method), and optionally, a purification method described herein.For example, in some embodiments, the product of this method is an anti-CoV-S antigen-binding protein which is an antibody or fragment comprising an HCVR comprising the amino acid sequence described in Table 1 and an LCVR comprising the amino acid sequence described in Table 1, the HCVR and LCVR sequences being selected from a single antibody listed in Table 1. In some embodiments, the product of this method is an anti-CoV-S antigen-binding protein which is an antibody or fragment comprising HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences described in Table 1 and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences described in Table 1, the six CDR sequences being selected from a single antibody listed in Table 1. In some embodiments, the product of this method is an anti-CoV-S antigen-binding protein which is an antibody or fragment comprising a heavy chain comprising the HC amino acid sequence described in Table 1 and a light chain comprising the LC amino acid sequence described in Table 1.

[0076] Eukaryotic and prokaryotic host cells, including mammalian cells, can be used as hosts for the expression of anti-CoV-S antigen-binding proteins. Such host cells are well known in the art and many can be obtained from the American Type Culture Collection (ATCC). These host cells include, among others, Chinese hamster ovary (CHO) cells, NS0, SP2 cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), A549 cells, 3T3 cells, HEK-293 cells, and several other cell lines. Mammalian host cells include human, mouse, rat, dog, monkey, pig, goat, cattle, horse, and hamster cells. Other cell lines that can be used are insect cell lines (e.g., Spodoptera frugiperda or Trichoplusia ni), amphibian cells, bacterial cells, plant cells, and fungal cells. Fungal cells include yeast and filamentous fungal cells, such as Pichia pastoris, Pichia finlandica, Pichia trehalophila, Pichia koclamae, Pichia membranaefaciens, Pichia minuta (Ogataea minuta, Pichia lindneri), Pichia opuntiae, Pichia thermotolerans, and Pichia This includes salictaria, Pichia guercuum, Pichia pijperi, Pichia stiptis, Pichia methanolica, Pichias sp., Saccharomyces cerevisiae, Saccharomyces sp., Hansenula polymorpha, Kluyveromyces sp., Kluyveromyces lactis, Candida albicans, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Trichoderma reesei, Chrysosporium lucknowense, Fusarium sp., Fusarium gramineum, Fusarium venenatum, Physcomitrella patens, and Neurospora crassa. The present invention comprises isolated host cells (e.g., CHO cells) containing antigen-binding proteins such as those listed in Table 1, or polynucleotides encoding such polypeptides.

[0077] The term "specifically binds" refers to K when measured by real-time label-free biolayer interferometry assays, e.g., at 25°C or 37°C, e.g., by an Octet® HTX biosensor, or by surface plasmon resonance, e.g., by BIACORE®, or by solubility ELISA. D The binding affinity to antigens such as the CoV-S protein (e.g., SARS-CoV-2-S), which is represented as such, is at least about 10. -8 This refers to those antigen-binding proteins (e.g., mAbs) that are M. The present invention includes antigen-binding proteins that specifically bind to the CoV-S protein.

[0078] As used herein, the terms “antigen-binding portion” or “antigen-binding fragment” of an antibody, or “antigen-binding protein,” and similar terms include any spontaneously occurring, enzymatically available, synthetic, or genetically engineered polypeptides or glycoproteins that specifically bind to an antigen to form a complex. Non-limiting examples of antigen-binding fragments include: (i) Fab fragments, (ii) F(ab')2 fragments, (iii) Fd fragments, (iv) Fv fragments, (v) single-chain Fv(scFv) molecules, (vi) dAb fragments, and (vii) the hypervariable region of an antibody (e.g., an isolated complementarity-determining region (CDR) such as the CDR3 peptide), or the smallest recognition unit consisting of amino acid residues that mimic a constrained FR3-CDR3-FR4 peptide. Domain-specific antibodies, single-domain antibodies, domain deletion antibodies, chimeric antibodies, CDR-transplanted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (as defined, for example, in International Publication No. 08 / 020079 or International Publication No. 09 / 138519) (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunoassays (SMIPs), and other manipulated molecules such as shark variable IgNAR domains are also included within the expression “antigen-binding fragment” as used herein. In one embodiment of the present invention, the antigen-binding fragment comprises three or more CDRs of the antibody listed in Table 1 (e.g., CDR-H1, CDR-H2, and CDR-H3, or CDR-L1, CDR-L2, and CDR-L3).

[0079] In embodiments of the present invention, the antigen-binding fragment of the antibody comprises at least one variable domain. The variable domain may be of any size or an amino acid composition and generally comprises at least one CDR that is adjacent to or in-frame with one or more framework sequences. H Domain is V L In antigen-binding fragments associated with the domain, V H Domain and V L The domains may be positioned relative to each other in any preferred arrangement. For example, the variable region is a dimer, V H -V H , V H -VL or V L -V L It may contain dimers. Alternatively, the antigen-binding fragment of the antibody may be a monomer V. H Domain or V L You may include a domain name.

[0080] In certain embodiments, the antigen-binding fragment of the antibody is covalently bound to at least one constant domain. It may include at least one combined variable domain. Non-limiting exemplary configurations of variable and constant domains that may be found within the antigen-binding fragment of the antibody of the present invention include: (i)V H -C H 1. (ii)V H -C H 2, (iii)V H -C H 3, (iv)V H -C H 1-C H 2. (v)V H -C H 1-C H 2-C H 3. (vi)V H -C H 2-C H 3. (vii)V H -C L (viii)V L -C H 1. (ix)V L -C H 2, (x)V L -C H 3. (xi)V L -C H 1-C H 2. (xii)V L -C H 1-C H 2-C H 3. (xiii)V L -C H 2-C H 3, and (xiv)V L -C LIn any configuration of the variable domain and the constant domain, including any of the exemplary configurations listed above, the variable domain and the constant domain may be directly linked to each other or linked by a complete or partial hinge region or linker region. The hinge region may consist of at least two (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids that result in flexible or semi-flexible linkage between adjacent variable domains and / or constant domains in a single polypeptide molecule. Furthermore, the antigen-binding fragment of the antibody of the present invention may be linked to each other and / or one or more monomers V H Or V L In non-covalent bonds with domains (for example, via disulfide bonds), the domain may contain a homodimer or heterodimer (or other polymer) among the variable domain configurations and constant domain configurations listed above.

[0081] Antigen-binding proteins (e.g., antibodies and antigen-binding fragments) can be monospecific or multispecific (e.g., bispecific). Multispecific antigen-binding proteins are discussed further herein.

[0082] In certain embodiments, the antibody or antibody fragment of the present invention may be conjugated to a portion such as a ligand, or to a therapeutic portion such as an antiviral drug, a second anti-influenza antibody, or any other therapeutic portion useful for treating a viral infection, such as influenza virus infection ("immunoconjugate"). See below.

[0083] The present invention also provides a complex comprising an anti-CoV-S antigen-binding protein, e.g., an antibody or antigen-binding fragment, as discussed herein, conjugated with an anti-CoV-S polypeptide or its antigenic fragment and / or an anti-CoV-S antibody or a secondary antibody or its antigen-binding fragment that specifically binds to the anti-CoV-S antibody or fragment (e.g., a detectably labeled secondary antibody). In embodiments of the present invention, the antibody or fragment is either in vitro (e.g., immobilized on a solid substrate) or present in the body of the subject. In embodiments of the present invention, CoV-S is either in vitro (e.g., immobilized on a solid substrate), on the surface of the virus, or present in the body of the subject. Immobilized anti-CoV-S antibodies and their antigen-binding fragments covalently bound to an insoluble matrix material (e.g., glass or polysaccharides such as agarose or Sepharose, e.g., beads or other particles) are also part of the present invention, wherein the immobilized antibody optionally conjugates with CoV-S or its antigenic fragment, or with a secondary antibody or its fragment.

[0084] "Isolated" antigen-binding proteins, antibodies or their antigen-binding fragments, polypeptides, polynucleotides, and vectors do not contain, at least partially, other biological molecules from the cells or cell cultures from which they are produced. Such biological molecules include nucleic acids, proteins, other antibodies or antigen-binding fragments, lipids, carbohydrates, or other materials such as cell debris and growth media. Isolated antibodies or antigen-binding fragments may also not contain, at least partially, expression system components such as biological molecules from host cells or their growth media. In general, the term "isolated" is not intended to refer to the complete absence of such biological molecules, or the absence of water, buffers, or salts, or components of a pharmaceutical formulation containing antibodies or fragments.

[0085] The term "epitope" refers to an antigenic determinant (e.g., a CoV-S polypeptide) that interacts with a specific antigen-binding site on an antigen-binding protein, such as a variable region of an antibody molecule known as a paratope. A single antigen may have two or more epitopes. Therefore, different antibodies may bind to different regions on an antigen and have different biological effects. The term "epitope" also refers to the site on an antigen to which B cells and / or T cells respond. This term also refers to the region of the antigen to which an antibody binds. Epitopes can be defined as structural or functional. Functional epitopes are generally a subset of structural epitopes and have residues that directly contribute to the affinity of the interaction. Epitopes may be linear or three-dimensional, i.e., they may consist of non-linear amino acids. In certain embodiments, epitopes may include determinants, which are chemically active surface groups of molecules such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and in certain embodiments, they may have specific three-dimensional structural features and / or specific charge features.

[0086] Methods for determining the epitopes of antigen-binding proteins, such as antibodies, fragments, or polypeptides, include alanine scanning mutagenesis, peptide blot analysis (Reineke (2004) Methods Mol. Biol. 248:443-63), peptide cleavage analysis, crystallographic studies, and NMR analysis. In addition, methods such as epitope excision, epitope extraction, and chemical modification of antigens can be used (Tomer (2000) Prot. Sci 9:487-496). Another method (e.g., coversin) that can be used to identify amino acids within polypeptides that interact with antigen-binding proteins (e.g., antibodies, fragments, or polypeptides) is hydrogen / deuterium exchange detected by mass spectrometry. Generally speaking, hydrogen / deuterium exchange methods involve deuterizing the protein of interest and then conjugating the antigen-binding protein, such as antibodies, fragments, or polypeptides, to the deuterium-labeled protein. Next, the CoV-S protein / antigen-binding protein complex is transferred to water. The exchangeable protons within the amino acids protected by the antibody complex undergo a slower deuterium-to-hydrogen reverse exchange than the exchangeable protons within amino acids that are not part of the interface. As a result, the amino acids that form part of the protein / antigen-binding protein interface can retain deuterium and therefore exhibit a relatively larger mass compared to amino acids not included in the interface. After dissociation of the antigen-binding protein (e.g., antibody, fragment, or polypeptide), the target protein is subjected to protease cleavage and mass spectrometry to identify the deuterium-labeled residues corresponding to the specific amino acids that the antigen-binding protein interacts with. See, for example, Ehring (1999) Analytical Biochemistry 267:252-259; Engen and Smith (2001) Anal. Chem. 73:256A-265A.

[0087] As used herein, the term “competing” refers to an antigen-binding protein (e.g., an antibody or its antigen-binding fragment) that binds to an antigen (e.g., CoV-S) and inhibits or blocks the binding of another antigen-binding protein (e.g., an antibody or its antigen-binding fragment) to the antigen. The term also includes competition between two antigen-binding proteins in both orientations, e.g., antibodies, i.e., a primary antibody that binds and blocks the binding of a secondary antibody, and vice versa. In certain embodiments, a first antigen-binding protein (e.g., an antibody) and a second antigen-binding protein (e.g., an antibody) may bind to the same epitope. Alternatively, the first and second antigen-binding proteins (e.g., antibodies) may bind to different but overlapping epitopes, such that the binding of one inhibits or blocks the binding of the secondary antibody, e.g., via steric hindrance. Competition between antigen-binding proteins (e.g., antibodies) can be measured by methods known in the art, e.g., by real-time label-free biolayer interferometry assays. Epitope mapping (e.g., via alanine scanning or hydrogen-deuterium exchange (HDX)) is used to determine whether two or more antibodies are not competing (e.g., on spike protein receptor-binding domain (RBD) monomers), are competing for the same epitope, or are competing but for diverse microepitopes (e.g., identified via HDX). It is possible to determine whether competition exists. In embodiments of the present invention, competition between the first and second anti-CoV-S antigen-binding proteins (e.g., antibodies) is determined by measuring the ability of the immobilized first anti-CoV-S antigen-binding protein (e.g., antibody) (which does not initially complex with the CoV-S protein) to bind to a soluble CoV-S protein complexed with the second anti-CoV-S antigen-binding protein (e.g., antibody). A decrease in the ability of the first anti-CoV-S antigen-binding protein (e.g., antibody) to bind to the complexed CoV-S protein compared to the uncomplexed CoV-S protein indicates competition between the first and second anti-CoV-S antigen-binding proteins (e.g., antibodies). The degree of competition can be expressed as a percentage decrease in binding. Such competition can be measured using real-time label-free biolayer interferometry assays, for example, with the Octet RED384 biosensor (Pall ForteBio Corp.), ELISA (enzyme-linked immunosorbent assay), or SPR (surface plasmon resonance).

[0088] Binding competition between anti-CoV-S antigen-binding proteins (e.g., monoclonal antibodies (mAbs)) can be determined using a real-time, label-free biolayer interference assay with the Octet RED384 biosensor (Pall ForteBio Corp.). For example, to determine competition between two anti-CoV-S monoclonal antibodies, an anti-CoV-S mAb can first be captured on an Octet biosensor chip (Pall ForteBio Corp., #18-5060) coated with an anti-hFc antibody by immersing the chip in a solution of the anti-CoV-S mAb (hereinafter referred to as "mAb1"). Then, as a positive control for blockade, the antibody-captured biosensor chip can be saturated with a known blockade isotype control mAb (hereinafter referred to as "blockade mAb") by immersing it in a solution that blocks the mAb. To determine whether mAb2 competes with mAb1, the biosensor chip can then be immersed in a cocomposited solution of CoV-S polypeptide and a second anti-CoV-S mAb (hereinafter referred to as "mAb2") that has been pre-incubated for a certain period of time, and the binding of mAb1 to the CoV-S polypeptide can be determined. The biosensor chip may be washed with buffer between each step of the experiment. The binding response may be monitored in real time throughout the course of the experiment, and the binding response at the end of each step may be recorded.

[0089] For example, in embodiments of the present invention, competitive assays were performed at 25°C and a pH of about 7, for example, 7.4, in the presence of, for example, a buffer, salt, surfactant, and a nonspecific protein (e.g., bovine serum albumin).

[0090] Typically, the antibody or antigen-binding fragment of the present invention, modified in some way, retains the ability to specifically bind to CoV-S, for example, retaining at least 10% of its CoV-S binding activity (compared to the parent antibody) when its activity is expressed in molar terms. Preferably, the antibody or antigen-binding fragment of the present invention retains at least 20%, 50%, 70%, 80%, 90%, 95%, or 100% or more of the CoV-S binding affinity of the parent antibody. The antibody or antigen-binding fragment of the present invention is also intended to contain conserved or non-conserved amino acid substitutions (referred to as “conserved variants” or “function-conserving variants” of the antibody) that do not substantially alter its biological activity.

[0091] Immunoglobulin chains (e.g., mAb8021 V) H , V L HC, or LC, mAb8028 V H , V L HC, or LC, or mAb8029 V H , V L A "variant" of a polypeptide such as HC or LC is defined as a polypeptide that is compared by the BLAST algorithm, where the algorithm's parameters are selected to provide the greatest possible match between the sequences across the entire length of each reference sequence (e.g., prediction threshold: 10; word size: 3; maximum number of matches within query range: 0; BLOSUM 62 matrix; gap cost: presence 11, extension 1; conditional configuration score matrix adjustment). This refers to polypeptides that contain at least approximately 70-99.9% (e.g., 70, 72, 74, 75, 76, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5, 99.9%) identical or similar amino acid sequences to the reference amino acid sequences listed in the book (e.g., SEQ ID NOs: 2, 10, 18, 20, 22, 30, 38, 40, 42, 50, 58, or 60).

[0092] A "variant" of a polynucleotide refers to a polynucleotide containing a nucleotide sequence that is at least about 70–99.9% (e.g., at least about 70, 72, 74, 75, 76, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5, 99.9%) identical to the reference nucleotide sequences described herein (e.g., SEQ ID NOs. 1, 9, 17, 19, 21, 29, 37, 39, 41, 49, 57, or 59) when compared by the BLAST algorithm, where the algorithm's parameters are selected to provide the greatest possible match between each sequence across the entire length of each reference sequence (e.g., prediction threshold: 10; word size: 28; maximum number of matches in query range: 0; match / mismatch score: 1, -2; gap cost: linear).

[0093] In embodiments of the present invention, the anti-CoV-S antigen-binding protein of the present invention, for example, an antibody and its antigen-binding fragment, includes a heavy-chain immunoglobulin variable region having at least 70% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) amino acid sequence identity with the HCVR amino acid sequence listed in Table 1, and / or a light-chain immunoglobulin variable region having at least 70% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) amino acid sequence identity with the LCVR amino acid sequence listed in Table 1.

[0094] In addition, variant anti-CoV-S antigen-binding proteins may include polypeptides comprising the amino acid sequences described herein, excluding one or more mutations (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) such as missense mutations (e.g., conservative substitutions), nonsense mutations, deletions, or insertions. For example, the present invention includes antigen-binding proteins comprising an immunoglobulin light chain variant comprising the LCVR amino acid sequence described in Table 1 but having one or more such mutations, and / or an immunoglobulin heavy chain variant comprising the HCVR amino acid sequence described in Table 1 but having one or more such mutations. In embodiments of the present invention, the variant anti-CoV-S antigen-binding protein comprises an immunoglobulin light chain variant including CDR-L1, CDR-L2, and CDR-L3 (one or more of these CDRs (e.g., 1, 2, or 3) having one or more such mutations (e.g., conservative substitutions)), and / or an immunoglobulin heavy chain variant including CDR-H1, CDR-H2, and CDR-H3 (one or more of these CDRs (e.g., 1, 2, or 3) having one or more such mutations (e.g., conservative substitutions)). The substitutions may be included in the CDR, framework, or constant region.

[0095] The present invention further provides a variant anti-CoV-S antigen-binding protein, such as an antibody or its antigen-binding fragment, comprising, for example, the heavy chain and light chain CDRs of Table 1 and one or more variant CDRs described herein (e.g., one or more of CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and / or CDR-H3) having sequence identity or similarity of at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.9%.

[0096] Embodiments of the present invention are also the corresponding V described herein. H , V L , HC, Alternatively, an immunoglobulin V containing an amino acid sequence having overall amino acid sequence identity or similarity of 70% or more (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) with the amino acid sequence of LC. H and V L This also includes variant antigen-binding proteins, such as anti-CoV-S antibodies and their antigen-binding fragments, which include HC and LC, but the CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 of such immunoglobulins are not variants and contain the CDR amino acid sequences listed in Table 1. Therefore, in such embodiments, the CDR within the variant antigen-binding protein is not a variant in itself.

[0097] Conservatively modified variant anti-CoV-S antibodies and their antigen-binding fragments are also part of the present invention. “Conservatively modified variant” or “conservative substitution” refers to a variant in which one or more amino acids in a polypeptide are substituted by other amino acids having similar characteristics (e.g., charge, side chain size, hydrophobic / hydrophilicity, skeletal structure, and rigidity). Such modifications can be frequently made without significantly disrupting the biological activity of the antibody or fragment. Those skilled in the art generally recognize that a single amino acid substitution in a non-essential region of a polypeptide does not substantially alter its biological activity (e.g., Watson et al. (1987) Molecular Biology of the Gene, The Benjamin / Cummings Pub.Co.,p.224(4 th See Ed.). In addition, substitutions of structurally or functionally similar amino acids are less likely to significantly disrupt biological activity.

[0098] Examples of amino acids having side chains with similar chemical properties include: 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic hydroxyl side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; 6) acidic side chains: aspartate and glutamate; and 7) sulfur-containing side chains: cysteine ​​and methionine. Preferred conserved amino acid substituents are valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine. Alternatively, a conservative permutation is any change that has a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) Science 256:1443 45.

[0099] Function-conserving variants of anti-CoV-S antibodies and their antigen-binding fragments are also part of the present invention. Any variant of an anti-CoV-S antibody and its antigen-binding fragment (discussed herein) may be a “function-conserving variant.” Such function-conserving variants may, in some cases, be characterized as conservatively modified variants. As used herein, “function-conserving variant” refers to a variant of an anti-CoV-S antibody or its antigen-binding fragment in which one or more amino acid residues are modified without significantly altering one or more functional properties of the antibody or fragment. In embodiments of the present invention, the function-conserving variant anti-CoV-S antibody or its antigen-binding fragment comprises a variant amino acid sequence and exhibits one or more of the following functional properties. • Inhibiting the proliferation of coronaviruses (e.g., SARS-CoV-2, SARS-CoV, and / or MERS-CoV) in ACE2 and / or TMPRSS2-expressing cells (e.g., Calu-3 cells). • Does not significantly bind to MDCK / Tet-on cells that do not express ACE2 and / or TMPRSS2. • Limiting the spread of coronavirus infection in cells in vitro, e.g., Calu-3 (e.g., by SARS-CoV-2, SARS-CoV, and / or MERS-CoV), and / or To protect mice engineered to express human TMPRSS2 and / or ACE2 proteins from death caused by coronavirus infection (e.g., SARS-CoV-2, SARS-CoV, or MERS-CoV) (e.g., mice would otherwise be infected with a lethal dose of the virus if selectively combined with a second therapeutic agent). To protect mice engineered to express human TMPRSS2 and / or ACE2 proteins from weight loss caused by coronavirus infection (e.g., SARS-CoV-2, SARS-CoV, or MERS-CoV) (e.g., when optionally combined with a second therapeutic agent, mice are infected with a dose of the virus that would otherwise cause weight loss).

[0100] "Neutralizing" or "antagonist" anti-CoV-S antigen-binding proteins, such as antibodies or antigen-binding fragments, refer to molecules that inhibit the activity of CoV-S to any detectable degree, for example, by inhibiting the ability of CoV-S to be cleaved by proteases such as TMPRSS2, or to bind to receptors such as ACE2, which mediate viral entry into or replication in host cells.

[0101] Table 1 shows the heavy chain or V listed below. H (or its variant) and light chain or V L V containing (or its variant), or containing the CDR (CDR-H1 (or its variant), CDR-H2 (or its variant), and CDR-H3 (or its variant)) H , and V including its CDR (CDR-L1 (or its variant), CDR-L2 (or its variant), and CDR-L3 (or its variant)) LThis refers to antigen-binding proteins, such as antibodies and their antigen-binding fragments, including, for example, immunoglobulin chains, variable regions and / or CDRs, which include the specific amino acid sequences described below.

[0102] The antibodies described herein are also V H This includes embodiments in which the compound is fused to wild-type IgG4 (e.g., residue 108 is S) or an IgG4 variant (e.g., residue 108 is P).

[0103] The antibodies and antigen-binding fragments of the present invention include immunoglobulin chains containing the amino acid sequences described herein, as well as cellular and in vitro post-translational modifications of the antibodies. For example, the present invention includes antibodies and antigen-binding fragments thereof that specifically bind to CoV-S containing the heavy and / or light chain amino acid sequences described herein (e.g., CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and / or CDR-L3), as well as antibodies and fragments in which one or more amino acid residues are glycosylated, antibodies and fragments in which one or more Asn residues are deamidated, antibodies and fragments in which one or more residues (e.g., Met, Trp, and / or His) are oxidized, antibodies and fragments in which the N-terminal Gln is pyroglutamate (pyroE), and / or antibodies and fragments lacking a C-terminal lysine.

[0104] The amino acid and nucleotide sequences of an example anti-SARS-CoV-2 spike protein (SARS-CoV-2-S) antibody are shown below. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8]

[0105] Antibody administration The present invention involves administering the anti-CoV-S antigen-binding protein of the present invention, for example, one of those listed in Table 1. The present invention provides a method for introducing an antigen-binding protein into the body of a subject (e.g., a human). For example, the method involves puncturing the subject's body with a syringe needle and injecting the antigen-binding protein into the subject's body, for example, into the subject's vein, artery, tumor, muscle tissue, or subcutaneous tissue.

[0106] The present invention provides a container (for example, a plastic or glass vial having a cap or chromatography column, a hollow bore needle, or a syringe cylinder) containing the anti-CoV-S antigen-binding protein of the present invention, for example, those listed in Table 1.

[0107] The present invention also provides an injection device comprising one or more antigen-binding proteins (e.g., antibodies or antigen-binding fragments) or a pharmaceutical composition thereof that specifically bind to CoV-S, for example, those listed in Table 1. The injection device may be packaged in a kit. The injection device is a device for introducing a substance into a subject's body via parenteral routes, e.g., intramuscular, subcutaneous, or intravenous. For example, the injection device may be a syringe (e.g., pre-filled with the pharmaceutical composition, such as an autoinjector) comprising, for example, a cylinder or barrel for holding the fluid to be injected (e.g., an antibody or fragment or a pharmaceutical composition thereof), a needle for suturing the skin and / or blood vessels for injecting the fluid, and a plunger for pushing the fluid out of the cylinder and through the needle hole. In one embodiment of the present invention, the injection device comprising an antigen-binding protein, e.g., an antibody or an antigen-binding fragment thereof, or a pharmaceutical composition thereof, from the combination of the present invention is an intravenous (IV) injection device. Such a device may be a cannula or The IV device may include an antigen-binding protein or its pharmaceutical composition within a cannula or trocar / needle that can be attached to a tube that can be attached to a bag or reservoir for holding a fluid (e.g., saline solution) introduced into the subject's body through the trocar / needle. In one embodiment of the present invention, an antibody or fragment thereof or its pharmaceutical composition may be introduced into the device after the trocar and cannula are inserted into the subject's vein and the trocar is removed from the inserted cannula. The IV device may be inserted, for example, into a peripheral vein (e.g., in the hand or arm), a superior or inferior vena cava, or the right atrium of the heart (e.g., central IV), or into a subclavian, internal jugular, or femoral vein, advancing toward the heart until it reaches, for example, the superior vena cava or right atrium (e.g., a central venous line). In one embodiment of the present invention, the injection device is an auto-syringe, a jet injector, or an external infusion pump. The jet injector uses a narrow, high-pressure liquid jet that penetrates the epidermis to introduce the antibody or fragment thereof or its pharmaceutical composition into the subject's body. An external infusion pump is a medical device that delivers antibodies or fragments or their pharmaceutical compositions into a target body in a controlled amount. External infusion pumps can be powered electrically or mechanically. Various pumps operate in various ways; for example, a syringe pump holds fluid in a syringe reservoir, and a movable piston controls the fluid supply; an elastomer pump holds fluid in a retractable balloon reservoir, and the pressure from the elastic wall of the balloon facilitates the fluid supply; in a peristaltic pump, a set of rollers grips the length of a flexible tube, pushing the liquid forward; and in a multi-channel pump, fluid can be supplied from multiple reservoirs at multiple speeds.

[0108] Preparation of human antibodies Methods for generating human antibodies in transgenic mice are known in the art. Any of these known methods can be used in the context of the present invention to produce human antibodies that specifically bind to CoV-S. Antibodies against CoV-S can be produced using an immunogen comprising any one of the following: In certain embodiments of the present invention, the antibodies of the present invention are obtained from full-length natural CoV-S, or attenuated or inactivated live viruses, or mice immunized with DNA encoding a protein or fragment thereof. Alternatively, CoV-S proteins or fragments thereof can be produced and modified using standard biochemical techniques and used as immunogens. In one embodiment of the present invention, the immunogen is a recombinantly produced CoV-S protein or fragment thereof. In certain embodiments, the immunogen may be a CoV-S polypeptide vaccine. In certain embodiments, one or more booster immunization injections may be administered. In certain embodiments, the immunogen may be a recombinant CoV-S polypeptide expressed in E. coli or in any other eukaryotic or mammalian cell, such as Chinese hamster ovary (CHO) cells.

[0109] High-affinity chimeric antibodies against CoV-S having human variable regions and mouse constant regions can first be isolated using VELOCIMMUNE® technology (see, for example, U.S. Patent No. 6,596,541, Regeneron Pharmaceuticals, VELOCIMMUNE®) or any other known method to generate monoclonal antibodies. VELOCIMMUNE® technology involves generating transgenic mice in which the genome containing human heavy chain variable regions and human light chain variable regions is operably ligated to endogenous mouse constant region loci, so that the mouse produces antibodies containing human variable regions and mouse constant regions in response to antigen stimulation. The DNA encoding the variable regions of the antibody's heavy and light chains is isolated and operably ligated to the DNA encoding the human heavy chain constant region and human light chain constant region. The DNA is then expressed in cells capable of expressing fully human antibodies.

[0110] Generally, VELOCIMMUNE® mice are loaded with an antigen of interest, and lymphocytes (such as B cells) are collected from mice that express antibodies. Immortalized hybridoma cell lines can be prepared by fusing these lymphocytes with myeloma cell lines, and such hybridoma cell lines are screened and selected to identify hybridoma cell lines that produce antibodies specific to the antigen of interest. DNA encoding the variable regions of the heavy and light chains can be isolated and ligated to the desired isotype constant regions of the heavy and light chains. Such antibody proteins can be produced in cells such as CHO cells. Alternatively, antigen-specific chimeric antibodies or DNA encoding the variable domains of the light and heavy chains can be directly isolated from antigen-specific lymphocytes.

[0111] First, a high-affinity chimeric antibody having a human variable region and a mouse constant region is isolated. As in the following experimental sections, the antibody is characterized and selected for desired features, including affinity, selectivity, and epitopes. The mouse constant region is replaced with a desired human constant region to produce a fully human antibody of the present invention, e.g., wild-type or modified IgG1 or IgG4. The selected constant region may vary depending on the specific application, but the high-affinity antigen-binding features and target-specific features reside in the variable region.

[0112] Anticoronavirus spike protein antibodies containing Fc variants According to certain embodiments of the present invention, for example, an anti-CoV-S antigen-binding protein, such as an antibody or antigen-binding fragment, is provided, comprising an Fc domain containing one or more mutations that enhance or decrease antibody binding to, for example, an FcRn receptor at an acidic pH compared to a neutral pH. For example, the present invention provides an Fc domain with C H 2 or C HThe anti-CoV-S antibody contains mutations in three regions, and these mutations increase the affinity of the Fc domain to FcRn in an acidic environment (e.g., in endosomes with a pH in the range of approximately 5.5 to 6.0). Such mutations may result in an increased serum half-life of the antibody when administered to animals. Non-restrictive examples of such Fc modifications include, for example, modifications at position 250 (e.g., E or Q), positions 250 and 428 (e.g., L or F), position 252 (e.g., L / Y / F / W, or T), position 254 (e.g., S or T), and position 256 (e.g., S / R / Q / E / D, or T), or modifications at position 428 and / or 433 (e.g., H / L / R / S / P / Q, or K) and / or position 434 (e.g., A, W, H, F, or Y [N434A, N434W, N434H, N434F, or N434Y]), or modifications at position 250 and / or 428, or positions 307 or 308 (e.g., 308F, V308F), and 4 Modifications at position 34 are included. In one embodiment, the modifications include 428L (e.g., M428L) and 434S (e.g., N434S) modifications, 428L, 259I (e.g., V259I), and 308F (e.g., V308F) modifications, 433K (e.g., H433K), and 434 (e.g., 434Y) modifications, 252, 254, and 256 (e.g., 252Y, 254T, and 256E) modifications, 250Q and 428L modifications (e.g., T250Q and M428L), and 307 and / or 308 modifications (e.g., 308F or 308P). In yet another embodiment, the modifications include 265A (e.g., D265A) and / or 297A (e.g., N297A) modifications.

[0113] For example, the present invention includes an anti-CoV-S antigen binding protein, such as an antibody or an antigen-binding fragment thereof, comprising an Fc domain containing one or more pairs or groups of mutations selected from the group consisting of: 250Q and 248L (e.g., T250Q and M248L); 252Y, 254T, and 256E (e.g., M252Y, S254T, and T256E); 428L and 434S (e.g., M428L and N434S); 257I and 311I (e.g., P257I and Q311I); 257I and 434H (e.g., P257I and N434H); 376V and 434H (e.g., D376V and N434H); 307A, 380A, and 434A (e.g., T307A, E380A, and N434A); and 433K and 434F (e.g., H433K and N434F).

[0114] Anti-CoV-S antigen binding proteins described herein, such as antibodies and antigen-binding fragments thereof, comprising any possible combination of the aforementioned Fc domain mutations and the V H and / or V L described herein are contemplated within the scope of the present invention.

[0115] The present invention also includes an anti-CoV-S antigen binding protein, antibody, or antigen-binding fragment comprising the V H described herein and a chimeric heavy chain constant (C H ) region, wherein the chimeric C H region comprises segments derived from the C H regions of more than one immunoglobulin isotype. For example, an antibody of the present invention may have a chimeric C H region comprising part or all of a C H 2 domain derived from a human IgG1, human IgG2, or human IgG4 molecule, combined with part or all of a C H 3 domain derived from a human IgG1, human IgG2, or human IgG4 molecule. According to certain embodiments, an antibody of the present invention comprises a chimeric C HThe region includes. For example, the chimeric hinge may include an "upper hinge" amino acid sequence (amino acid residues at EU numbering positions 216-227) derived from the human IgG1 hinge region, human IgG2 hinge region, or human IgG4 hinge region, combined with a "lower hinge" sequence (amino acid residues at EU numbering positions 228-236) derived from the human IgG1 hinge region, human IgG2 hinge region, or human IgG4 hinge region. According to certain embodiments, the chimeric hinge region includes amino acid residues derived from the human IgG1 or human IgG4 upper hinge and amino acid residues derived from the human IgG2 lower hinge. Chimeric C as described herein. H Antibodies containing the region may, in certain embodiments, exhibit modified Fc effector function without adversely affecting the therapeutic or pharmacokinetic properties of the antibody. (See, for example, International Publication No. 2014 / 022540).

[0116] immunoconjugate The present invention encompasses an anti-CoV-S antigen-binding protein, such as an antibody or antigen-binding fragment, conjugated to another part, such as a toxoid, for example, a therapeutic part ("immune conjugate"), or an antiviral drug for treating influenza virus infection. In embodiments of the present invention, the anti-CoV-S antibody or fragment is conjugated to one of the further therapeutic agents described herein. As used herein, the term "immune conjugate" refers to an antigen-binding protein, such as an antibody or antigen-binding fragment, chemically or biologically linked to a radioactive substance, cytokine, interferon, target part or reporter part, enzyme, peptide or protein, or therapeutic agent. The antigen-binding protein is conjugated to its target (C As long as it can bind to CoV-S, radioactive substances, cytokines, interferons, target or reporter portions, enzymes, peptides, or therapeutic agents can be conjugated at any position along the molecule. Examples of immunoconjugates include antibody-drug conjugates and antibody-toxin fusion proteins. In one embodiment of the present invention, the drug may be a second, distinct antibody that specifically binds to CoV-S. The type of therapeutic portion that can be conjugated to an anti-CoV-S antigen-binding protein (e.g., an antibody or fragment) will take into account the condition to be treated and the desired therapeutic effect to be achieved. For example, Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., “Antibodies For Drug Delivery”,Controlled Drug Delivery(2 nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, “Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review”, Monoclonal Antibodies 1984: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic See Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates," Immunol. Rev., 62:119-58 (1982).

[0117] multispecific antibodies The present invention includes anti-CoV-S antigen-binding proteins, e.g., antibodies and their antigen-binding fragments, as well as methods for using them and methods for producing such antigen-binding proteins. The term "anti-CoV-S" antigen-binding protein, e.g., antibody or antigen-binding fragment, includes multispecific (e.g., bispecific or biparatopic) molecules comprising at least one first antigen-binding domain that specifically binds to CoV-S (e.g., the antigen-binding domain from the antibodies in Table 1), and at least one second antigen-binding domain that binds to a different antigen or a different CoV-S epitope than that of the first antigen-binding domain. In some embodiments, both the first and second antigen-binding domains are selected from the antigen-binding domains in Table 1. In embodiments of the present invention, the first and second epitopes overlap. In other embodiments of the present invention, the first and second epitopes do not overlap. For example, in one embodiment of the present invention, the multispecific antibody is a bispecific IgG antibody (e.g., IgG1 or IgG4) comprising a first antigen-binding domain that specifically binds to CoV-S, including the immunoglobulin heavy and light chains of the antibody in Table 1, and a second antigen-binding domain that specifically binds to a different epitope of CoV-S. In some embodiments, the bispecific IgG antibody (e.g., IgG1 or IgG4) comprises a first antigen-binding domain that specifically binds to CoV-S and a second binding domain that binds to a host cell protein, such as ACE2 or TMPRSS2.

[0118] The antibodies in Table 1 are CDR-H, CDR-L, and V, respectively. H , and V L , or including HC and LC (including their variants as described herein), multispecific a molecule, for example, an antibody or an antigen-binding fragment.

[0119] In an embodiment of the present invention, the antigen-binding domain that specifically binds to CoV-S, which can be included in a multispecific molecule, is (1) (i) a heavy chain variable domain sequence comprising the CDR-H1, CDR-H2, and CDR-H3 amino acid sequences set forth in Table 1, and (ii) a light chain variable domain sequence comprising the CDR-L1, CDR-L2, and CDR-L3 amino acid sequences set forth in Table 1, or (2) (i) a heavy chain variable domain sequence comprising the amino acid sequence set forth in Table 1, and (ii) a light chain variable domain sequence comprising the amino acid sequence set forth in Table 1, or (3) (i) a heavy chain immunoglobulin sequence comprising the amino acid sequence set forth in Table 1, and (ii) a light chain immunoglobulin sequence comprising the amino acid sequence set forth in Table 1.

[0120] In an embodiment of the present invention, the multispecific antibody or fragment comprises more than two different binding specificities (e.g., a trispecific molecule), for example, one or more additional antigen-binding domains that are the same as or different from the first and / or second antigen-binding domains.

[0121] In one embodiment of the present invention, the bispecific antigen-binding fragment comprises a first scFv having binding specificity for a first epitope (e.g., CoV-S) (e.g., the V set forth in Table 1 H and V L comprising the sequences) and a second scFv having binding specificity for a second different epitope. For example, in an embodiment of the present invention, the first and second scFvs are linked via a linker, for example, a peptide linker (e.g., (GGGGS) nThe sequences are linked by a GS linker (such as SEQ ID NO: 834), where n is, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. Other bispecific antigen-binding fragments include F(ab)2 of the bispecific IgG antibody containing the heavy and light chain CDRs in Table 1, and that of another antibody that binds to a different epitope. Treatment method

[0122] The present invention provides a method for treating or preventing a viral infection (e.g., coronavirus infection), which involves administering a therapeutically effective amount of an anti-CoV-S antigen-binding protein, such as an antibody or antigen-binding fragment (e.g., from Table 1), to a subject (e.g., a human) in need of such treatment or prevention.

[0123] Coronavirus infection can be treated or prevented in subjects by administering the anti-CoV-S antigen-binding protein of the present invention.

[0124] The effective or therapeutically effective dose of an anti-CoV-S antigen-binding protein, such as an antibody or antigen-binding fragment (e.g., Table 1), for treating or preventing viral infection refers to the amount of antibody or fragment sufficient to alleviate one or more signs and / or symptoms of infection in the subject, whether by inducing the regression or elimination of such signs and / or symptoms, or by inhibiting the progression of such signs and / or symptoms. The dose may vary depending on the age and size of the subject, the target disease, the condition, the route of administration, etc. In embodiments of the present invention, for example, the effective or therapeutically effective dose of the antibody or its antigen-binding fragment for treating or preventing viral infection in an adult subject is about 0.01 to about 200 mg / kg, for example, up to 150 mg / kg. In one embodiment of the present invention, the dose is up to about 10.8 or 11 grams (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, The dose is 9, 10, or 11 grams. The frequency and duration of treatment can be adjusted depending on the severity of the infection. In certain embodiments, the antigen-binding protein of the present invention may be administered in an initial dose, followed by one or more secondary doses. In certain embodiments, the initial dose may be approximately the same as or less than the initial dose, and subsequent doses of the antibody or its antigen-binding fragment may be administered in succession, with intervals of at least 1 to 3 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 9 weeks, at least 10 weeks, at least 12 weeks, or at least 14 weeks.

[0125] As used herein, the term “Subject” refers to mammals (e.g., rats, mice, cats, dogs, cattle, sheep, horses, goats, rabbits), preferably humans, that require prevention and / or treatment of diseases or disorders such as viral infections or cancer. Subjects may have a viral infection, such as influenza infection, or may be predisposed to developing an infection. Subjects predisposed to developing an infection, or at high risk of contracting an infection (e.g., coronavirus or influenza virus), include subjects with a weakened immune system due to autoimmune disease, subjects undergoing immunosuppressive therapy (e.g., after organ transplantation), subjects suffering from human immunodeficiency syndrome (HIV) or acquired immunodeficiency syndrome (AIDS), subjects with a form of anemia that depletes or destroys white blood cells, subjects undergoing radiation or chemotherapy, or subjects suffering from inflammatory disorders. Furthermore, subjects who are very young (e.g., under 5 years of age) or elderly (e.g., over 65 years of age) are at higher risk. Furthermore, the subjects may be at risk of contracting the virus due to their proximity to the disease outbreak, for example, by living in a densely populated city, or by living in close proximity to individuals with confirmed or suspected viral infections, or by choosing employment options such as hospital workers, pharmaceutical researchers, travelers to or frequent visitors to infected areas.

[0126] "To treat" or "to treat" means a subject having one or more signs or symptoms of a disease or infection, such as a viral infection, to which the antigen-binding protein is effective when administered to the subject in an effective or therapeutically effective amount or dose (as discussed herein) of an anti-CoV-S antigen-binding protein, such as the antibody or antigen-binding fragment of the present invention (e.g., Table 1).

[0127] The present invention also encompasses the prophylactic administration of anti-CoV-S antigen-binding proteins, such as the antibodies or antigen-binding fragments thereof (e.g., those in Table 1), to subjects at risk of viral infection in order to prevent such infection. Passive antibody-based immunoprevention has been proven to be an effective strategy for preventing subjects from becoming infected with the virus. For example, Berry et al., Passive broad-spectrum influenza immunoprophylaxis. Influenza Res Treat. 2014;2014:267594. Epub 2014 Sep 22; and Jianqiang et al., Passive immune neutralization strategies for prevention and control of influenza A infections. Immunotherapy. 2012 February;4(2):175-186; Prabhu et al.,Antivir Ther.2009;14(7):911-21,Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 hemagglutinin against lethal H5N1 See influenza. "Preventing" or "preventing" means administering an anti-CoV-S antigen-binding protein, such as the antibody or antigen-binding fragment of the present invention (e.g., Table 1), to a target to inhibit signs of disease or infection (e.g., viral infection) in the target's body. This means that the antigen-binding protein is effective when administered to the subject in an effective or therapeutically effective amount or dose (as discussed herein).

[0128] In one embodiment of the present invention, the signs or symptoms of viral infection in a subject are the survival or replication of the virus within the subject's body, as determined, for example, by a viral titer assay (e.g., coronavirus replication in fertilized chicken eggs or coronavirus spike protein assays). Other signs and symptoms of viral infection are discussed herein.

[0129] As described above, in some embodiments, the subject may be a non-human animal, and the antigen-binding proteins (e.g., antibodies and antigen-binding fragments) discussed herein may be used in animal contexts to treat and / or prevent diseases in non-human animals (e.g., cats, dogs, pigs, cattle, horses, goats, rabbits, sheep, etc.).

[0130] The present invention provides for the treatment or prevention of viral infection (e.g., coronavirus infection), or the induction of regression or elimination or inhibition of progression of at least one sign or symptom of viral infection (the sign or symptom is secondary to the viral infection), by administering a therapeutically effective amount of anti-CoV-S antigen-binding protein (e.g., as shown in Table 1) to a target, for example, by injection of the protein into the target's body. • Fever or feeling of fever / chills, ·cough, ·sore throat, • Runny nose or nasal congestion, ·sneeze, • Muscle or body pain, ·headache, • Fatigue (tiredness) ·vomiting, ·diarrhea, • Respiratory tract infections, • Chest discomfort, ·Difficulty breathing, • Bronchitis, and / or ·pneumonia, This provides a method for performing this action on subjects that require it (e.g., humans).

[0131] Combinations and pharmaceutical compositions To prepare pharmaceutical compositions of anti-CoV-S antigen-binding proteins, such as antibodies and their antigen-binding fragments (e.g., Table 1), the antigen-binding proteins are mixed with pharmaceutically acceptable carriers or excipients. For example, Remington's Pharmaceutical Sciences and USPharmacopeia:National Formulary, Mack Publishing Company, Easton, Pa. (1984); Hardman, et al. (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, NY; Gennaro (2000) Remington: The Science and Practice of Pharmacy, Lippincott, Williams, and Wilkins, New York, NY; Avis, et al. al.(eds.)(1993)Pharmaceutical Dosage Forms:Parental Medications,Marcel Dekker,NY;Lieberman,et al.(eds.)(1990)Pharmaceutical See Dosage Forms: Tablets, Marcel Dekker, NY; Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Disperse Systems, Marcel Dekker, NY; Weiner and Kotkoskie (2000) Excipient Toxicity and Safety, Marcel Dekker, Inc., New York, NY. In embodiments of the present invention, the pharmaceutical composition is sterile. Such a composition is part of the present invention.

[0132] The scope of the present invention includes dried, for example, lyophilized compositions, or pharmaceutically acceptable compositions thereof (containing a pharmaceutically acceptable carrier but substantially lacking water), comprising an anti-CoV-S antigen-binding protein, such as an antibody or an antigen-binding fragment thereof (for example, those in Table 1).

[0133] In further embodiments of the present invention, further therapeutic agents administered to a subject, relating to anti-CoV-S antigen-binding proteins disclosed herein, such as antibodies or antigen-binding fragments thereof (e.g., Table 1), are as described in Physicians' Desk Reference 2003 (Thomson Healthcare; 57 th The medication will be administered to the subjects according to the edition (Nov. 1, 2002) of the edition.

[0134] The method of administration may vary. Routes of administration include oral, rectal, transmucosal, intestinal, parenteral, intramuscular, subcutaneous, intradermal, intramedullary, intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, intraocular, inhalation, inhalation, topical, cutaneous, transdermal, or intraarterial.

[0135] The present invention provides a method for administering an anti-CoV-S antigen-binding protein, such as an antibody or an antigen-binding fragment thereof (e.g., Table 1), which involves introducing the protein into the body of a subject. For example, the method involves puncturing the body of the subject with a syringe needle and injecting the antigen-binding protein into the body of the subject, for example, into the subject's vein, artery, tumor, muscle tissue, or subcutaneous tissue.

[0136] The present invention relates to anti-CoV-S antigen-binding proteins, such as antibodies or antigen-binding fragments thereof (e.g., Table 1), polypeptides (e.g., HC, LC, V in Table 1). H , or V L The present invention provides a container (for example, a plastic or glass vial having a cap or chromatography column, a hollow bore needle, or a syringe cylinder) containing any of the following: a vector described herein, or a pharmaceutically acceptable carrier, or a polynucleotide (for example, those listed in Table 2), or a pharmaceutically acceptable carrier.

[0137] In one embodiment of this disclosure, an anti-CoV-S antigen-binding protein, such as an antibody or antigen-binding fragment of the present invention (e.g., of Table 1), is administered in association with one or more further therapeutic agents. These further therapeutic agents include, but are not limited to, anti-inflammatory agents, antimalarial agents, secondary antibodies or antigen-binding fragments that specifically bind to TMPRSS2, and secondary antibodies or antigen-binding fragments that specifically bind to CoV-S. In some embodiments, the antimalarial agent is chloroquine or hydroxychloroquine. In some embodiments, the anti-inflammatory agent is an antibody such as sarilumab, tocilizumab, or gymcirumab. In some embodiments, the further therapeutic agents are secondary antibodies or antigen-binding fragments disclosed herein, such as those of Table 1. In certain embodiments, one, two, three, four, or more antibodies or their antigen-binding fragments from Table 1 may be administered in combination (e.g., simultaneously or sequentially). In certain embodiments, two, three, four, or more antibodies bind to non-overlapping or partially overlapping epitopes of the spike protein, for example, within the receptor-binding domain of the spike protein. Various methods for determining whether two or more antibodies have non-overlapping or partially overlapping epitopes, such as cross-competition assays, are known in the art. Specific combinations of antibodies in Table 1 are listed below (specific combinations Each antibody is assigned a number representing a combination (for example, mAb10989 and mAb10987 are combination 1, mAb10989 and mAb10934 are combination 2, etc.). In some embodiments, antibody combinations may be selected from those that bind to different epitope clusters. For example, the specific antibodies described herein belong to the following epitope clusters: cluster 1, mAb10987, mAb10922, mAb10936, mAb10934; cluster 2, mAb10989, mAb10977, and mAb10933; cluster 3, mAb10920; cluster 4, mAb10954, mAb10986, and mAb10964; and cluster 5, mAb10984. Therefore, the combination of two antibodies can be selected from, for example, cluster 1 and cluster 2, cluster 1 and cluster 3, cluster 1 and cluster 4, cluster 1 and cluster 5, cluster 2 and cluster 3, cluster 2 and cluster 4, cluster 2 and cluster 5, cluster 3 and cluster 4, cluster 3 and cluster 5, and cluster 4 and cluster 5. In certain embodiments, three antibodies can be administered in combination (for example, simultaneously or sequentially).For example, such a combination can be selected from a group consisting of mAb10987 and mAb10933, plus one of the following antibodies: mAb10913, mAb10915, mAb10916, mAb10917, mAb10918, mAb10920, mAb10921, mAb10922, mAb10923, mAb10924, mAb10925, mAb10926, mAb10927, mAb10928, mAb10929, mAb10930, mAb10 931, mAb10932, mAb10934, mAb10935, mAb10936, mAb10937, mAb10940, mAb10938, mAb10939, mAb10941, mAb10942, mAb10943, mAb1094 4, mAb10945, mAb10946, mAb10947, mAb10948, mAb10949, mAb10951, mAb10950, mAb10954, mAb10955, mAb10956, mAb10957, mAb10958, m Ab10959, mAb10960, mAb10961, mAb10964, mAb10965, mAb10966, mAb10967, mAb10969, mAb10970, mAb10971, mAb10973, mAb10974, mAb 10975, mAb10976, mAb10977, mAb10978, mAb10979, mAb10980, mAb10981, mAb10982, mAb10983, mAb10984, mAb10985, mAb10986, mAb109 88, mAb10989, mAb10990, mAb10991, mAb10992, mAb10993, mAb10994, mAb10995, mAb10996, mAb10997, mAb10998, mAb10999, mAb11000, mAb11001, mAb11002, mAb11003, mAb10914, mAb11004, mAb11005, mAb11006, mAb11007, mAb11008, mAb11009, mAb11010, and mAb11011. In some embodiments, combinations include mAb10933, mAb10987, and mAb10985. No cross-competition was observed between mAb10933, mAb10987, and mAb10985.In some embodiments, the antibody that specifically binds to TMPRSS2 is H1H7017N, as described in International Publication No. 2019 / 147831. [Table 2]

[0138] Because RNA viruses can accumulate mutations over time, a significant concern for any direct antiviral therapy is the possibility of selecting escape variants induced by the treatment. Strategies to protect against escape of antibody therapies include selecting conserved binding epitopes or including multiple antibodies with non-overlapping epitopes. However, the occurrence of escape variants and their locations are unpredictable. For example, mutations do not necessarily occur at antibody-binding sites that are escape variants. While some informative analysis regarding epitope conservation can be performed based on sequence and structural analysis, the possibility of escape still exists under strong selective pressure. Furthermore, simply selecting non-overlapping epitopes for antibody combination therapy may not be sufficient to prevent escape. Rather, those skilled in the art will understand that antibody combinations are more effective when antibodies bind to epitopes where a single mutation is less likely to disrupt the binding of both antibodies. Since escape mutations can occur outside the epitope region, and a single mutation can disrupt the binding of one or both antibodies, antibody combinations should be tested for their ability to prevent escape rather than simply selecting an antibody that binds to non-overlapping epitopes. This further highlights the unpredictability of whether antibodies binding to two non-overlapping epitopes will prevent escape, or whether an antibody needs to bind to non-overlapping epitopes to prevent escape.

[0139] Indeed, escape studies using anti-influenza HA stem-binding antibodies have shown that escape variants can occur despite the high conservation of stem epitopes across diverse influenza subtypes, and that some escape variants occur outside the antibody epitope region. Furthermore, evaluation of antibodies demonstrating broad neutralization across multiple coronavirus species shows that more conserved residues can be targeted, and the neutralizing potency of these antibodies is orders of magnitude lower than that of the potent neutralizing antibodies specific to SARS-CoV-2 described herein. Neutralizing potency is considered the primary mechanism of action of anti-SARS-CoV-2 spike antibodies and may prove to be a key driver of clinical efficacy. Clinical candidate selection criteria for broad efficacy, including functional evaluation against naturally occurring cyclic sequence variants and inclusion of multiple antibodies containing non-overlapping epitopes, may provide enhanced protection against loss of efficacy. Therefore, in some embodiments of this disclosure, as discussed herein, a combination of potent neutralizing, non-competitive anti-SARS-CoV-2 spike glycoprotein antibodies can deliver optimal antiviral efficacy while minimizing the possibility of viral escape, representing an antibody cocktail-based therapeutic for the treatment and prevention of COVID-19. In particular, escape against multiple non-competitive antibodies (e.g., mAb10987 and mAb10933) requires the simultaneous selection of two different amino acid mutations that allow the virus to maintain replication adaptability, which is significantly less likely than the selection of a single mutation.

[0140] In some embodiments, further therapeutic agents are antiviral drugs and / or vaccines. As used herein, the term “antiviral drug” refers to a viral infection in a subject. This refers to any anti-infective drug or therapy used to treat, prevent, or improve [a specific condition]. The term “antiviral drug” includes, but is not limited to, cationic steroid antibacterial agents, leupeptin, aprotinin, ribavirin, or interferon alpha 2b. A method for treating or preventing a viral (e.g., coronavirus) infection in a subject requiring such treatment or prevention by administering the antibodies or antigen-binding fragments listed in Table 1 in conjunction with further therapeutic agents is part of the present invention.

[0141] For example, in one embodiment of the present invention, a further therapeutic agent is a vaccine, such as a coronavirus vaccine. In one embodiment of the present invention, the vaccine is an inactivated / dead virus vaccine, a live attenuated virus vaccine, or a virus subunit vaccine.

[0142] For example, in one embodiment of the present invention, further therapeutic agents include: [ka] [ka] It is (polyamide). See Shen et al. Biochimie 142:1-10 (2017).

[0143] In one embodiment of the present invention, the antiviral agent is an antibody or antigen-binding fragment that specifically binds to coronaviruses, such as SARS-CoV-2, SARS-CoV, or MERS-CoV. Exemplary anti-CoV-S antibodies include H4sH15188P, H1H15188P, H1H15211P, H1H15177P, H4sH15211P, H1H15260P2, H1H15259P2, H1H15203P, H4sH15260P2, H4sH15231P2, H1H15237P2, H1H15208P, and H1H15 described in International Patent Application Publication No. 2015 / 179535. The antibody or fragment may include, but is not limited to, 228P2, H1H15233P2, H1H15264P2, H1H15231P2, H1H15253P2, H1H15215P, and H1H15249P2, or their antigen-binding fragments. For example, the antibody or fragment may contain any of the aforementioned anti-CoV-S antibodies, CDR-L1, CDR-L2, and CDR-L3, as well as light chain immunoglobulin (e.g., V L or its light chain), and heavy chains (e.g., V) containing CDR-H1, CDR-H2, and CDR-H3. H (or its heavy chain)

[0144] In certain embodiments of the present invention, further therapeutic agents include aprotinin, leupeptin, and catio. It is not a steroid antibacterial agent, an influenza vaccine (e.g., dead, live, attenuated whole virus or subunit vaccine), or an antibody against the influenza virus (e.g., an antihemagglutinin antibody).

[0145] The term "in relation to" indicates that the components, anti-CoV-S antigen-binding proteins, e.g., the antibody of the present invention or its antigen-binding fragment, can be formulated together with another drug, for example, in a single composition for co-delivery, or separately in two or more compositions (e.g., a kit). Each component can be administered to a subject at a different time than when the other components are administered, for example, each administration can be given at intervals over a given period or continuously (e.g., separately or continuously). Furthermore, separate components can be administered to a subject via the same or different route (e.g., by an anti-CoV-S antibody or its antibody-binding fragment).

[0146] kit Further kits are provided comprising one or more components, including but not limited to anti-CoV-S antigen-binding proteins, such as antibodies or antigen-binding fragments (e.g., Table 1) as discussed herein, in association with one or more additional components, including but not limited to further therapeutic agents as discussed herein. Antigen-binding proteins and / or further therapeutic agents can be formulated in a pharmaceutical composition as a single composition or separately in two or more compositions, for example, together with a pharmaceutically acceptable carrier.

[0147] In one embodiment of the present invention, the kit contains an anti-CoV-S antigen-binding protein, for example, the antibody of the present invention or its antigen-binding fragment (for example, from Table 1), or its pharmaceutical composition in one container (for example, in a sterile glass or plastic vial), and further therapeutic agents in another container (for example, in a sterile glass or plastic vial).

[0148] In another embodiment, the kit comprises, in a single common container, an anti-CoV-S antigen-binding protein, such as the antibody of the present invention or its antigen-binding fragment (e.g., Table 1), or the pharmaceutical composition thereof, in combination with one or more further therapeutic agents formulated together in the pharmaceutical composition, in an optional manner.

[0149] If the kit contains a pharmaceutical composition for parenteral administration to a subject, the kit may include equipment for carrying out such administration (e.g., an injection device). For example, the kit may include one or more subcutaneous needles or other injection devices containing an anti-CoV-S antigen-binding protein, such as the antibody of the present invention or its antigen-binding fragment (e.g., from Table 1).

[0150] The kit may include an insert containing information about the pharmaceutical compositions and dosage forms contained within the kit. Generally, such information helps patients and physicians to use the enclosed pharmaceutical compositions and dosage forms effectively and safely. For example, the following information relating to the combination of the present invention may be provided in the insert: pharmacokinetics, pharmacodynamics, clinical studies, efficacy parameters, indications and uses, contraindications, warnings, precautions, side effects, overdose, appropriate dosage and administration, methods provided, appropriate storage conditions, references, manufacturer / distributor information, and patent information.

[0151] Diagnostic use of antibodies Anti-CoV-S antigen-binding proteins, such as the antibodies or antigen-binding fragments thereof of the present invention (e.g., Table 1), can be used to detect and / or measure CoV-S in a sample. An exemplary assay for CoV-S may include, for example, contacting a sample with the anti-CoV-S antigen-binding protein of the present invention, where the anti-CoV-S antigen-binding protein is labeled with a detectable label or reporter molecule, or selectively detecting CoV-S from the sample. It is used as a capture ligand for isolation. The presence of an anti-CoV-S antigen-binding protein that has formed a complex with CoV-S indicates the presence of CoV-S in the sample. Alternatively, an unlabeled anti-CoV-S antibody can be used in combination with a secondary antibody that is itself detectably labeled. The detectable label or reporter molecule is a radioisotope, for example, 3 H, 14 C, 32 P, 35 S, or 125I may be a fluorescent or chemiluminescent moiety, such as fluorescein isothiocyanate or rhodamine, or an enzyme, such as alkaline phosphatase, β-galactosidase, horseradish peroxidase, or luciferase. Specific exemplary assays that can be used to detect or measure CoV-S in a sample include neutralization assays, enzyme-linked immunosorbent assays (ELISA), and radioimmunoassays. This includes radioimmunoassay (RIA) and fluorescence-activated cell sorting (FACS). Therefore, the present invention provides samples to be treated with anti-CoV-S antibodies. The method for detecting the presence of a spike protein polypeptide in a sample includes contacting it with a protoconjugated protein and detecting the presence of a CoV-S / anti-CoV-S antigen-binding protein, wherein the presence of the complex indicates the presence of CoV-S.

[0152] The anti-CoV-S antigen-binding proteins of the present invention (e.g., those in Table 1) can be used in Western blotting or immunoprotein blotting procedures for detecting the presence of CoV-S or fragments thereof in a sample. Such procedures form part of the present invention and include, for example, the following steps: (1) Providing a membrane or other solid substrate containing a sample to be tested for the presence of CoV-S, for example, comprising the steps of optionally transferring a protein from the sample to be tested for the presence of CoV-S (e.g., from PAGE or SDS-PAGE electrophoretic separation of proteins in the sample) to a membrane or other solid substrate using a method known in the art (e.g., semi-dry blotting or tank blotting), and contacting the membrane or other solid substrate to be tested for the presence of CoV-S or fragments thereof with the anti-CoV-S antigen-binding protein of the present invention.

[0153] Such membranes can take the form of, for example, nitrocellulose or vinyl-based (e.g., polynylidene fluoride (PVDF)) membranes, to which proteins to be tested for the presence of CoV-S in a non-denaturing PAGE (polyacrylamide gel electrophoresis) gel or SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) gel have been transferred (e.g., after electrophoretic separation within the gel). Before contacting the membrane with the anti-CoV-S antigen-binding protein, the membrane is selectively blocked, for example, with skim milk powder, to bind to nonspecific protein-binding sites on the membrane. (2) Wash the membrane once or more to remove unbound anti-CoV-S antigen-binding proteins and other unbound substances, (3) Detect the bound anti-CoV-S antigen-binding protein.

[0154] The detection of bound antigen-binding proteins indicates the presence of CoV-S proteins on the membrane or substrate and in the sample. Detection of bound antigen-binding proteins may be achieved by binding the antigen-binding protein to a detectably labeled secondary antibody (anti-immunoglobulin antibody) and then detecting the presence of the secondary antibody label.

[0155] The anti-CoV-S antigen-binding proteins disclosed herein (e.g., antibodies and antigen-binding fragments (e.g., Table 1)) may also be used for immunohistochemistry. Such methods form part of the present invention and include, for example, the following: (1) Contacting the tissue to be tested for the presence of CoV-S protein with the anti-CoV-S antigen-binding protein of the present invention, and (2) To detect antigen-binding proteins on or within tissues.

[0156] If the antigen-binding protein itself is detectably labeled, it can be detected directly. Alternatively, the antigen-binding protein can be bound by a detectably labeled secondary antibody, and then the label can be detected. [Examples]

[0157] The following examples are presented to provide those skilled in the art with a complete disclosure and description of how to make and use the methods and compositions of the present invention, and are not intended to limit the scope of what the inventors regard as the present invention. Efforts have been made to ensure accuracy with respect to numerical values used (e.g., amounts, temperature, etc.), but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weights are average molecular weights, temperature is in degrees Celsius, room temperature is about 25°C, and pressure is at or near atmospheric pressure.

[0158] Example 1: Generation of human antibodies against SARS-CoV-2 spike protein (SARS-CoV-2-S) Human antibodies against SARS-CoV-2 spike protein (SARS-CoV-2-S) were generated in VELOCIMMUNE® mice comprising DNA encoding human immunoglobulin heavy chain and kappa light chain variable regions or human immunoglobulin heavy chain and lambda light chain variable regions. Each mouse was immunized with a vector expressing the SARS-CoV-2-S receptor binding domain (RBD) (amino acids 1-1273 of NCBI accession number (MN908947.3), SEQ ID NO: 832), followed by a SARS-CoV-2-S vector or SARS-CoV-2-S protein. Antibody immune responses were monitored by SARS-CoV-2-S-specific immunoassay. When the desired immune response was achieved, splenocytes were harvested and fused with mouse myeloma cells to maintain their viability and form hybridoma cell lines. Hybridoma cell lines were screened and selected to identify cell lines producing SARS-CoV-2-S-specific antibodies. Anti-SARS-CoV-2-S antibodies were isolated directly from antigen-positive mouse B cells without fusion to myeloma cells, as described in U.S. Patent No. 7,582,298, which is specifically incorporated herein by reference in its entirety. Using this method, fully human anti-SARS-CoV-2-S antibodies (i.e., antibodies having human variable domains and human constant domains) were obtained.

[0159] Antibodies were also isolated from human blood samples. Whole blood was collected from patients 3 to 4 weeks after PCR-positive tests confirmed in the laboratory for SARS-CoV-2 and symptomatic COVID-19 disease. Red blood cells were lysed with ACK lysis buffer (Life Technologies), and peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll gradient. Single B cells binding to SARS-CoV-2 spike protein from PBMCs were isolated by fluorescent-activated cell sorting (FACS). Isolated B cells were single-well plated and mixed with antibody light and heavy variable region-specific PCR primers. cDNA from each single B cell was synthesized via a reverse transcriptase (RT) reaction. Next, each obtained RT product was divided into 2 corresponding wells, and subsequent antibody heavy chain and light chain PCR were performed. One set of the obtained RT products was first amplified by PCR using 5' degenerate primers specific for the antibody heavy variable region leader sequence or 5' degenerate primers specific for the antibody light chain variable region leader sequence and 3' primers specific for the antibody constant region to form amplicons. Next, the amplicons were re-amplified by PCR using 5' degenerate primers specific for antibody heavy variable region framework 1 or 5' degenerate primers specific for antibody light chain variable region framework 1 and 3' primers specific for the antibody constant region to generate amplicons for cloning. PCR products derived from antibody heavy chains and light chains were cloned into expression vectors comprising a heavy constant region and a light constant region, respectively. An expression vector that expresses a full-length heavy and light chain pair was transfected into CHO cells to prepare antibody proteins for testing.

[0160] The biological properties of exemplary antibodies generated according to the method of this example are described in detail in the examples set forth below.

[0161] Example 2: Amino acid and nucleotide sequences of heavy chain variable regions and light chain variable regions Table 1 shows the amino acid sequence identifiers for the heavy and light chain variable regions and CDRs of exemplary anti-SARS-CoV-2-S antibodies, as well as the heavy and light chain sequences. The corresponding nucleic acid sequence identifiers are shown in Table 2. [Table 3-1] [Table 3-2] [Table 4-1] [Table 4-2]

[0162] The antibodies disclosed herein have a fully human variable region, but may have a mouse constant region (e.g., mouse IgG1 Fc or mouse IgG2 Fc (a or b isotype)) or a human constant region (e.g., human IgG1 Fc or human IgG4 Fc). As will be recognized by those skilled in the art, an antibody having a particular Fc isotype can be converted to an antibody having a different Fc isotype (e.g., an antibody having mouse IgG1 Fc can be converted to an antibody having human IgG4, etc.), but any In the event, the variable domains (including the CDR) indicated by the numerical identifiers shown in Tables 1 and 2 remain the same, and the binding properties to the antigen are expected to be identical or substantially similar, regardless of the properties of the constant domains.

[0163] The variable regions of antibodies derived from VELOCIMMUNE® mice and human samples were sequenced by next-generation sequencing, and the repertoire of heavy and light chain pairs was identified (Figures 10A and 10B). The main strains of VI antibodies utilized VH3-53 paired with VK1-9, VK1-33, or VK1-39, while the human-derived antibodies utilized VH3-66 paired with VK1-33 or VH2-70 paired with VK1-39. Further analysis of the overlaid sequences showed strong overlap in the isolated kappa chain repertoire between VI and human-derived antibodies. The lambda chain repertoire did not overlap well, which may be due to the fact that only two lambda mice were included in this study. The mean CDR length of the heavy chains was similar between VI and human-derived antibodies, with mean lengths of 13 amino acids and 14.5 amino acids, respectively. The average kappa CDR length was the same for both VI and human-derived antibodies, with 9 amino acids, and the lambda chains were similar in average length, at 11.1 and 10.6 amino acids, respectively. The availability of humanized mouse and human-derived antibodies has increased the diversity of the V gene, allowing for the later identification of non-competitive antibodies.

[0164] As described above, antibodies were obtained from hybridomas generated from VELOCIMMUNE® mice, directly isolated from antigen-positive VELOCIMMUNE® mouse B cells, or derived from variable regions cloned from antigen-positive human B cells. A summary of these sources is shown in Table 3. [Table 5-1] [Table 5-2]

[0165] Example 3: Characterization of hybridoma supernatant by conjugated ELISA An ELISA binding assay was performed to identify antibody supernatant bound to the SARS-CoV-2 spike protein receptor-binding domain (RBD). A protein consisting of SARS-CoV-2 RBD (amino acids 319-541) expressed with a 6X histidine tag and two myc epitope tags at the C-terminus (SARS-CoV-2-S-RBD-mmH, see NCBI accession number MN908947.3) was coated overnight at 4°C with 1 μg / ml in 96-well plates in PBS buffer. Nonspecific binding sites were then blocked using a 0.5% (wt / vol) solution of BSA in PBS. Only the antibody supernatant or medium was diluted 1:40 or 1:50 with PSA + 0.5% BSA blocking buffer and washed. The samples were transferred to microtiter plates. After incubation at room temperature for 1 hour, the wells were washed, and the supernatant bound to the plates was detected with either horseradish peroxidase (HRP)-bound goat anti-human IgG antibody (Jackson Immunoresearch) or horseradish peroxidase (HRP)-bound anti-mouse IgG antibody (Jackson Immunoresearch). The plates were then developed using TMB substrate solution (BD Biosciences) according to the manufacturer's recommendations, and the absorbance at 450 nm was measured using a Victor X5 plate reader.

[0166] The ability of anti-SARS-CoV-2-S antibodies to bind to the receptor-binding domain of SARS-CoV-2-S (SARS-CoV-2-S-RBD) was evaluated using a binding ELISA with the SARS-CoV-2-S-RBD-mmH protein coated on microplates, as described above. Single-point antibody supernatants bound to SARS-CoV-2-S-RBD-mmH coated on 96-well microtiter plates were detected with HRP-conjugated anti-hFc or anti-mFc antibodies.

[0167] The combined results of the three tests are summarized in Table 4. SARS-CoV-2 binding signals (absorbance at 450 nm) are shown, and a medium-only background is provided as a negative reference for each experiment. Samples marked IC (indeterminate) are reported without values due to experimental abnormalities on the plate. As shown compared to the medium-only control, the tested supernatants exhibited substantial binding to SARS-CoV-2-S-RBD. [Table 6]

[0168] Example 4: Antibodies that bind to virus-like particles expressing SARS-CoV-2-S To investigate the ability of a panel of anti-SARS-CoV-2-S monoclonal antibodies to bind to the SARS-CoV-2 spike glycoprotein, an electrochemiluminescence-based in vitro binding assay has been developed that utilizes virus-like particles (VLPs) expressing SARS-CoV-2 spike protein on a detection platform (MSD).

[0169] To transiently express SARS-CoV-2 spike protein (NCBI Accession No. MN908947.3, amino acids 16-1211, SEQ ID NO: 833), vesicular stomatitis virus (VSV) lacking glycoprotein G (VSV delta G) was pseudotyped with SARS-CoV-2 spike protein (VSV-SARS-CoV-2-S) and produced in HEK293T cells. As a negative binding control, VSV delta G was pseudotyped with VSV G protein (VSV-G).

[0170] The experiment was conducted using the following procedure. The two types of VLPs described above were diluted in PBS and seeded onto a 96-well carbon electrode plate (MULTI-ARRAY high-bind plate, MSD). The VLPs were incubated overnight at 4°C to adhere to the plate. Nonspecific binding sites were blocked at room temperature for 1 hour with 2% (weight / volume) BSA in PBS. The supernatant containing antibodies generated from SARS-CoV-2 immunized mice or infected human serum was added to the plate-bound particles along with a control of only medium diluted 1:10 or 1:20 in 1×PBS + 0.5% BSA buffer. The plates were then incubated at room temperature for 1 hour with shaking, after which the plates were washed with 1×PBS and unbound antibodies were removed using an AquaMax2000 plate washer (MDS Analytical Technologies). Plate-bound antibodies were detected at room temperature for 1 hour using SULFO-TAG™-conjugated anti-human IgG antibody (Jackson Immunoresearch) or SULFO-TAG™-conjugated anti-mouse IgG antibody (Jackson Immunoresearch). After washing, the plates were developed with read buffer (MSD) according to the manufacturer's recommended procedure, and the luminescence signals were recorded using a SECTOR Imager 600 (Meso Scale Development) instrument. Direct binding signals (at RLUs) were captured, and the ratio of VLPs expressing SARS-CoV-2-S to VLPs unrelated to SARS-CoV-2-S was calculated.

[0171] The ability of anti-SARS-CoV-2-S monoclonal antibodies to bind to SARS-CoV-2-S expressing VLPs compared to binding to unrelated VSV-expressing VLPs was evaluated using immunobinding assays as described above. Single-point binding to VLPs immobilized on 96-well High Bind plates (MSDs) was performed with 1:10 or 1:20 antibody supernatant dilutions, bound for 1 hour, and detected using SULFO-TAG™-conjugated anti-human IgG or anti-mouse IgG antibodies. Binding signals from electrochemiluminescence were recorded using a Sector Imager 600 (MSD). The RLU values ​​of antibodies binding to VLPs were determined. The ratio was calculated by comparing the binding signal of SARS-CoV-2-S expressing VLPs to that of control VLPs.

[0172] Table 5 summarizes the binding results from the three experiments. Signals observed from VLPs expressing SARS-CoV-2-S indicate binding, and comparison with negative VLPs provides relative background. Medium-only samples provide baseline signals for secondary antibodies that bind to samples without supernatant. Forty-six antibodies bound more than four times more specifically to SARS-CoV-2-S expressing VLPs than to medium-only samples (20–35 RLU), showing binding signals in the range of 85–13,600 RLU. The ratio of SARS-CoV-2-S expressing VSV to VSV-VLP (negative control) ranged from 1.1 to 22.7, with many showing higher background for VSV-VLP. The ratio of 0.9 for mAb11002 may be due to the low concentration of monoclonal antibody in the supernatant sample. [Table 7]

[0173] Example 5: Antibody neutralization of VSV-SARS-CoV-2-S pseudovirus infection To investigate the ability of a panel of anti-SARS-CoV-2-S monoclonal antibodies to neutralize SARS-CoV-2, an in vitro neutralization assay using the VSV-SARS-CoV-2-S pseudovirus was developed.

[0174] As described above, VSV pseudotype viruses were generated by transiently transfecting 293T cells with a plasmid encoding the SARS-CoV-2 spike protein. Cells were transfected one day prior to transfection with 15 μg / plate of spike protein DNA in DMEM complete medium at a rate of 1.2 × 10⁶ per plate, using 125 μL of lipofectamine LTX, 30 μL of PLUS reagent, and up to 3 mL of Opti-Mem. 7 Cells were seeded individually on a 15 cm plate. 24 hours after transfection, the cells were washed with 10 mL of PBS and then treated with 0.1 VSV in 10 mL of Opti-Mem. ΔG:mNeon Cells were infected with the virus at its MOI. The virus was incubated on the cells for 1 hour, gently agitated every 10 minutes. The cells were washed three times with 10 mL of PBS, then overlaid with 20 mL of infection medium and incubated for 24 hours at 37°C and 5% CO2. The supernatant was collected in a 250 mL centrifuge tube on ice and centrifuged at 3000 rpm for 5 minutes to pellet any cell debris. The pellets were dispensed on ice and frozen at -80°C. Infectivity was tested in Vero cells before use in a neutralization assay. This material is called VSV-SARS-CoV-2-S.

[0175] Neutralization assay using VSV-SARS-CoV-2-S On day 1, Vero cells were seeded in a T225 flask at an 80% concentration. To seed the cells, the culture medium was removed from the cells, the cells were washed with 20 mL of PBS (Gibco:20012-043), 5 mL of TrypLE was added, and the cells were incubated at 37°C for approximately 5 minutes until the cells detached. 5 mL of complete DMEM was added to inactivate the trypsin, and the cells were dispersed by pipetting up and down. To count the resuspended cells, 20,000 Vero cells were seeded in 100 μL of preheated complete DMEM per well in a 96-well black polystyrene microplate (Corning:3904).

[0176] On the second day, VSV-SARS-CoV-2-S was thawed on ice and diluted 1:1 with infection medium.

[0177] In a V-bottom 96-well plate, a dilution of each supernatant was prepared with 60 μl of infection medium. For the medium (negative) control, 60 μl of diluted conditioned medium was added to the well. 60 μL of diluted VSV-SARS-CoV-2-S was added to all wells except the medium control well. 60 μL of infection medium was added to those wells. The pseudovirus was then incubated with the supernatant dilution at room temperature for 30 minutes. The medium was removed from the Vero cell plate, 100 μL of the supernatant / pseudovirus mixture was transferred to the cells, and the plate was incubated at 37°C and incubated with 5% CO2 for 24 hours. Neutralization of the VSV-SARS-CoV-2-S pseudovirus was evaluated using 1:4 and 1:20 final supernatant dilutions, and 1:100 for some samples.

[0178] On day 3, after 24 hours of incubation, the supernatant was removed from the cell wells and replaced with 100 μL of PBS. The plates were then read using a SpectraMax i3 equipped with a MiniMax imaging cytometer.

[0179] The ability of anti-SARS-CoV-2-S antibodies to neutralize VSV-based SARS-CoV-2-S expressing pseudotyped viruses was evaluated using a neutralization fluorescence focus assay. The binding results of the three assays are summarized below. The neutralizing potency of the antibody at each dilution was compared to a simulated supernatant control. This is expressed as a percentage compared to the original value. All antibodies exhibit neutralizing ability, and in particular, within a set of antibodies rated at 1:100, antibodies showing higher neutralization may represent stronger neutralizing ability. [Table 8] * NT: Not tested

[0180] Example 6: Characterization of antibodies in antibody-dependent cell-mediated toxicity surrogate assays The ability of antibodies targeting the SARS-CoV-2 spike protein to interact with FcγR3a, an Fc receptor prominently expressed in natural killer (NK) cells that induce antibody-dependent cell-mediated cytotoxicity (ADCC), was measured using a surrogate bioassay with antibody-bound reporter and target cells. This assay targeted high-affinity human FcγR3a 176 Val allotype receptor (Jurkat / NFAT-Luc / hFcγR3a 176 Along with Val, Jurkat T cells engineered to express the reporter gene luciferase under the control of the transcription factor NFAT (NFAT-Luc) were used. Target cells were engineered Jurkat T cells expressing the full-length SARS-CoV-2 spike protein regulated by human CD20 (used as a positive control for a human IgG1 antibody targeting CD20) and a doxycycline-inducible promoter. Reporter cells were incubated with target cells, and the transcription factor NFAT in the reporter cells was activated via the Fc domain of the human IgG1 antibody bound to the target cells, promoting luciferase expression, which was then measured via luminescence readout.

[0181] Jurkat T cells were engineered to constitutively express full-length human CD20 (amino acids M1-P297 of NCBI accession number NP_690605.1), Tet3G transactivating protein (cloned using Takara pEF1α-Tet3G vector, catalog number 631167), and doxycycline-inducible full-length SARS-CoV-2 spike protein (amino acids M1-T1273 of NCBI accession number YP_009724390.1). Engineered Jurkat / Tet3G / hCD20 / SARS-CoV-2 spike protein expressing cells were sorted for high spike protein expression and subsequently maintained in RPMI + 10% Tet-free FBS + P / S / G + 500 μg / ml G418 + 1 μg / ml puromycin + 250 μg / ml hygromycin growth medium.

[0182] Jurkat T cells have high affinity for human FcγR3a 176 The luciferase reporter construct was engineered to stably express the Val allotype receptor along with nuclear factor-activated T cells (NFAT) (amino acids M1-K254 of NCBI accession number P08637 VAR_003960). The engineered reporter cells were maintained in RPMI1640 + 10% FBS + P / S / G + 0.5 μg / ml puromycin + 500 μg / ml G418 growth medium.

[0183] 36 hours until the start of the surrogate ADCC assay, 5 × 10 5 Target cells were induced in RPMI + 10% Tet-free FBS + P / S / G cell culture medium containing 1 μg / ml doxycycline (Sigma). The day before the experiment, reporter cells were induced in RPMI1640 + 10% FBS + P / S / G + 0.5 μg / ml puromycin + 500 μg / ml G418 growth medium (7.5 × 10⁶ cells). 5 The cells were divided into densities of cells / ml.

[0184] To put it simply, on the day of the experiment, target cells and reporter cells are transferred to assay medium (RPMI + 10% Tet-free FBS + P / S / G) in a 3:2 ratio (3 × 10⁻¹⁰). 4 / well target cells and 2×10 4 (Well reporter cells) were added to 384-well white microtiter plates, followed by the addition of various concentrations of anti-SARS-CoV-2-S antibody supernatant. To normalize the detected ADCC activity of the anti-SARS-CoV-2-S antibody supernatant, a positive control sample (CD20 antibody containing human IgG1) and a negative control sample without antibody were included in each plate. After incubating the plates at 37°C / 5% CO2 for 5 hours, cells were lysed with an equal volume of ONE-Glo® (Promega) reagent, and luciferase activity was detected. The emitted light was captured by relative light units (RLU) on a multi-label plate reader Envision (PerkinElmer), and the following The data was analyzed and normalized using equations.

number

[0185] The ability of anti-SARS-CoV-2-S antibodies to activate the FcγR3a receptor was evaluated using Jurkat / NFAT-Luc / FcγR3a as a reporter cell. 176 Val) was used to evaluate the antibodies in a surrogate ADCC assay using Jurkat / hCD20 / SARS-CoV2 spike cells as target cells. Each antibody tested contained an IgG1 domain.

[0186] Table 7 summarizes the results, showing the raw luciferase activity and the calculated percentage of the positive control. A certain range of %ADCC activity indicating FcγR3a activation by antibody supernatant was observed. All samples showed some degree of surrogate ADCC activity, and 10% of the antibody supernatant showed better surrogate ADCC activity than that observed in the positive control. [Table 9]

[0187] Example 7: Anti-SARS-CoV-2-S antibody binding specificity assay To determine the binding of anti-SARS-CoV-2-S antibodies to a panel of antigens, a Luminex binding assay was performed. In this assay, antigens are either amine-bound or streptococcal. Luminex microspheres were captured with toavidin as follows: Approximately 10 million MagPlex microspheres (Luminex Corp., MagPlex Microspheres, catalog numbers MC10000 and MC12000) were vortexed into 500 μL of 0.1 M NaPO4, pH 6.2 (activation buffer) to resuspend them, and the supernatant was removed by centrifugation. Since the microspheres are sensitive to light, they were protected from light. The microspheres were resuspended in 160 μL of activation buffer, and the carboxylic acid group (-COOH) was activated by adding 20 μL of 50 mg / mL N-hydroxysuccinimide (NHS, Thermo Scientific, catalog number 24525), followed by 20 μL of 50 mg / mL 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC, Thermo Scientific, catalog number 22980) at 25°C. After 10 minutes, 600 μL of 50 mM MES, pH 5 (coupling buffer) was added to lower the pH of the reaction mixture to 5.0. Microspheres were vortexed, and the supernatant was removed by centrifugation. The activated microspheres were immediately mixed with 500 μL of 25 μg / mL protein antigen or streptavidin in the coupling buffer and incubated at 25°C for 2 hours. 50 μL of 1 M Tris-HCl, pH 8.0 was added to stop the coupling reaction. Microspheres were vortexed, centrifuged, and washed three times with 800 μL of PBS 0.005% (Tween20 0.05%) to remove uncoupling proteins and other reaction components. The microspheres were resuspended in 1 mL of PBS 2% BSA 0.05% sodium azide at a concentration of 10 million microspheres / mL. For antigen capture by streptavidin, 500 μL of 12.5 μg / mL biotinylated protein in PBS was added to streptavidin-conjugated microspheres and incubated at 25°C for 1 hour. The microspheres were vortexed, centrifuged, washed three times with 800 μL of PBS, and then blocked with 500 μL of 30 mM biotin (Millipore-Sigma, catalog number B4501) in 0.15 M Tris pH 8.0.After incubating the microspheres for 30 minutes, they were vortexed, centrifuged, and washed three times with 800 μL of PBS. The microspheres were resuspended in 1 mL of PBS 2% BSA 0.05% sodium azide at a concentration of 10 million microspheres / mL.

[0188] Microspheres of different proteins and biotinylated proteins were mixed at 2700 beads / ml, and 75 μL of microspheres per well were seeded into a 96-well ProcartaPlex flat-bottom plate (ThermoFisher, catalog no. EPX-44444-000). These were then mixed with 25 μL of individual anti-SARS-CoV-2 supernatant containing antibodies. After incubation at 25°C for 2 hours, the samples and microspheres were washed twice with 200 μL of DPBS containing 0.05% Tween 20. To detect the level of antibody binding to individual microspheres, 100 μL of 2.5 μg / mL- R-phycoerythrin-conjugated goat F(ab')2 anti-human kappa (Southern Biotech, catalog no. 2063-09) or 100 μL of 1.25 μg / mL R-phycoerythrin Affinipure F(ab')2 fragment goat anti-mouse IgG, F(ab')2 fragment specific (Jackson Immunoresearch, catalog no. 115-116-072) was added to the blockage buffer (for antibodies with human Fc region) and incubated at 25°C for 30 minutes. After 30 minutes, the samples were washed twice with 200 μL of wash buffer and resuspended in 150 μL of wash buffer. The plates were read using Luminex FlexMap 3D® (Luminex Corp.) and Luminex xPonent® software version 4.3 (Luminex Corp.). The SARS-CoV-2 proteins used in the assay were as follows: RBD_(R319-F541).mmh: Sequence ID 829 RBD_(R319-F541).mFc: Sequence ID 830 RBD_(R319-F541).hFc): Sequence ID 831

[0189] Luminex binding results are shown in Tables 8 and 9 as median fluorescence intensity (MFI) signal intensities. The results indicate that 46 anti-SARS-CoV-2-S antibody supernatants specifically bound to the SARS-CoV-2-S RBD protein. These results also show that five of these antibodies cross-reacted with the SARS coronavirus spike RBD protein, exhibiting binding signals exceeding 1000 MFI. [Table 10] [Table 11]

[0190] Example 8: Anti-SARS-CoV-2-S antibody diversity assay A binding assay was performed to determine the binding profile of the anti-SARS-CoV-2-S antibody. In this assay, the antigen was amine-conjugated as described in the Luminex binding assay above. Briefly, approximately 9 million MagPlex microspheres (Luminex Corp., MagPLex Microspheres, catalog numbers MagPLex MC10000 and MC12000) were vortexed into 500 μL of 0.1 M NaPO4, pH 6.2 to resuspend the microspheres, and then the supernatant was removed by centrifugation. Microspheres were resuspended in 160 μL of activation buffer, and the carboxylic acid group (-COOH) was activated by adding 20 μL of 50 mg / mL N-hydroxysuccinimide (NHS, Thermo Scientific, catalog no. 24525), followed by 20 μL of 50 mg / mL 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC, Thermo Scientific, catalog no. 22980) at 25°C. After 10 minutes, the pH of the reaction mixture was lowered to 5.0 by adding 600 μL of 50 mM MES, pH 5 (coupling buffer), the microspheres were vortexed, and the supernatant was removed by centrifugation. The activated microspheres were immediately mixed with 500 μL of 20 μg / mL SARS-CoV-2 spike protein (RBD)(R319-F541)-mmH in coupling buffer and incubated at 25°C for 2 hours. The coupling reaction mixture was quenched by adding 50 μL of 1 M Tris-HCl, pH 8.0, the microspheres were vortexed, centrifuged, and washed three times with 1000 μL of PBS. The microspheres were resuspended in 250 μL of PBS at a concentration of 9 million microspheres / mL.

[0191] Fifteen of the sixteen microsphere regions containing amine-binding proteins were modified for the binning assay as follows: The microspheres were washed twice with 5% DMSO in PBS, and 500 μl of the chemical or enzyme was dissolved according to manufacturing recommendations and added to the amine-binding microspheres at 10 nM. This was then vortexed and incubated at room temperature for 2 hours. The microspheres were washed three times with BSA in 2% PBS. The microspheres were resuspended in 1 mL of PBS at a concentration of 9 million microspheres / mL.

[0192] Protein-modified and protein-unmodified (intact) microspheres were mixed at 2700 beads / ml, and 75 μL of microspheres were seeded into a 96-well ProcartaPlex 96-well flat-bottom plate (ThermoFisher, catalog no. EPX-44444-000). These were then mixed with 25 μL of individual anti-SARS-CoV-2-S supernatant-containing antibodies. The samples and microspheres were incubated at 25°C for 2 hours, and then washed twice with 200 μL of DPBS containing 0.05% Tween 20. To detect the level of antibody binding to individual microspheres, 100 μL of 2.5 μg / mL- of R-phycoerythrin-conjugated goat F(ab')2 anti-human kappa (Southern Biotech, catalog no. 2063-09) was added to the blocking buffer (for hFc antibodies), or 100 μL of 1.25 μg / mL of R-phycoerythrin Affinipure F(ab')2 fragment goat anti-mouse IgG, F(ab')2 fragment specific (Jackson Immunoresearch, catalog no. 115-116-072) was added to the blocking buffer (for antibodies with human Fc regions), or 100 μL of 1.25 μg / mL of R-phycoerythrin anti-His (Biolegend, catalog no. 362603) was added to the blocking buffer (ACE-2 control, R&D, catalog no. 933-ZN), and incubated at 25°C for 30 minutes. After 30 minutes, the samples were washed twice with 200 μl of washing buffer and resuspended in 150 μl of washing buffer. The plates were read using FlexMap 3D® (Luminex Corp.) and Luminex xPonent® software version 4.3 (Luminex Corp.).

[0193] The results of Luminex binning are shown in Table 10 as median fluorescence intensity (MFI) signal intensity. To determine the clusters, the data was collected from intact proteins (unmodified). The samples were normalized to microspheres and clustered. 46 anti-SARS-CoV-2 antibodies were classified into 9 clusters with two or more antibodies, and 11 antibodies were classified as single nodes. Clusters were assigned based on these results in hierarchical clustering and dendrograms. These results indicate that the 46 anti-SARS-CoV-2-S antibody supernatants possess diverse binding characteristics and profiles, suggesting a collection of antibodies bound to different epitopes of the SARS-CoV-2 spike protein. [Table 12]

[0194] Example 9: Biacore binding rate of anti-SARS-CoV-2-S monoclonal antibody Equilibrium dissociation constant (K) of different SARS-CoV-2-S antibodies from the primary supernatant of CHOt cells or hybridomas D ) is a real-time surface plasmon resonance-based Biacore The binding was determined using a T200 / Biacore 8K biosensor. All binding studies were performed at 25°C with 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, and 0.05 v / v% Surfactant Tween-20, pH 7.4 (HBS-ET) running buffer. The Biacore CM5 sensor chip surface was first derivatized by amine coupling with a mouse anti-human Fc-specific mAb or a rabbit anti-mouse Fcγ monoclonal antibody (GE, catalog no. BR-1008-38) to capture the anti-SARS-CoV-2 antibody. Binding studies were performed using human SARS-CoV-2 expressed with a C-terminal myc-myc-hexahistidine tag (SARS-CoV-2 RBD-MMH). CoV-2 RBD extracellular domain, C-terminal mouse IgG2a (SARS-CoV-2 The tests were performed using the SARS-CoV-2 RBD extracellular domain expressed in RBD-mFc or the SARS-CoV-2 RBD extracellular domain expressed in C-terminal human IgG1 (SARS-CoV-2 RBD-hFc). Single concentrations of SARS-CoV-2 RBD-MMH (100 nM), SARS-CoV-2 RBD-mFc (50 nM), or SARS-CoV-2 RBD-hFc (50 nM), prepared in HBS-ET running buffer, were injected at a flow rate of 30 μL / min for 1.5 minutes, and the dissociation of various antibody-bound SARS-CoV-2 RBD reagents was monitored in HBS-ET running buffer for 2 minutes. At the end of each cycle, the SARS-CoV-2 RBD antibody capture surface was regenerated using either a 10-second injection of 20 mM phosphate for the mouse anti-human Fc-specific monoclonal antibody surface, or a 40-second injection of 10 mM glycine, HCl, pH 1.5 for the rabbit anti-mouse Fcγ-specific polyclonal antibody. The association rate (k a ) and dissociation rate (k d The bond dissociation equilibrium constant was determined by fitting the real-time bond sensorgram to a 1:1 bond model with a mass transport limitation using BiaEvaluation software v3.1, Biacore Insight Evaluation software v2.0, or curve fitting software. (K D The half-life (t1 / 2) and dissociation half-life were calculated from the motion velocity as follows.

number

[0195] Tables 11 and 12 show the binding rate parameters of different SARS-CoV-2 monoclonal antibodies that bind to different anti-SARS-CoV-2 RBD reagents of the present invention at 25°C. [Table 13] [Table 14] * : Estimated values ​​based on the measurement limits of the dissociation rate constant and dissociation half-life under experimental conditions.

[0196] Example 10: Characterization of anti-SARS-CoV-2-S monoclonal antibodies by blocking ELISA. An ELISA-based blockade assay was developed to determine the ability of anti-SARS-CoV-2-S antibodies to block the binding of the SARS-CoV-2 spike protein receptor-binding domain (RBD) to human angiotensin-converting enzyme 2 (hACE2).

[0197] The SARS-CoV-2 protein used in the experiment consisted of the receptor-binding domain (RBD) portion (amino acids Arg319~Phe541) of the SARS-CoV-2 spike protein, which was expressed at the Fc portion of human IgG1 at the C-terminus. (See RBD-hFc, NCBI accession number MN908947.3). The human ACE2 protein used in the experiment was purchased from the R&D system and consists of 18 glutamine-740 serine amino acids with a 10X histidine tag at the C-terminus (hACE2-His, NCBI accession number Q9BYF1).

[0198] The experiment was conducted using the following procedure: Monoclonal anti-Penta-His antibody (Qiagen) was coated overnight at 4°C with 1 μg / ml of PBS on a 96-well microtiter plate. The hACE2-His receptor was added at 0.2 μg / ml in PBS and conjugated at room temperature for 2 hours. Subsequently, nonspecific binding sites were blocked using a 0.5 (wt / vol)% solution of BSA in PBS. On other microtiter plates, a fixed amount of 10 pM or 15 pM (shown in Table 13) of SARS-CoV-2 RBD-hFc protein was conjugated with antibody diluted 1:10 or 1:20 in PBS + 0.5% BSA. After 1 hour of incubation, these antibody-protein complexes were transferred to microtiter plates coated with hACE2-His. After incubation at room temperature for 1.5 hours, the wells were washed, and the SARS-CoV-2 RBD-hFc protein bound to the plates was detected with goat anti-human IgG antibody conjugated to horseradish peroxidase (HRP) (Jackson). The plates were then developed using TMB substrate solution (BD Biosciences, catalog no. 555214) according to the manufacturer's recommendations, and the absorbance at 450 nm was measured using a Victor X5 plate reader.

[0199] Data analysis was performed by calculating the percentage decrease in signal for fixed SARS-CoV-2-S RBD-hFc concentrations in the presence and absence of the antibody. In the calculation, the binding signal of a sample with constant SARS-CoV-2-S RBD-hFc in the absence of the antibody for each plate was referred to as 100% binding or 0% blockage, while the baseline signal of a culture medium sample in the absence of SARS-CoV-2 RBD-hFc was referred to as 0% binding or 100% blockage.

[0200] The ability of anti-SARS-CoV-2-S antibodies to block the binding of SARS-CoV-2-S RBD to human ACE2 was evaluated using a blocking ELISA format. Single-point test antibody supernatant blockade of 10 pM or 15 pM SARS-CoV-2-S RBD-hFc binding to hACE2-His, presented on anti-His antibody coated on 96-well microtiter plates, was detected with HRP-conjugated anti-hFc antibody.

[0201] Table 13 summarizes the blockade results of the three assays. The SARS-CoV-2-S binding signal (450 nm) and the % blockade calculated in G are shown. Various blockades were observed in the test samples. For samples where NA is shown in columns 6 and 7, plate-corrected values ​​are included in columns 4 and 5 because the data were consistent with the single-plate switch occurring in these samples. Of the 46 antibody supernatants, 43 blocked more than 50% of SARS-CoV-2-S RBD-hFc binding to plate-coated human ACE2, and so on. Of these, 16 blocked more than 90% of the signals. [Table 15]

[0202] Example 11: Epitope mapping of anti-SARS-CoV-2-S monoclonal antibody against spike glycoprotein by hydrogen-deuterium exchange mass spectrometry. Hydrogen-deuterium exchange mass spectrometry (HDX-MS) was performed to determine the amino acid residues of the SARS-CoV-2 spike protein receptor-binding domain (RBD (amino acids R319-F541)) that interact with mAb10989, mAb10987, mAb10934, mAb10933, mAb10920, mAb10922, mAb10936, mAb10954, mAb10964, mAb10977, mAb10984, and mAb10986. A general description of the HDX / MS method is provided, for example, in Ehring (1999) Analytical Biochemistry 267(2):252-259 and Engen and Smith (2001) Anal. Chem. 73:256A-265A.

[0203] HDX-MS experiments are performed on an integrated HDX / MS platform, which consists of a Leaptec HDX PAL system for deuterium labeling and quenching, a Waters Acquity I-Class (Binary Solvent Manager) for sample digestion and loading, a Waters Acquity I-Class (Binary Solvent Manager) for analytical gradients, and a Thermo Q Exactive HF mass spectrometer for peptide mass measurement.

[0204] The labeling solution was prepared as PBS buffer in D2O at pD 7.0 (equivalent to 10 mM phosphate buffer, 140 mM NaCl, and 3 mM KCl, pH 7.4 at 25°C). For deuterium labeling, 10 μL of RBD protein or RBD protein pre-mixed with each of the 12 antibodies listed above was incubated twice at 20°C with 90 μL of D2O labeling solution at various time points. For mAb10989, mAb10987, mAb10934, and mAb10933, the time points were 0 min (undeuterated control), 5 min, and 10 min. For mAb10920, mAb10922, mAb10936, mAb10954, mAb10964, mAb10977, mAb10984, and mAb10986, the time points were 0 minutes (undeuterated control) and 10 minutes. Deuteration was performed by adding 90 μL of pre-cooled quench buffer (0.5 M TCEP-HCl, 4 M urea, 0.5% formic acid) to each sample and incubating at 20°C for 90 seconds. The quenched samples were then injected into a Leaptec HDX PAL system for online pepsin / protease XIII digestion. The digested peptides were trapped on a C18 column (2.1 mm × 5 mm, Waters) and separated on another C18 column (2.1 mm × 50 mm, Waters) using a gradient of -5°C for 20 minutes (for mAb10989, mAb10987, mAb10934, and mAb10933), or a 10-minute gradient from 0% to 90% mobile phase B solution (mobile phase A solution: 0.5% formic acid and 4.5% aqueous acetonitrile solution; mobile phase B solution: 0.5% formic acid in acetonitrile) (for mAb10920, mAb10922, mAb10936, mAb10954, mAb10956, mAb10964, mAb10977, and mAb10984). The eluted peptides were analyzed by Thermo Q Exactive HF mass spectrometry in LC-MS / MS or LC-MS mode.

[0205] LC-MS / MS data from undeuterated RBD protein samples were analyzed using the Byonic search engine (Protein Metrics) for RBD proteins and pepsin. The database was searched for amino acid sequences of protease XIII and its reverse sequence. Search parameters were set to default, with nonspecific enzymatic digestion and human glycosylation used as common variable modifications. The list of identified peptides was then imported into HDExaminer software (version 3.1) to analyze deuterium uptake (D uptake) and the difference in deuterium uptake percentages for all deuterated samples. The (Δ%D) was calculated. The difference in deuterium incorporation percentage (Δ%D) was calculated as follows:

number

[0206] A total of 190 peptides from RBD were identified from both RBD alone and RBD complexed with mAb10989 samples, representing an 86.06% sequence coverage of RBD. Peptides showing a decrease of 5% or more in deuterium uptake upon mAb binding (i.e., Δ%D values ​​less than -5%, such as -6%, -10%) were defined as significantly protected. The peptide corresponding to amino acids 467-513 of RBD (DISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVL) (SEQ ID NO: 835) was significantly protected by mAb10989.

[0207] A total of 187 peptides from RBD were identified from both RBD alone and RBD complexed with mAb10987 samples, representing an 86.06% sequence coverage of RBD. Peptides showing a decrease of 5% or more in deuterium uptake upon mAb binding (i.e., Δ%D values ​​less than -5%, such as -6%, -10%) were defined as significantly protected. The peptide corresponding to amino acids 432-452 of RBD (CVIAWNSNNLDSKVGGNYNYL) (SEQ ID NO: 836) was significantly protected by mAb10987.

[0208] A total of 188 peptides from RBD were identified from both RBD alone and RBD complexed with mAb10934 samples, representing an 86.06% sequence coverage of RBD. Peptides showing a decrease of 5% or more in deuterium uptake upon mAb binding (i.e., Δ%D values ​​less than -5%, such as -6%, -10%) were defined as significantly protected. Peptides corresponding to amino acids 432-452 (CVIAWNSNNLDSKVGGNYNYL) (SEQ ID NO: 836), 467-474 (DISTEIYQ) (SEQ ID NO: 837), and 480-513 (CNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVL) (SEQ ID NO: 838) of RBD were significantly protected by mAb10934.

[0209] A total of 188 peptides from RBD were identified from both RBD alone and RBD complexed with mAb10933 samples, representing an 86.06% sequence coverage of RBD. Peptides showing a decrease of 5% or more in deuterium uptake upon mAb binding (i.e., Δ%D values ​​less than -5%, such as -6%, -10%) were defined as significantly protected. The peptide corresponding to amino acids 467-510 of RBD (DISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRV) (SEQ ID NO: 839) was significantly protected by mAb10933.

[0210] A total of 75 peptides from RBD were identified from both RBD alone and RBD complexed with mAb10920 samples, representing an 83.27% sequence coverage of RBD. Peptides showing a decrease of 5% or more in deuterium uptake upon mAb binding (i.e., Δ%D values ​​less than -5%, such as -6%, -10%) were defined as significantly protected. Peptides corresponding to amino acids 471-486 (EIYQAGSTPCNGVEGF) (SEQ ID NO: 840) and 491-515 (PLQSYGFQPTNGVGYQPYRVVVLSF) (SEQ ID NO: 841) of RBD were significantly protected by mAb10920.

[0211] A total of 86 peptides from RBD were identified from both RBD alone and RBD complexed with mAb10922 samples, representing an 87.25% sequence coverage of RBD. Peptides showing a decrease of 5% or more in deuterium uptake upon mAb binding (i.e., Δ%D values ​​less than -5%, such as -6%, -10%) were defined as significantly protected. The peptide corresponding to amino acids 432-452 of RBD (CVIAWNSNNLDSKVGGNYNYL) (SEQ ID NO: 836) was significantly protected by mAb10922.

[0212] A total of 81 peptides from RBD were identified from both RBD alone and RBD complexed with mAb10936 samples, representing an 82.07% sequence coverage of RBD. Peptides showing a decrease of 5% or more in deuterium uptake upon mAb binding (i.e., Δ%D values ​​less than -5%, such as -6%, -10%) were defined as significantly protected. Peptides RBD corresponding to amino acids 351-360 (YAWNRKRISN) (SEQ ID NO: 842), 432-452 (CVIAWNSNNLDSKVGGNYNYL) (SEQ ID NO: 836), 467-486 (DISTEIYQAGSTPCNGVEGF) (SEQ ID NO: 843), and 491-513 (PLQSYGFQPTNGVGYQPYRVVVL) (SEQ ID NO: 844) were significantly protected by mAb10936.

[0213] A total of 84 peptides from RBD were identified from both RBD alone and RBD complexed with mAb10954 samples, representing an 87.25% sequence coverage of RBD. Peptides showing a decrease of 5% or more in deuterium uptake upon mAb binding (i.e., Δ%D values ​​less than -5%, such as -6%, -10%) were defined as significantly protected. Peptides corresponding to amino acids 400-422 (FVIRGDEVRQIAPGQTGKIADYN) (SEQ ID NO: 845), 453-486 (YRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGF) (SEQ ID NO: 846), and 490-515 (FPLQSYGFQPTNGVGYQPYRVVVLSF) (SEQ ID NO: 847) of RBD were significantly protected by mAb10954.

[0214] A total of 109 peptides from RBD were identified from both RBD alone and RBD complexed with mAb10964 samples, representing an 83.67% sequence coverage of RBD. Peptides showing a decrease of 5% or more in deuterium uptake upon mAb binding (i.e., Δ%D values ​​less than -5%, such as -6%, -10%) were defined as significantly protected. Peptides corresponding to amino acids 401-424 (VIRGDEVRQIAPGQTGKIADYNYK) (SEQ ID NO: 848) and 471-513 (EIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVL) (SEQ ID NO: 849) of RBD were significantly protected by mAb10964.

[0215] A total of 78 peptides from RBD were identified from both RBD alone and RBD complexed with mAb10977 samples, representing an 87.25% sequence coverage of RBD. Peptides showing a decrease of 5% or more in deuterium uptake upon mAb binding (i.e., Δ%D values ​​less than -5%, such as -6%, -10%) were defined as significantly protected. Peptides corresponding to amino acids 351-364 (YAWNRKRISNCVAD) (SEQ ID NO: 850) and 471-486 (EIYQAGSTPCNGVEGF) (SEQ ID NO: 840) of RBD were significantly protected by mAb10977.

[0216] A total of 88 peptides from RBD were identified from both RBD alone and RBD complexed with mAb10984 samples, representing an 87.25% sequence coverage of RBD. Peptides showing a decrease of 5% or more in deuterium uptake upon mAb binding (i.e., Δ%D values ​​less than -5%, such as -6%, -10%) were defined as significantly protected. Amino acids 400-422 of RBD (FVIRGDEVRQIAPGQTGKIADYN) The peptides corresponding to )(SEQ ID NO: 845) and 453-486(YRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGF)(SEQ ID NO: 846) were significantly protected by mAb10984.

[0217] A total of 84 peptides from RBD were identified from both RBD alone and RBD complexed with mAb10986 samples, representing an 87.25% sequence coverage of RBD. Peptides showing a decrease of 5% or more in deuterium uptake upon mAb binding (i.e., Δ%D values ​​less than -5%, such as -6%, -10%) were defined as significantly protected. Peptides corresponding to amino acids 400-422 (FVIRGDEVRQIAPGQTGKIADYN) (SEQ ID NO: 845), 453-486 (YRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGF) (SEQ ID NO: 846), and 490-515 (FPLQSYGFQPTNGVGYQPYRVVVLSF) (SEQ ID NO: 847) of RBD were significantly protected by mAb10986.

[0218] In short, the majority of the neutralizing antibodies tested contacted the RBDs in a manner that overlapped with the RBD residues constituting the ACE2 interface, and furthermore, the antibodies could be grouped based on their contact pattern with the RBD surface, as shown in Figure 15. The above data is also summarized in Tables 14-25. [Table 16] [Table 17] [Table 18] [Table 19] [Table 20] [Table 21] [Table 22] [Table 23] [Table 24] [Table 25] [Table 26] [Table 27]

[0219] Example 12: Identification of escape mutants under selective pressure Studies were conducted to determine whether the selective pressure in the presence of individual anti-SARS-CoV-2 spike glycoprotein antibodies, or combinations of such antibodies, leads to the generation of escape variants. Antibodies were serially diluted 1:5, starting at 100 μg / mL, in 500 μL of bullous stomatitis virus medium (DMEM high-glucose medium containing 3% heat-inactivated fetal bovine serum and penicillin / -streptomycin-L-glutamine). A non-antibody control was included to account for any possible tissue culture variability. The total amount of replicated VSV-SARS-CoV-2-S viruses in 500 μL of medium was 1.5 × 10⁶. 6 Plaque-forming units (PFU) were added to each dilution and incubated at room temperature for 30 minutes. After incubation, the mixture was divided into 3 × 10⁻⁶ units. 5The virus was added to Vero E6 cells and incubated at 37°C and 5% CO2 for 96 hours. Viral replication was monitored by screening for cytopathic effects. The supernatant and cell layers were collected from the wells with the highest antibody concentration showing clear viral replication. Total RNA, including viral RNA, was extracted from the cells using TRIzol (Life Technologies) according to the manufacturer's protocol for next-generation sequencing. In the second round of selection, 100 μL of supernatant containing the virus was diluted to 500 μL in VSV medium and passaged under the same or higher antibody concentrations as before. In this case as well, the supernatant was collected. RNA was extracted from cells in the wells that showed the highest antibody concentration in clear viral replication.

[0220] RNA was quantified using the Qubit RNA HS Assay Kit (ThermoFisher). 1–50 ng of RNA was treated with FastSelect-rRNA HMR (Qiagen) to remove host rRNA, and the incubation conditions for fragmentation were as follows: 85°C for 6 minutes, 75°C for 2 minutes, 70°C for 2 minutes, 65°C for 2 minutes, 60°C for 2 minutes, 55°C for 2 minutes, 37°C for 5 minutes, 25°C for 5 minutes, and held at 4°C. Strand-specific RNA-seq libraries were prepared from the treated RNA using the KAPA RNA HyperPrep Kit (Roche Sequencing). Ligation was performed with UDI including a UMI adapter (IDT). 16 cycles of PCR were performed to amplify the libraries. Sequencing was performed on MiSeq (Illumina) by multiplexed paired read-throughs over 2 × 70 cycles.

[0221] Sequencing analysis was performed using the Array Studio software package platform (Omicsoft). The quality of paired-end RNA Illumina reads was evaluated using "Raw Data QC for RNA-Seq Data Suite". Minimum and maximum read lengths, total nucleotide count, and GC% were calculated. An overall quality report was generated summarizing the quality of all reads for each sample along with each base pair. Next, paired-end RNA Illumina reads were mapped to the VSV-SARS-CoV-2-S virus genome using Omicsoft Sequence Aligner (OSA) version 4. Reads were trimmed by quality score using default parameters (the aligner trimmed the remainder of the read if it encountered nucleotides with a quality score of 2 or less). OSA outputs were analyzed and annotated using the Summarize Variant Data and Annotated Variant Data Package (Omicsoft). Target coverage was calculated for each sample. SNP calling was performed using samples with an average target coverage of more than 500 reads. SNPs with a minimum frequency of 1% and an applicability of more than 50 were identified and annotated.

[0222] Escape variants were selected under monoantibody suppression and antibody combinations using the above method with replicated VSV-SARS-CoV-2-S virus (Figure 18A). Multiple independent escape variants were identified for each of the four individual antibodies within the first passage (Figures 18B, 18C, and 19). As shown in Figure 1, the combination of two non-competitive antibodies (mAb10987 + mAb10933) prevented the selection of escape variants of the SARS-CoV-2 spike protein. Escape variants were identified using all four individual antibodies tested in this assay. Some of these variants were fixed in the population after a single passage and were present in 100% of sequencing reads at antibody concentrations up to 50 μg / ml (concentrations approximately 10,000–100,000 higher than the IC50). Sequencing of the escape variant (Figure 19) revealed a broad selection of variants for all known RBD variants, demonstrating that even binding to antibodies that neutralize the parental virus at low pM IC50 can be eliminated by a single amino acid change.

[0223] To further analyze the observed escape variants, we studied 22,872 publicly available, unique genome sequences. The complete SARS-CoV-2 genome sequence was downloaded from the GISAID nucleotide database (www.gisaid.org). Using a custom pipeline, we screened sequences across 7,684 high-quality genome sequences and assessed the genetic diversity of the spike-coding gene. Briefly, we used Blastn to analyze the Wuhan_Hu_1 spike nucleotide sequence (commissioned: MN90). The 8947) sequence was aligned to each individual genome. The results were analyzed, and the presence of the gene was verified if the aligned length exceeded 95% and the identity percentage exceeded 70%. Homologous spike sequences were extracted, translated, aligned, and amino acid changes relative to the reference were identified.

[0224] This analysis revealed the presence of polymorphisms in two of the escape amino acid residues identified in this study, each at a very low frequency. In particular, this study included evaluations of both non-competitive (mAb10987+mAb10933) and competitive (mAb10989+mAb10934) antibodies, but the only condition that did not result in the generation of escape variants was the non-competitive antibody combination. While this study was performed using surrogate viruses in tissue culture cells, it was expected that similar escapes would occur under pressure in SARS-CoV-2 viruses in vivo in the presence of only a single antibody. Escape against multiple non-competitive antibodies requires the simultaneous selection of two different amino acid mutations, which is significantly less likely than the selection of a single mutation.

[0225] Escape after treatment with an antibody cocktail (mAb10987 + mAb10933) was evaluated. This antibody cocktail is designed to evade escape by including two antibodies that bind to distinct, non-overlapping regions of the RBD, allowing for simultaneous binding and blockage of RBD function. Attempts to grow VSV-SARS-CoV-2-S virus in the presence of this antibody cocktail did not result in the growth of escape variants (Figures 18B, 18C, 19, and 20). Therefore, this selected cocktail was not rapidly selected for variants because the likelihood of simultaneous viral mutations occurring at two distinct genetic sites was low, thus eliminating binding and neutralization by both antibodies in the cocktail.

[0226] In addition to the cocktails described above, we also evaluated escapes after treatment with additional combinations, using RBD (mAb10989+mAb10934 and mAb10989+mAb10987), i.e., antibodies that completely or partially compete with each other for two antibodies that bind to overlapping regions of RBD to varying degrees. Under selective pressure from these combination treatments, there was a rapid development of escape mutants that were resistant to one combination but not to the other (Figures 18B, 18C, 19, and 20). For the mAb10989+mAb10934 combination, where the antibodies completely compete, a single amino acid substitution was sufficient to remove the neutralization of the cocktail, indicating that both of these antibodies require binding to the E484 residue to neutralize SARS-CoV-2. Interestingly, in combined treatment with mAb10989 + mAb10987, if mAb10989 was pre-bound, mAb10987 showed only partial competition to weakly bind to RBD, and such rapid escape did not occur. Therefore, even antibody combinations not selected to bind simultaneously may occasionally resist escape because only their epitopes partially overlap, and / or the residues resulting in escape are not readily tolerated by the virus and therefore not readily selected.

[0227] Furthermore, we evaluated the ability of the mAb10933 and mAb10987 combination to neutralize pseudotyped VSV expressing the SARS-CoV-2 variant known as B.1.1.7, also called the "UK variant." This variant is rapidly spreading and may have different effects than wild-type SARS-CoV-2, including more severe symptoms than wild-type virus, as well as potential resistance to vaccines and / or therapeutics. It is classified in part by the following mutations in the spike protein: H69-70 deletion, Y144 deletion, N501Y, A570D, P681H, T716I, S982A, and D1118H. The mAb10933 and mAb10987 combination was shown to neutralize the virus more effectively than either antibody alone (Figure 21). [Table 28]

[0228] Further experiments were conducted to evaluate whether escape occurs in the presence of three antibody combinations (mAb10933 + mAb10987 + mAb10985). Complete escape occurred rapidly with each of the three individual antibodies (mAb10933: passage 2; mAb10987: passage 3; mAb10985: passage 1). However, the combination of mAb10933 and mAb10987 extended the occurrence of complete escape up to passage 7, and when mAb10985 was added to the combination of mAb10933 and mAb10987, no escape was observed even after passage 11. See Figure 22. Example 13: Neutralization of SARS-CoV-2 wild-type and variant spike proteins

[0229] To test whether anti-SARS-CoV-2 spike protein antibodies could neutralize SARS-CoV-2 variants, these antibodies were screened against a panel of VSV pseudotyped viruses expressing wild-type and variant spike proteins. VSV pseudotyped viruses were generated by transiently transfecting 293T cells with plasmids encoding the SARS-CoV-2 spike protein or the same plasmids containing nucleotide variants encoding known variants of the SARS-CoV-2 spike protein amino acid sequence. All plasmids were confirmed by Sanger sequencing. Cells were transfected one day before transfection with 15 μg / plate of spike protein DNA in DMEM complete medium (1000 mL DMEM, Gibco; 100 mL FBS, Gibco; 10 mL PSG, Gibco) using 125 μL lipofectamine LTX, 30 μL PLUS reagent, and up to 3 mL Opti-Mem, at a rate of 1.2 × 10⁶ cells per plate. 7 Cells were seeded individually on a 15 cm plate. 24 hours after transfection, the cells were washed with 10 mL of PBS and then treated with 0.1 VSV in 10 mL of Opti-Mem. ΔG:mNeonCells were infected with the virus at MOI. The virus was incubated on cells for 1 hour, gently agitated every 10 minutes. The cells were then washed three times with 10 mL of PBS, and then topped with 20 mL of infection medium (1000 mL DMEM, Gibco; 10 mL sodium pyruvate, Gibco; 7 mL BSA, Sigma; 5 mL gentamicin, Gibco) and incubated for 24 hours at 37°C and 5% CO2. The pseudoviral supernatant was collected on ice in a 250 mL centrifuge tube, and centrifuged at 3000 rpm for 5 minutes to pellet any cell debris. The pellets were dispensed on ice and frozen at -80°C. Infectivity was tested in Vero cells before use in a neutralization assay. This material is VSV ΔG:mNeon / Spike fake virus, or VSV ΔG:mNeon / Spike_(Variant amino acid mutation)(e.g., VSV) ΔG:mNeon It is referred to as / Spike_H49Y).

[0230] On day 1, Vero cells were seeded in a T225 flask to a concentration of 80%, washed with PBS (Gibco:20012-043), separated from the flask with TrypLE, and inactivated trypsin with complete DMEM. 20,000 Vero cells were seeded in 100 μL of preheated complete DMEM per well of a 96-well black polystyrene microplate (Corning:3904). On day 2, VSV ΔG:mNeon The spike pseudovirus was thawed on ice and diluted in infection medium. Antibodies were diluted in a U-bottom 96-well plate, and dilutions of each antibody were prepared at 2-fold assay concentrations in 210 μl of infection medium. 120 μl of diluted antibody was transferred to a new U-bottom plate, and medium and IgG1 control antibody were added to each plate. 120 μl of diluted pseudovirus was added to the medium control well. The antibody was added to all wells except those with 120 μL of infection medium. After incubating the pseudovirus containing the antibody at room temperature for 30 minutes, the medium was removed from the Vero cells. 100 μL of the antibody / pseudovirus mixture was added to the cells and then incubated for 24 hours in 5% CO2 at 37°C. On day 3, the supernatant was removed from the cell wells and replaced with 100 μL of PBS. The plates were read using a SpectraMax i3 with a MiniMax imaging cytometer.

[0231] For the replication VSV-SARS-CoV-2-S virus neutralization assay, the antibody was diluted as described above, but was further diluted in VSV medium (DMEM high-glucose medium containing 3% heat-inactivated fetal bovine serum and penicillin / -streptomycin-L-glutamine). An equal volume of medium containing 2000 pfu of VSV-SARS-CoV-2-S virus was mixed with the antibody dilution and incubated at room temperature for 30 minutes. The mixture was then added to Vero cells and incubated at 37°C and 5% CO2 for 24 hours. The cells were fixed for 20 minutes (PBS containing 2% paraformaldehyde), permeabilized for 15 minutes (PBS containing 5% fetal bovine serum and 0.1% Triton-X100), and blocked for 1 hour (PBS containing 3% bovine serum albumin). Infected cells were immunostained with rabbit anti-VSV serum (Imanis Life Sciences) and Alexa Fluor® 488 secondary antibody in PBS + 3% bovine serum albumin. The fluorescence focus was quantified using a SpectraMax i3 plate reader equipped with a MiniMax imaging cytometer.

[0232] In addition to testing neutralization ability with replicated and non-replicated VSV-SARS-CoV-2-S viruses, antibodies were also tested against SARS-CoV-2 virus. Monoclonal antibodies and antibody combinations were serially diluted in DMEM (Quality Biological) and supplemented with 10% (v / v) heat-inactivated fetal bovine serum (Sigma), 1% (v / v) penicillin / streptomycin (Gemini Bio-products), and 1% (v / v) L-glutamine (final concentration of 2 mM, Gibco) (VeroE6 medium) to a final volume of 250 μL. Next, 250 μL of VeroE6 medium containing SARS-CoV-2 (WA-1) (1000 PFU / mL) was added to each serum dilution and to 250 μL of medium as an untreated control. The virus-antibody mixtures were incubated at 37°C for 60 minutes. After incubation, the viral titer of the mixtures was determined by plaque assay. Finally, the 50% plaque reduction neutralizing titer (PRNT50) value (serum dilution in which plaque formation was reduced by 50% compared to the untreated control) was calculated using a four-parameter logistic curve fitted to the neutralization percentage data (GraphPad software, La Jolla, CA).

[0233] Half of the maximum inhibitory concentrations (IC50) of individual monoclonal antibodies against a pseudovirus expressing the VSV-SARS-CoV-2 spike protein (S) encoding the Wuhan-Hu-1 (NCBI accession number MN908947.3) sequence of the spike protein (S-wt) were measured in Vero cells (Table 26). Most antibodies showed neutralizing efficacy in the picomolar range (pM), while some showed neutralizing efficacy in the nanomolar range (nM).

[0234] As previously reported, recombinant ACE2 was able to mediate the neutralization of VSV spike pseudoparticles, but its potency was far inferior to that of monoclonal antibodies, showing a decrease of more than 1000-fold compared to the best-performing neutralizing mAb (Figures 11A and 11B). In addition, the potent neutralizing activity of mAb10987, mAb10989, mAb10933, and mAb10934 was confirmed by neutralization assays, including neutralization of pVSV-SARS-CoV-2-S(mNeon) in human lung epithelial Calu-3 cell lines, neutralization of replicated VSV-SARS-CoV-2-S in Vero cells, and neutralization of SARS-CoV-2 in VeroE6 cells (Figures 11B, 11C, and 11D). All neutralization assays use four mAbs (mAb10987, mAb10989, mAb10933, and mAb109 34) No combination produced similar efficacy and showed synergistic neutralizing activity (Figure 11C, Figure 11D). [Table 29]

[0235] Amino acid variants of the spike (S) protein were identified from over 7,000 publicly available SARS-CoV-2 sequences representing isolates circulating worldwide and cloned into VSV pseudoparticles. To evaluate the effect of each variant on the neutralizing efficacy of monoclonal antibodies, neutralization assays were performed using pseudoparticles encoding the variants. Table 27 illustrates the relative neutralizing efficacy of monoclonal antibodies against variants encoding pseudoparticles compared to SARS-CoV-2 spike (S-wt) at a single concentration of 5 μg / ml. The percentage of neutralization relative to S-wt was obtained for each individual antibody and variant. With the exception of mAb10985 and R408I variants, no antibodies showed loss of neutralizing efficacy at a concentration of 5 μg / ml. These data demonstrate the broad functional neutralization range of monoclonal antibodies against globally circulating SARS-CoV-2 spike variants.

[0236] To further investigate the effect of S protein variants on the neutralizing efficacy of monoclonal antibodies, full neutralization curves were performed to determine the IC50 values ​​of the most potent neutralizing antibodies against a subset of variants localized within the receptor-binding domain (RBD) of the S protein. Table 28 shows the IC50 neutralization values ​​for each variant pseudoparticle. Intrinsic variability of up to 3-fold was observed between pseudoparticle neutralization assays and does not indicate a change in neutralizing efficacy. These data indicate that the antibodies retain neutralizing efficacy against a diverse panel of S protein RBD variants. [Table 30] [Table 31] [Table 32] [Table 33]

[0237] Nonclinical studies using sequential passages of recombinant vesicular stomatitis virus (VSV) encoding the SARS-CoV-2 spike protein with each of the individual antibodies in a combination of mAb10933-mAb10987 identified spike protein variants that reduced sensitivity to each of those individual antibodies by more than 15-fold (mAb10933 monotherapy identified K417E, K417R, K417N, Y453F, L455F, F486V, and Q493K substitutions in the spike protein receptor-binding domain, while mAb10987 monotherapy identified K444N, K444Q, K444T, and V445A substitutions in the spike receptor-binding domain). These variants were identified within a single passage, and some were fixed into the viral population by a second passage. None of these variants, selected through passaging in the presence of individual antibodies, exhibited reduced sensitivity to the REGN-COV2 two-antibody cocktail. Furthermore, no resistance substitutions were identified after the same number of passages in the presence of the REGN-COV2 two-antibody cocktail.

[0238] Genotyping and phenotypic testing can be used to monitor potential REGN-COV2 resistance-associated spike variants in clinical trials. No known resistance variants to the mAb10933 antibody were observed in the 288 sequences sequenced from the Phase I study of 66 patients analyzed. The G446V variant, which showed reduced susceptibility to neutralization by mAb10987 (approximately a 135-fold reduction in neutralization IC50), was identified in 3 out of 288 samples analyzed from two baseline samples with >15% allele frequencies (one in the placebo group and one in the 2400 mg study group, but not in subsequence samples from the same individuals) and 25 daily samples from the 8000 mg study group (4 sequence reads out of a total of 1,292 reads in the sample). The G446V variant was susceptible to neutralization by a two-antibody cocktail of mAb10933-mAb10987, and no variants resistant to the mAb10933-mAb10987 two-antibody cocktail were identified in any clinical samples, either baseline or post-treatment. These results still do not correlate with clinical relevance.

[0239] Example 14: Biacore binding rate of purified anti-SARS-CoV-2-S monoclonal antibody Equilibrium dissociation constant (K) of various SARS-CoV-2 RBD reagents that bind to purified CHOt anti-SARS-CoV-2 monoclonal antibody (mAb). DThe binding was determined using a real-time surface plasmon resonance-based Biacore T200 / Biacore 8K biosensor. All binding studies were performed at 25°C and 37°C with 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, and 0.05 v / v% surfactant Tween-20, pH 7.4 (HBS-ET) running buffer. The Biacore CM5 sensor chip surface was initially derivatized by amine coupling with one of the mouse anti-human Fc-specific mAbs (Regeneron, mAb2567) to capture anti-SARS-CoV-2 bmAb. Binding studies were performed using the C-terminal myc-my The tests were performed using the human SARS-CoV-2 RBD extracellular domain expressed with c-hexahistidine (SARS-CoV-2 RBD-MMH), the SARS-CoV-2 RBD extracellular domain expressed with C-terminal mouse IgG2a (SARS-CoV-2 RBD-mFc), and the SARS-CoV-2 spike ectofoldon trimer expressed with C-terminal myc-myc-hexahistidine (SARS-CoV-2 spike ECD-foldon). Using these reagents, we were able to test the ability of antibodies to bind to monomeric, dimeric, and trimeric RBD peptides, respectively.

[0240] [Table 34]

[0241] Different concentrations of hSARS-COV-2 RBD-MMH (90nM-3.33nM, 3-fold dilution), SARS-COV-2 RBD-mFc (30nM-1.11nM, 3-fold dilution), and SARS-CoV-2 spike ECD Foldon (0.78nM-25nM, 3-fold dilution), prepared with HBS-ET running buffer, were injected at a flow rate of 50 μL / min for 3 minutes. The dissociation of various SARS-CoV-2 RBD reagents, which were injected and bound to mAbs, was monitored for 6–10 minutes in HBS-ET running buffer. At the end of each cycle, the SARS-CoV-2 RBD mAb capture surface was regenerated using either 20 mM phosphate injection for 12 seconds onto a mouse anti-human Fc-specific mAb surface. The association rate (k a ) and dissociation rate (k d The coupling ratio was determined by fitting the real-time coupling sensorgram to a 1:1 coupling model with a mass transport limitation using BiaEvaluation software v3.1, Biacore Insight Evaluation software v2.0, or curve fitting software. Bond-dissociation equilibrium constant (K D The half-life (t1 / 2) and dissociation half-life were calculated from the motion velocity as follows.

number

[0242] The binding rate parameters of different SARS-CoV-2 mAbs that bind to different anti-SARS-CoV-2 RBD reagents of the present invention at 25°C and 37°C are shown in Tables 29 to 34, respectively. [Table 35] [Table 36] [Table 37] [Table 38] [Table 39] [Table 40]

[0243] Example 15: Characterization of anti-SARS-CoV-2-SmAb in antibody-dependent cytotoxicity (ADCC) assay The ability of antibodies targeting the SARS-CoV-2 spike protein to interact with FcγR3a, an Fc receptor prominently expressed in natural killer (NK) cells, and induce antibody-dependent cell-mediated cytotoxicity (ADCC) was measured using purified NK cells from three donors and target cells bound to the antibody. In this assay, effector cells were NK cells isolated from LeukoPaks, isolated from three different donors. Target cells were engineered Jurkat T cells expressing human CD20 (used as a positive control for a human IgG1 antibody targeting CD20) alone or in combination with the full-length SARS-CoV-2 spike protein. NK cells were incubated with target cells, and activation of NK cells and target cell death were induced by the involvement of FcγR3a via the Fc domain of the human IgG1 antibody bound to the target cells. Cell killing was measured by evaluating dead cell protease activity that increases luminescence and was used as the assay readout.

[0244] Jurkat T cells were engineered to constitutively express full-length human CD20 (amino acids M1-P297 of NCBI accession number NP_690605.1). Jurkat / hCD20 cells were stained for CD20 expression and maintained in RPMI + 10% FBS + P / S / G + 250 μg / ml hygromycin growth medium. These cells were used as a negative control without further modification and are referred to as Jurkat / hCD20 cells.

[0245] Next, the cells described above were manipulated to constitutively express the full-length SARS-CoV-2 spike protein (amino acids M1-T1273 of NCBI accession number YP_009724390.1). These cells were then selected for high spike protein expression and maintained in RPMI + 10% FBS + P / S / G + 1 μg / ml puromycin + 250 μg / ml hygromycin growth medium, and were referred to as Jurkat / hCD20 / SARS-CoV-2 spike cells.

[0246] NK cells were isolated from donor Leuko Paks using the Stem Cell Technologies RosetteSep Human NK Cell Concentration Kit, following the manufacturer's protocol.

[0247] One day before the assay, Jurkat / hCD20 and Jurkat / hCD20 / SARS-CoV-2 spike cells were grown in 5x10⁶ cells in their respective growth media. 5 The cells were divided into cells / ml. On the day of the assay, following the manufacturer's instructions, NK RosetteSep Human NK Cell Enrichment Cocktail (Stem Cell Technologies) and SepMate tubes (Stem Cell Unstimulated human NK cells were isolated from leukocyte-concentrated whole blood by density gradient centrifugation using (Technologies). NK cell enrichment was confirmed by a hematopoietic phenotyping cocktail of fluorophore conjugate antibodies (anti-CD56, anti-CD3, anti-CD19, and anti-CD14).

[0248] Jurkat / hCD20 or Jurkat / hCD20 / SARS-CoV-2 spike cells were resuspended in assay medium (RPMI supplemented with 1% BSA, 100 U / ml penicillin, 100 μg / ml streptomycin, and 292 μg / ml L-glutamine) and 5 × 10⁶ cells were placed in an opaque white 96-well flat-bottom plate. 3 The antibodies were added in triple doses at the cell / well concentration. Four anti-SARS-CoV-2 spike antibodies and isotype-matched negative control antibodies were titrated in assay medium at 1:4 serial dilutions ranging from 191 fM to 200 nM final concentrations. Non-antibody controls were included in each titration (e.g., to provide a background signal for nonspecific lysis of target cells in the presence of NK cells). A positive control antibody for ADCC (anti-CD20) was titrated at 1:4 serial dilutions ranging from 9.5 fM to 10 nM final concentrations. Human NK cells were diluted in assay medium and 2.5 x 10⁶ cells were added. 4The final cell / well concentration was added to the assay plate. To assess spontaneous lysis, untreated Jurkat cells only (target cells) and NK cells only (effector cells) were incubated in separate wells. The plates were incubated at 37°C and 5% CO2 for 3.5 hours. After incubation, the plates were equilibrated at room temperature for 10 minutes, followed by the addition of CytoTox Glo reagent (Promega) to the wells for 15 minutes with shaking. The luminescence signal was measured as a cytotoxicity reading using an ENVISION plate reader.

[0249] The cytotoxic response was calculated as follows: Cytotoxicity (%) = (Experimental signal - SBS) (標的細胞) -SBS (エフェクター細胞) ) / (Max signal (標的細胞w / ジギトニン) -SBS (標的細胞) ) × 100 In the formula, SBS represents the spontaneous background signal. Subtracting the background from this value gives: (value) - (mean of the antibody-free control).

[0250] EC 50 For the measurements, cytotoxicity % was analyzed using GraphPad Prism with a 4-parameter logistic equation on a 12-point dose-response curve including a control without antibody. The experiment was performed in triple replication with three donors.

[0251] EC from various donors 50 The values ​​and maximum cytotoxicity % ranges are summarized in Table 35.

[0252] In Jurkat / hCD20 / SARS-CoV-2 spike target cells, all four SARS-CoV-2 spike antibodies showed greater maximal cytotoxicity compared to the IgG1 control antibody. EC of SARS-CoV-2 spike antibodies 50 The values ​​ranged from 20.0 pM to 25.1 nM, and the Max (cytotoxicity %) values ​​ranged from 6.1% to 19.8%. Positive CD20 control antibody showed EC levels ranging from 16.9 pM to 38.6 pM across three donor NK cells. 50The value indicates a range of Max (cytotoxicity %) from 27.5% to 44.6%. did.

[0253] In Jurkat / hCD20 (negative control) target cells, all four SARS-CoV-2 spike antibodies behaved similarly to the negative control antibody, showing minimal activity. On the other hand, the positive CD20 control antibody showed EC levels ranging from 16.3 pM to 32.9 pM across three donor NK cells. 50 The values ​​indicated a range of Max (cytotoxicity %) from 24.5% to 26.4%. [Table 41]

[0254] Example 16: Characterization of anti-SARS-CoV-2-SmAb in antibody-dependent cell phagocytosis (ADCP) assay The ability of antibodies targeting the SARS-CoV-2 spike protein to induce phagocytosis in Jurkat cells engineered to express the full-length SARS-CoV-2 spike protein was evaluated. Macrophages differentiated from monocytes in the presence of macrophage colony-stimulating factor (M-CSF) were used as effector cells in antibody-dependent cell phagocytosis (ADCP) assays. IgG1 isotypes were evaluated concurrently as a negative control. Phagocytosis was assessed by measuring the number of fluorescently labeled target cells co-localizing with fluorescently labeled macrophages using the Opera Phenix High-Content Screening System.

[0255] To generate Jurkat / hCD20 target cells, Jurkat T cells were manipulated to constitutively express full-length human CD20 (amino acids M1-P297 of accession number NP_690605.1). Jurkat / hCD20 cells were stained for CD20 expression and maintained in RPMI + 10% FBS + P / S / G + 250 μg / ml hygromycin growth medium. These cells were used as negative controls.

[0256] To generate Jurkat / hCD20 / SARS-CoV-2 spike target cells, Jurkat / hCD20 T cells were engineered to constitutively express the full-length SARS-CoV-2 spike protein (accession number YP_009724390.1, amino acids M1-T1273). Jurkat / hCD20 / SARS-CoV-2 spike cells were selected for high spike protein expression and treated with RPMI+10%FBS+P / S / G The cells were maintained in a growth medium containing 1 μg / ml puromycin and 250 μg / ml hygromycin.

[0257] To generate effector cells, macrophages were differentiated from monocytes in the presence of M-CSF. Frozen CD14+ monocytes (Lonza) were thawed and resuspended in assay medium supplemented with 100 ng / ml M-CSF (RPMI 1640 supplemented with 10% FBS, 100 U / ml penicillin, 100 μg / ml streptomycin, and 292 μg / ml L-glutamine, NaPyr, HEPES, NEAA, and 10 μg MBME), and 5.5 × 10⁶ cells were used. 4 Cells were seeded at a rate of one cell per well into 96-well plates with a clear bottom and collagen coating, and differentiated into macrophages over 7 days. Fresh M-CSF (100 ng / ml) was added on day 4.

[0258] One day before the assay, Jurkat target cells were placed in their respective growth media in 5 × 10⁶ cells. 5 The cells were divided into cells / ml. On the day of the experiment, target cells and monocyte-derived macrophages were incubated for 15 minutes at 37°C and 5% CO2 in PBS supplemented with either CellTrace CFSE dye or CellTrace Violet dye, respectively. The CFSE-labeled target cells were washed and resuspended in assay medium (RPMI 1640 supplemented with 10% FBS, 100 U / ml penicillin, 100 μg / ml streptomycin, and 292 μg / ml L-glutamine, NaPyr, HEPES, NEAA, and 10 μg MBME) and 6 × 10⁶ 4Cells were added in double doses to 96-well U-bottom plates at the cell / well density. Four anti-SARS-CoV-2 spike and IgG1 control antibodies were titrated in assay medium at 1:5 serial dilutions ranging from 51 fM to 20 nM final concentrations and added to the plates. Zero antibody points were represented at 10 fM using GraphPad Prism.

[0259] After incubating a mixture of target cells, with or without the titrated antibody, on ice for 15 minutes, the mixture was transferred to a plate containing violet-labeled macrophages, and the plate was incubated at 37°C in 5% CO2 for 30 minutes. The wells were washed three times with PBS, and then 4.21% formaldehyde in PBS supplemented with 2.5 μM DRAQ5 was added.

[0260] After a 20-minute incubation, the wells were washed with PBS and imaged using the Opera Phenix High-Content Screening System with both 488 nm (CFSE-labeled target cells) and 375 nm (violet-labeled macrophages) excitation channels. Image analysis was performed using Harmony software. Macrophage populations were identified using image segmentation in the 375 nm excitation channel. Target cells were identified using image segmentation in the 488 nm excitation channel. Phagocytosis was quantified by identifying macrophage populations that contained target cells among them.

[0261] Phagocytosis percentage was calculated by comparing the number of macrophages undergoing phagocytosis to the total number of macrophage cells. The background was subtracted from this value to derive ADCP%: (value) - (average without antibody = background phagocytosis). EC 50 For the measurements, ADCP% was analyzed using GraphPad Prism with a 4-parameter logistic equation on a 10-point dose-response curve including an antibody-free control. Maximum %ADCP was determined as the highest mean ADCP% value measured within the tested dose range. The assay was performed in duplicate across two donors, and the results from one representative donor are shown.

[0262] EC 50 The values ​​and maximum ADCP% are summarized in Table 36. When tested with Jurkat / hCD20 / SARS-CoV-2 spike cells, all four anti-SARS-CoV-2 spike antibodies showed a higher maximum ADCP% compared to the IgG1 control antibody. EC of anti-SARS-CoV-2 spike antibodies 50 The values ​​range from 2.72 pM to 6.33 pM. Within the range, the Max ADCP% was between 40.1% and 56.7%. When tested on Jurkat / hCD20 (negative control) target cells, all four anti-SARS-CoV-2 spike antibodies behaved similarly to the negative control antibody, exhibiting minimal activity. [Table 42]

[0263] Example 17: As determined by ELISA, the anti-SARS-CoV-2 antibody blocks RBD binding to hACE2. We used an ELISA-based blockade assay to determine the ability of anti-SARS-CoV-2 antibodies to block the binding of the SARS-CoV-2 spike protein receptor-binding domain (RBD) to its receptor, human angiotensin-converting enzyme 2 (hACE2).

[0264] The SARS-CoV-2 protein used in this assay consisted of the receptor-binding domain (RBD) portion (amino acids Arg319~Phe541) of the SARS-CoV-2 spike protein, expressed at the Fc portion of human IgG1 at the c-terminus (SARS-CoV-2 RBD-hFc). The human ACE2 protein used in the experiment was purchased from the R&D system and consisted of amino acids Gln18~Ser740 with a C-terminal 10X histidine tag (hACE2-His, NCBI accession number Q9BYF1).

[0265] The experiment was conducted using the following procedure: Monoclonal anti-Penta-His antibody (Qiagen) was coated overnight at 4°C with 1 μg / ml of PBS on a 96-well microtiter plate. The hACE2-His receptor was added at 0.2 ug / ml in PBS and bound at room temperature (RT) for 2 hours. Subsequently, nonspecific binding sites were blocked using a 0.5 (wt / vol)% solution of BSA in PBS. On other microtiter plates, a fixed amount of 100 pM SARS-CoV-2 RBD-hFc protein was bound to anti-SARS-CoV-2 antibody and isotype IgG1 antibody controls at dilutions of 0.0008 nM to 50 nM with PBS + 0.5% BSA. After 1 hour incubation, the mixed solution was transferred to the hACE2-His receptor coated on the microtiter plate. After incubation at room temperature for 1.5 hours, the wells were washed, and SARS-CoV-2 bound to the plates was detected with goat anti-human IgG antibody conjugated to horseradish peroxidase (HRP) (Jackson). The plates were then developed using TMB substrate solution (BD Biosciences, #555214) according to the manufacturer's recommendations, and the absorbance at 450 nm was measured using a Victor X5 plate reader.

[0266] Binding data were analyzed using a sigmoid dose-response model within Prism™ software (GraphPad). The calculated IC50 value, defined as the antibody concentration required to block 50% of SARS-CoV-2 RBD-hFc binding to plate-coated hACE2-His, was used as an indicator of blocking efficacy. The rate was observed at the highest antibody concentration tested using this formula and was defined based on the background-corrected binding signal reported for all antibodies tested.

number

[0267] Antibodies that blocked less than 50% of binding at the highest concentration tested are classified as non-blocking agents, and IC50 values ​​have not been reported for these antibodies.

[0268] The ability of anti-SARS-CoV-2 antibodies to block SARS-CoV-2 RBD binding to human ACE2 was evaluated using a blocking ELISA. In this assay, 100 pM SARS-CoV-2 RBD-hFc was titrated with a wide range of concentrations of anti-SARS-CoV-2-S antibody, and the inhibition of RBD binding to hACE2-His by the presence of the antibody was evaluated. Plate-bound RBD-hFc was detected with HRP-conjugated anti-hFc antibody.

[0269] Table 37 summarizes the blockade IC50 and maximum blockade of anti-SARS-CoV-2-S antibodies at the highest test concentrations, and the blockade curves are shown in Figures 2-9. Of the 46 antibodies tested, 44 showed concentration-dependent blockade of RBD.hFc binding to hACE-2. IC50 values ​​ranged from 41 pM to 4.5 nM, and maximum blockade ranged from 55% to approximately 100% at the highest antibody concentration tested. Two of the 46 antibodies tested did not show blockade activity under assay conditions. As expected, unrelated isotype control antibodies did not show blockade activity. [Table 43-1] [Table 43-2] Note: 100 pM RBD-hFc was titrated with serially diluted anti-SARS-CoV-2-S antibody starting from 50 nM. RBD-hFc bound to immobilized hACE2 with 10 × histidine tags was detected with HRP-conjugated anti-hFc antibody. NBD; blockade was not detected.

[0270] Example 18: Neutralization of cleaved SARS-CoV-2 spike protein and neutralization by Fab Pseudoparticles containing SARS-CoV-2 spikes may be pre-cleaved by furin-like proteases at polybasic S1 / S2 cleavage sites during biosynthesis in HEK293T cells, and the effect of this cleavage on mAb neutralization efficacy was evaluated. Spike-stabilized pseudoparticles having single-nucleotide cleavage sites (FurMut) at the S1 / S2 interface or deletion region (FurKO) (Figure 12A) ) were generated. In Vero cells, no difference was observed in the neutralization of pseudoparticles containing FurMut or FurKO compared to wild-type (WT) (Figure 12B). Interestingly, stabilized pseudoparticles were as infectious as or more infectious than those with WT cleavage sites in Vero cells, but a dramatic loss of infectiousness was observed in Calu-3 cells (Figure 12C). SARS-CoV-2 with a spontaneous deletion of the S1 / S2 junction has also been observed to be defective in infectiousness in Calu-3 cells, but not in Vero cells, suggesting that the use of proteases differs between these two cell types. To investigate the neutralization mechanism, Fab fragments of these antibodies were generated. IgG antibodies were compared to their corresponding Fab for their ability to neutralize pseudotype VSV (Figure 13). The IC50 of all Fabs was shifted compared to their parent IgG, indicating enhanced neutralization with bivalent binding, crosslinking, and steric hindrance.

[0271] Example 19: Mutual competition among anti-SARS-CoV-2-S mAbs mAb10987, mAb10989, mAb10933, and mAb10934 were examined in a cross-competitive binding assay (Figure 14), and several pairs of non-competitive mAbs with picomolar neutralizing ability that could potentially form antibody cocktails in combination were identified (e.g., mAb10987 and mAb10933).

[0272] Epitope binning of anti-SARS-CoV-2-S mAbs was performed using a ForteBio Octet HTX biolayer interferometry system (Molecular Devices ForteBio) containing a running buffer of 10 mM HEPES, 150 mM NaCl, 0.05% (v / v) Tween-20, pH 7.4, and 1 mg / mL BSA. Using a pairwise combinatorial method, the assay was performed in a premix sandwich format containing competing mAbs to bind to the SARS-CoV-2 RBD-MMH protein. The assay was performed at 30°C with continuous agitation at 1000 rpm. After obtaining an initial baseline in running buffer, 20 μg / mL of anti-COVID19 mAb was captured on an anti-human Fc(AHC) biosensor tip for 300 seconds. To block any remaining free unsaturated binding sites at the tip of the AHC biosensor, all sensors were exposed to a well containing 100 μg / mL of unrelated IgG1 in a blockage solution for 240 seconds. Following this process, the biosensors were immersed for 300 seconds in a well containing a premix solution of 100 nM of SARS-CoV-2 RBD-MMH protein and 600 nM of a second mAb's anti-COVID19 mAb binding site. The binding response at each step was recorded, and specific signals were normalized by subtracting the self-blocking mAb competition control from the dataset. Data analysis was performed using Octet Data Analysis HT 10.0 software with Epitope Binning.

[0273] Comparing the cross-competition binding assay with the HDX-MS results described above provides structural insights into the mechanism by which non-competitive antibody pairs can simultaneously bind to RBD, thus potentially making them ideal partners in therapeutic antibody cocktails. mAb10987 and mAb10933 represent such an antibody pair. mAb10933 targets a spike-like loop region on one edge of the ACE2 interface. Within that region, the residues exhibiting the most significant HDX protection by mAb10933 are upward-facing, suggesting that the Fab region of mAb10933 binds to RBD from above, leading to a critical collision between mAb10933 and ACE2. To avoid competition with mAb10933, mAb10987 can only bind to the HDX-defined protection region from the front or lower left (front view of mAb10987 in Figure 15). This is consistent with the neutralization data described above, as mAb10987 is oriented to a position where it is likely to interfere with ACE2.

[0274] Example 20: Structural determination of antibody-binding spike protein To better understand the binding of mAb10933 and mAb10987 to the spike protein RBD, structural analysis was performed via cryo-electron microscopy (cryoEM). Fab fragments of mAb10933 and mAb10987 were separated using the FabALACTICA kit (Genovis). 600 μg of mAb10933 Fab and 600 μg of mAb10987 Fab were mixed with 300 μg of SARS-CoV-2-S RBD and incubated on ice for approximately 1 hour. The mixture was then injected into a Superdex200 increasing gel filtration column equilibrated to 50 mM Tris pH 7.5 and 150 mM NaCl. Peak fractions containing the mAb10933 Fab-mAb10987 Fab-RBD complexes were collected and concentrated using a 10 kDa MWCO centrifuge filter. For the preparation of the cryoEM grid, the protein sample was diluted to 1.5 mg / mL and 0.15% PMAL-C8 amphipol was added. 3.5 μL of protein was deposited onto a freshly plasma-washed UltrAufoil grid (1.2 / 1.3, 300 mesh). Excess solution was absorbed using filter paper and plunge-frozen in liquid ethane using a Vitrobot Mark IV. The cryoEM grid was transferred to a Titan Krios (Thermo Fisher) equipped with a K3 detector (Gatan). Movies were collected using an EPU (Thermo Fisher) at a magnification of 105,000x corresponding to a pixel size of 0.85 Å. A dose rate of 15 electrons per second per pixel was used, and each movie was 2 seconds long, corresponding to a total dose of approximately 40 electrons per Ų.

[0275] All cryoEM data processing was performed using cryoSPARC v2.14.2. 2,821 films were adjusted using patch motion correction and patch CTF estimation. Based on the estimated focus blur values ​​and CTF-fit resolution, 2,197 aligned micrographs were selected for further processing. The initial set of particles picked using a blob picker was subjected to 2D classification to generate a template for template picking. The 989,553 particles picked by template picking were subjected to multiple rounds of 2D classification to remove particles containing unbound fabs and incomplete complexes. Ab initio reconstruction using three classes generated a single class containing 61,707 particles corresponding to the mAb10933 Fab-mAb10987 Fab-RBD complex. Heterogeneous purification of this class of particles, followed by further heterogeneous purification, yielded a map with a resolution of 3.9 Å (FSC = 0.143) containing 48,140 particles used for model construction. Models for RBD (obtained from PDB code 6M17) and two Fabs (obtained from previous antibody structures of mAb10987 excluding the lambda light chain, obtained from PDB code 5U15) were manually placed on this map. These models were then manually reconstructed using Coot, and their real-space alignment with the map was adjusted using Phenix.

[0276] Reviewing the above data, single-particle cryoEMs of the SARS-CoV-2 spike RBD complex bound to the Fab fragments of mAb10933 and mAb10987 demonstrate that the two antibodies in this cocktail can simultaneously bind to different regions of the RBD (Figures 16 and 17). 3D reconstruction maps of the complex at a nominal resolution of 3.9 Å show that both Fab fragments bind to different epitopes of the RBD, confirming that they are non-competitive antibodies. mAb10933 binds to the upper part of the RBD and extensively overlaps with the ACE2 binding site. On the other hand, the epitope of mAb10987 is located on the side of the RBD, considerably farther away from the mAb10933 epitope, and has little to no overlap with the ACE2 binding site.

[0277] Example 21: Protection against the emergence of escape mutants Rapidly emerging viral variants have become the next major concern in the fight against the global pandemic, so it is important that therapeutic measures provide coverage for circulating variants and do not contribute to the development of resistance that emerges to treatment. For this purpose, spiker We investigated protein sequence diversity and monitored the emergence of minor viral variants in SARS-CoV-2 isolates found in nature or identified clinically in preclinical in vitro and in vivo studies. Non-competitive antibody combinations not only provide full coverage against circulating variants but also protect against the emergence of such variants and their potential presence in the population in a clinical setting.

[0278] In vitro escape studies using recombinant viruses strongly support the rationale for using non-competitive antibody combinations to avoid resistance, but questions remain regarding the relevance of these findings to the validated SARS-CoV-2 virus, in vivo infection models, and, most importantly, the clinical environment. In this example, in vitro escape variants were rapidly selected for all individual clinical-stage antibodies targeting the receptor-binding domain (RBD) of the spike protein, but this risk was mitigated by utilizing a non-competitive combination of two non-competitive antibodies, and further mitigated by combining three non-competitive antibodies. Escape variants were efficiently selected in vivo in a hamster model of infection, regardless of dosage or treatment setting (prevention or therapy), at the time of treatment with individual antibodies, while the combination of mAb10933 and mAb10987 completely protected against the development of such resistance. Importantly, these findings were confirmed in humans, and the overall genetic diversity of the spike protein was confirmed across 4,882 samples from 1,000 outpatients or hospitalized patients with confirmed COVID-19 from ongoing Phase 1–3 trials. Analysis of baseline and post-treatment sequence diversity in patients treated with placebo and mAb10933+mAb10987 showed that the non-competitive antibody combination protected against the selection of spike protein resistance variants.

[0279] The recent surge in rapidly emerging variants necessitated testing the hypothesis that non-competitive antibody combinations would retain their potency as the virus evolves during its spread through human populations and protect against selection of escape variants after treatment. This hypothesis was tested by evaluating the potency of individual antibodies against variants of concern, including UK B.1.1.7, California B.1.429, and E484K, as well as the combination of mAb10933 and mAb10987, including variants from multiple other global lineages such as South Africa B.1.351, Brazil P.1, and New York B.1.526. Even when one of the antibodies was affected, the combination retained its complete neutralizing potency, a key characteristic of this antibody combination's initial selection (Figures 23A and 23B).

[0280] Materials and methods In vitro escape studies and neutralization assays Methods for pseudoparticle generation, neutralization assays, and escape studies are described in detail above and in U.S. Patent No. 10,787,501.

[0281] Neutralization assay Epiprestomatitis virus (VSV) was pseudotyped with the SARS-CoV-2 spike protein and used in the neutralization assay as described above. Specifically, HEK293 T cells (ATCC CRL-3216) were transfected with a SARS-CoV-2 spike expression plasmid encoding either wild-type (Wuhan-Hu-1) or variant spike protein. 24 hours after transfection, the cells were infected with a single MOI of modified VSV encoding a reporter construct instead of the native viral glycoprotein. The supernatant containing pseudoparticles was collected 24 hours after infection and frozen at -80°C before use. The neutralization assay was performed by infecting Vero cells (ATCC:CCL-81) with SARS-CoV-2 pseudoparticles pre-incubated with serially diluted antibodies. The viral reporter signal was then read 24 hours after infection, and the IC50 values ​​of each antibody were determined.

[0282] In vitro escape research Escape studies were performed using recombinant VSV spike virus. Antibodies were started at 100 ug / mL and serially diluted 1:5. Viral replication was monitored by screening for cytopathic effects. Supernatants were collected from wells with the highest antibody concentration and evident viral replication. Total RNA was extracted from cells using TRIzol (Life Technologies) according to the manufacturer's protocol for next-generation sequencing. In the second round of selection, 100 μL of supernatant containing the virus was passaged at the same or higher antibody concentration as before. Again, the supernatant was collected, and RNA was extracted from cells in wells with the highest antibody concentration and evident viral replication for RNA-seq analysis.

[0283] Hamster research A total of 80 male golden hamsters, approximately 9 weeks old (130-150g), were used in the study. The animals' weight was measured before the start of the study. The animals were monitored twice daily for signs of COVID-19 disease (such as ruffled fur, curled posture, responsiveness, nasal discharge, and respiratory distress) throughout the study period. Their weight was measured once daily during the study period. Antibodies were administered by intraperitoneal (IP) injection (0.200 ml volume). Animals were loaded with 1 x 10^4 PFU (USA-WA1 / 2020 (NR-52281; BEI Resources)) by dropping a total of 0.05 ml of viral inoculum into each nostril in 0.025 ml increments (simulated exposed animals received the same amount of sterile PBS). Animals were sedated with inhaled isoflurane prior to treatment and viral administration. At the end of the study (7 days post-loading), animals were euthanized by CO2 inhalation, and tissue samples were collected sterile for RNA sequencing. Tissue samples were inactivated using Trizol Reagent (Invitrogen, Carlsbad, CA, USA). All animal studies were conducted in compliance with all applicable local, state, and federal regulations and were conducted by Texas Biomed Institutional Animal. Approved by the Care and Use Committee (IACUC; protocol number 1739MA).

[0284] Clinical trial design Outpatient clinical trials This is an ongoing adaptive, multicenter, randomized, double-blind, placebo-controlled, seamless Phase 1 / 2 / 3 clinical trial (clinicaltrials.gov:NCT04425629) for outpatients with COVID-19. Non-hospitalized patients over 18 years of age who had tested positive for SARS-CoV-2 less than 72 hours prior to the study and developed symptoms less than 10 days prior to randomization were randomized in a 1:1:1 ratio to receive placebo, 2.4 g (1.2 g each of mAb10933 (casiribimab) and mAb10987 (imudevimab)), or 8.0 g (4.0 g each of casirivimab and imudevimab). The primary virological endpoint was the time-weighted mean daily change in viral load from baseline (day 1) to day 7. The primary secondary clinical endpoint was the proportion of patients with at least one COVID-19-related outpatient visit (MAV) by day 29. In this study, we analyzed 3,523 nasopharyngeal, 17 transnasal, and 6 saliva samples obtained from a total of 728 patients.

[0285] Clinical trials for hospitalized patients This is an ongoing adaptive, multicenter, randomized, double-blind, placebo-controlled, seamless Phase 1 / 2 / 3 clinical trial (clinicaltrials.gov:NCT04426695) for hospitalized patients with Covid-19. Hospitalized patients over 18 years of age who have tested positive for SARS-CoV-2 less than 72 hours prior to randomization and have developed symptoms less than 7 days prior to randomization will be randomized in a 1:1:1 ratio to receive placebo, 2.4 g (1.2 g each of casirivimab and imudevimab), or 8.0 g (4.0 g each of casirivimab and imudevimab). The primary clinical endpoint was the incidence of death or the need for mechanical ventilation up to day 29. In this study, 968 nasopharyngeal, 249 transnasal, and 119 saliva samples were analyzed from a total of 272 patients.

[0286] Viral RNA, RT-PCR, and sequencing Viral RNA was extracted from hamster samples and samples collected in clinical trials (Viracor-Eurofins, MO, USA). For clinical samples, qualitative and quantitative viral load measurements were determined by quantitative RT-PCR (Viracor-Eurofins, MO, USA). 25 ng Human Universal 10 µl of RNA combined with reference RNA (Agilent) was purified using PureBeads (Roche Sequencing). cDNA synthesis was performed using a SuperScript® IV First-Strand Synthesis System (Thermal Fisher) according to the manufacturer's protocol. Subsequently, a library was generated using half of the cDNA (10 µl) with a Swift Normalase® Amplicon Panel (SNAP) SARS-CoV-2 Panel (Swift Biosciences), also according to the manufacturer's protocol. Sequencing was performed using NextSeq (Illumina) with multiplexed paired read runs of 2 × 150 cycles. An overall quality report was generated summarizing the quality of all reads for each sample along with each base pair.

[0287] Variant Call Analysis Swift amplicon bulk RNA-seq reads were aligned to the SARS-CoV-2 reference genome Wuhan-Hu-1 (commissioned: MN908947) using Minimap2 (v2.17). Alignments were sorted by read name, and primers were clipped using complementary Swiftbiosciences primer clipping software (v0.3.8) (github.com / swiftbiosciences / primerclip). Duplicate reads were removed using the Picard package (https: / / github.com / broadinstitute / picard), and target coverage was summarized for each sample using a custom script. Single nucleotide polymorphism (SNP) calls were performed using GATK HaplotypeCaller (v4.1.8). For each SNP, the frequency of viral mutations inferred from the sequence reads was calculated from the SUMTool (v1.9) pile-up output. A variant was flagged if a nucleotide position was covered by at least 10 reads and the frequency of variant reads at these positions was at least 15%.

[0288] Variant calling from the SARS-CoV-2 public genome Variants from the public SARS-CoV-2 genome were extracted as described in Baum et al., Science 370(6520):1110-1115(2020). The complete SARS-CoV-2 genome sequence was downloaded from the GISAID nucleotide database (https: / / www.gisaid.org) on ​​February 4, 2021. A custom pipeline was used to screen sequences across the entire high-quality genome sequence and assess the genetic diversity of spike-coding genes. Briefly, Blastn was used to align the Wuhan-Hu-1 spike nucleotide sequence (commission: MN908947) to each individual genome. The results were analyzed, and the presence of the gene was validated if the aligned length exceeded 95% and the identity percentage exceeded 70%. Homologous spike protein sequences were extracted, translated, and aligned to identify amino acid changes relative to the reference.

[0289] result As shown above, combination therapy with two anti-spike antibodies targeting non-overlapping epitopes of the SARS-CoV-2 spike protein minimizes the potential for rapid viral escape observed in vitro with monotherapy. Extending this study with VSV-SARS-CoV-2-spike recombinant virus and monitoring resistance to mAb treatment, escape studies were conducted as monotherapy and in duplex and triplex combinations using several RBD-targeting mAbs approved under emergency use authorization or in clinical trials. Complete viral resistance to all mAbs used as monotherapy was achieved with only 1-2 passages, but complete resistance to the REGEN-COV combination required 7 consecutive passages and multiple co-mutations to affect each antibody (Figures 24A and 24B). Escape variants identified with the comparative antibodies COV2-2130, COV2-2196, CB6, and COV555 were consistent with previous reports. Similar to the combination of mAb10933 + mAb10987 (also known as REGEN-COV), the COV2-2130 and COV2-2196 cocktails were also resistant to rapid escape (Figure 24A).

[0290] The rapid escape observed in monotherapy settings was independent of the target epitope or its sequence conservation; in fact, the escape variants were rapidly selected against antibodies targeting the pancoronavirus epitope, VIR-7831 (Figures 24A and 24B). All VIR-7831 escape residues mapped to the publicly available epitope of the antibody, and the resulting escaped viruses maintained their replication ability, indicating that these mutations were not harmful to the virus. Furthermore, the identified escape variants could be found in the publicly available genome sequence (GISAID), which suggests that they are tolerable and likely to be selected under pressure by the validated SARS-CoV-2 virus. These experiments highlight the inherent risks of monotherapy against SARS-CoV-2 with any anti-spike mAb, regardless of the target epitope or its conservation.

[0291] There is potential merit in combining three non-competitive neutralizing mAbs that target the RBD of SARS-CoV-2 (mAb10933 + mAb10987 + mAb10985). All three mAbs can conjugate simultaneously to the spike protein RBD in a non-overlapping manner, and the combination exhibits similar neutralizing efficacy to REGEN-COV (Figures 24C and 24D). The addition of a third non-competitive RBD mAb (mAb10985) resulted in further increased protection against viral escape without loss of antiviral efficacy observed throughout 11 consecutive passages (Figures 24A and 24B). These results indicate that a non-competitive combination of three mAb neutralizing mAbs targeting spike RBD offers further potential merit as a therapeutic agent for SARS-CoV-2.

[0292] To understand how these in vitro escape findings indicated that mAb combination therapy prevented the development of drug resistance and translated to a more physiological setting, we evaluated in vivo viral evolution after mAb administration in a SARS-CoV-2 hamster loading model, both as monotherapy (mAb10987 or mAb0933) and in combination with REGEN-COV. Animals were loaded with SARS-CoV-2 (USA-WA1 / 2020) and treated in both prophylactic and therapeutic settings (Figure 25A) with either mAb10987 or mAb10933 as monotherapy at either a high or low dose (50 mg / kg or 5 mg / kg), or in combination with REGEN-COV (50 mg / kg or 5 mg / kg). These doses have been previously shown to provide partial or complete efficacy in this animal model using REGEN-COV. Lungs from infected animals were collected 8 days post-loading, and viral RNA was isolated. RNA-seq analysis was used to detect spike protein variants present at low frequencies (>15%) in the viral population. To identify putative treatment-resistant variants, REGEN-COV antibodies are known to bind to them, and previously identified variants against any of these antibodies were identified. We focused our analysis on the spike RBD, where all identified resistance variants are located. Analysis of RBD sequences in saline-treated animals did not reveal any variants, but in the absence of treatment, it was evident that the virus was not under strong selective pressure in this model (Figures 25B and 25C). However, in animals treated with either of the single antibodies as monotherapy, several variants in the RBD were identified (Figures 25B and 25C). Surprisingly, the analysis showed that resistance variants were selected in almost half (18 / 40) of the animals treated with monotherapy, compared to none (0 / 20) in the animals treated with the REGEN-COV cocktail. Of the seven RBD variants identified in animals treated with monotherapy, six were either previously described as resistance variants or mapped to the same amino acid positions as other resistance variants against either mAb10933 or mAb10987 (Figure 34). Four of these variants were identified in in vitro escape studies, and the relevance of identifying SARS-CoV-2 escape mutations using VSV-SARS-CoV-2 spike recombinant virus was validated. Interestingly, variant selection occurred in monotherapy in both low-dose and high-dose groups, in both prophylactic and therapeutic settings.

[0293] To evaluate the emergence of drug resistance in COVID-19 patients treated with REGEN-COV, the genetic diversity of 1,336 and 3,546 SARS-CoV-2 RNA samples isolated from 272 hospitalized patients and 728 non-hospitalized patients, respectively, was characterized at baseline and at several time points after mAb cocktail administration (Figure 30). In both the hospitalized and non-hospitalized study groups, patients were randomly assigned (1:1:1) to receive placebo, 2.4 g of REGEN-COV2, or 8.0 g of REGEN-COV2, and patient samples were collected at multiple time points from baseline (day 1) to the end of the study (day 29). RNA-seq analysis was performed to characterize the genetic diversity of spike sequences from all SARS-CoV-2 RNA-positive swabs by qRTPCR. Minor variants present at a frequency of at least 15% in the viral population were identified. In total, 244 and 514 amino acid variations were identified across all samples from hospitalized and non-hospitalized patients, respectively. In both studies, the number and frequency of variants were similar across all three treatment groups, indicating that REGEN-COV did not increase spike protein diversity compared to placebo (Figure 30).

[0294] To determine whether REGEN-COV treatment contributed to the selection of spike protein resistance variants, the frequency of minor variants from each patient across all available RT-PCR-positive samples was compared over the long term. Across all patient samples from the hospitalized group, a total of 89, 87, and 108 amino acid changes were identified in the placebo, low-dose, and high-dose treatment groups, respectively. These mutations were uniformly distributed across the entire spike protein sequence (Figures 26A and 26B). The lower number of RBD variants observed in REGEN-COV-treated patient samples further indicated a lack of urgent selection for the treatment compared to placebo (15 RBD variants in placebo vs. 12 low-dose / 12 high-dose variants in the REGEN-COV treatment group). Only 17% (42 / 244) of all amino acid changes were observed at more than one point in at least one patient (Figure 26B), suggesting that the majority of variants were lost over time as a result of a lack of adaptability or population bottleneck. Three of these variants were observed in RBD only in the REGEN-COV treated group (S477N, N501T, and K537R). The S477N variant was present in seven REGEN-COV treated patients at multiple time points, including baseline (Figures 31A and 31B). S477N is a common SARS-CoV-2 variant present in over 5% of circulating viruses worldwide (Source: GISAID). K537R is a rare mutation identified in one treated patient and has been found in fewer than 10 virus isolates worldwide to date (Figures 27A and 27B, Source: GISAID). N501T was observed in three treated patients in this study. (Figures 27A and 27B). Notably, in all patients, three variants were identified at baseline or at the earliest time point (less than 5 days after REGEN-COV treatment), and no significant increase in their frequency was observed at the time point between the early and late stages, indicating no treatment-related choice.

[0295] A total of 216, 248, and 212 amino acid changes were identified in patient samples treated with 1,215 placebo, 1,203 low-dose, and 1,128 high-dose REGEN-COV, respectively, from the non-hospitalized group, and were spread throughout the entire spike protein sequence (Figures 28A and 28B). The RBDs contained 23, 27, and 31 amino acid changes, respectively, of which only S477N and two other variants (S494P and G446V) were identified at multiple time points in at least one REGEN-COV-treated patient (Figure 28B). The S477N variant was present in three REGEN-COV-treated patients and five placebo-treated patients at multiple time points, including baseline (Figures 32A and 32B). S494P is a rare circulating variant (approximately 0.15% GIDAID) observed only at multiple time points (including baseline) in two REGEN-COV-treated patients. G446V is a rare variant (approximately 0.02% GISAID) identified in four REGEN-COV treated patients and two placebo patients (Figure 29A, and Figures 29B-1 and 29B-2). One of these patients (Figure 29B-1 - Patient B4) represents the only instance with a consistent late-stage increase in the relative frequency of the variant, which may represent a treatment choice in this patient. However, it should be noted that there is no evidence that the absolute frequency of the variant increases over time as viral levels dramatically decrease over time. In all G446V patients, including Patient B4, the frequency of the variant had decreased to undetectable levels at the most recent time point, indicating that drug-mediated selection was not possible.

[0296] To determine the functional impact of RBD variants identified at multiple time points in REGEN-COV-treated patients, individual antibodies and combinations were evaluated for their neutralizing efficacy against the G446V, S494P, S477N, and K537R variants (Figures 33A and 33B). A decrease in neutralizing efficacy was observed with mAb10987 (135x) against the G446V variant and with mAb10933 (4.5x) against the S494P variant, but no effect was observed with any mAb against the S477N or K537R variants. The N501T variant was not evaluated, but the surrogate substitution N501Y did not affect either the antibody or the REGEN-COV combination. Importantly, in all cases, the REGEN-COV combinations maintained full neutralizing efficacy, thus providing full antiviral activity to the treated individuals and limiting the potential selection of any resistant variant.

[0297] ***************** All references cited herein are incorporated by reference to the same extent as each individual publication, database entry (e.g., Genbank sequence or GeneID entry), patent application, or patent is specifically and individually indicated as being incorporated by reference. This incorporation by reference is intended by the applicant to relate to all individual publications, database entries (e.g., Genbank sequence or GeneID entry), patent applications, or patents, even if such citations are not directly adjacent to the specific incorporation by reference. The inclusion of specific incorporations, where present, within this specification does not diminish this general incorporation by reference. References cited herein are not intended as an acknowledgment that the references are relevant prior art, nor do they constitute any acknowledgment of the content or date of these publications or documents.

Claims

1. A pharmaceutical composition for treating SARS-CoV-2 virus infection in a subject, comprising a first antibody or its antigen-binding fragment and a second antibody or its antigen-binding fragment, wherein the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment are a) To obtain a first antibody or antigen-binding fragment thereof that binds to a first epitope of the SARS-CoV-2 spike glycoprotein, wherein the first epitope includes the amino acid sequence described in SEQ ID NO: 836, b) To obtain a second antibody or antigen-binding fragment thereof that binds to a second epitope of the SARS-CoV-2 spike glycoprotein, wherein the second epitope includes the amino acid sequence described in SEQ ID NO: 839, c) Determining whether the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment each exhibit neutralizing efficacy against the virus, d) Determining whether the first antibody or its antigen-binding fragment competes with the second antibody or its antigen-binding fragment for binding to the SARS-CoV-2 spike glycoprotein, e) If the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment each exhibit neutralizing efficacy against the virus, and the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment do not compete for binding to the SARS-CoV-2 spike glycoprotein, then proceed to f) to i), f) Determining the first frequency of escape variants arising solely from the first antibody or its antigen-binding fragment, g) Determining a second frequency of escape variants arising solely from the second antibody or its antigen-binding fragment, h) Determining a third frequency of escape variants resulting from the combination of the first antibody or its antigen-binding fragment and the second antibody or its antigen-binding fragment, i) If the third frequency is lower than the first and second frequencies, the combination is selected for use in reducing the frequency of the escape variant, A pharmaceutical composition wherein the escape variant is a variant in the SARS-CoV-2 spike glycoprotein.

2. The frequency of the escape variant is a) Contacting a population of cells with the first antibody or its antigen-binding fragment and a virus expressing the SARS-CoV-2 spike glycoprotein, sequencing the nucleic acids from the population of cells, and determining the first frequency of SARS-CoV-2 spike glycoprotein mutations. b) Contacting a population of equivalent cells with the second antibody or its antigen-binding fragment and a virus expressing the SARS-CoV-2 spike glycoprotein, sequencing the nucleic acids from the cell population, and determining the second frequency of SARS-CoV-2 spike glycoprotein mutations. c) Contacting a population of equivalent cells with the first antibody or its antigen-binding fragment, the second antibody or its antigen-binding fragment, and a virus expressing the SARS-CoV-2 spike glycoprotein, sequencing the nucleic acids from the cell population, and determining a third frequency of SARS-CoV-2 spike glycoprotein mutations. d) The pharmaceutical composition according to claim 1, measured by comparing the first frequency, the second frequency, and the third frequency.

3. The pharmaceutical composition according to claim 1 or 2, wherein the subject is COVID-19.